WO2018112420A1 - Compositions and methods for treating cancer - Google Patents

Compositions and methods for treating cancer Download PDF

Info

Publication number
WO2018112420A1
WO2018112420A1 PCT/US2017/066839 US2017066839W WO2018112420A1 WO 2018112420 A1 WO2018112420 A1 WO 2018112420A1 US 2017066839 W US2017066839 W US 2017066839W WO 2018112420 A1 WO2018112420 A1 WO 2018112420A1
Authority
WO
WIPO (PCT)
Prior art keywords
substituted
unsubstituted
ras
membered
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2017/066839
Other languages
English (en)
French (fr)
Inventor
Kevan M. Shokat
Daniel Gentile
Steven Moss
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California Berkeley
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU2017378487A priority Critical patent/AU2017378487B2/en
Priority to CN201780086355.9A priority patent/CN110291084A/zh
Priority to KR1020197020051A priority patent/KR20190095355A/ko
Priority to JP2019532079A priority patent/JP7191828B2/ja
Priority to RU2019121922A priority patent/RU2019121922A/ru
Priority to BR112019012263-0A priority patent/BR112019012263A2/pt
Priority to US16/468,948 priority patent/US11136297B2/en
Priority to EP17881029.7A priority patent/EP3555077B1/en
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Priority to CA3047125A priority patent/CA3047125A1/en
Priority to MX2019007030A priority patent/MX392368B/es
Publication of WO2018112420A1 publication Critical patent/WO2018112420A1/en
Priority to IL267247A priority patent/IL267247B/en
Anticipated expiration legal-status Critical
Priority to US18/194,410 priority patent/US12077507B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/05—Hydrolases acting on acid anhydrides (3.6) acting on GTP; involved in cellular and subcellular movement (3.6.5)
    • C12Y306/05002—Small monomeric GTPase (3.6.5.2)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82—Translation products from oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Definitions

  • Ras proteins are small guanine nucleotide-binding proteins that act as molecular switches by cycling between active GTP-bound and inactive GDP-bound conformations. Ras signaling is regulated through a balance between activation by guanine nucleotide exchange factors (GEFs), most commonly son of sevenless (SOS), and inactivation by GTPase-activating proteins (GAPs) such as neurofibromin or p120GAP.
  • GEFs guanine nucleotide exchange factors
  • SOS most commonly son of sevenless
  • GAPs GTPase-activating proteins
  • the Ras proteins play a critical role in the regulation of cell proliferation, differentiation, and survival. Dysregulation of the Ras signaling pathway is almost invariably associated with disease. Hyper-activating somatic mutations in Ras are among the most common lesions found in human cancer.
  • K-Ras, N-Ras, or H-Ras mutation of any one of the three Ras isoforms
  • H-Ras mutations are by far the most common in human cancer.
  • K- Ras mutations are known to be often associated with pancreatic, colorectal and non-small-cell lung carcinomas.
  • H-Ras mutations are common in cancers such as papillary thyroid cancer, lung cancers and skin cancers.
  • N-Ras mutations occur frequently in hepatocellular carcinoma.
  • a compound e.g., Switch 2 - Binding Pocket binding compound which is capable of binding an amino acid residue of a Ras protein (e.g., K-Ras, N- Ras, H-Ras, human K-Ras, human N-Ras and/or human H-Ras protein).
  • R 1 is independently halogen, -CX 1 3, -CHX 1 2, -CH2X 1 , -OCX 1 3, - OCH 2 X 1 , -OCHX 1 2 , -CN, -SO n1 R 1D , -SO v1 NR 1A R 1B , -NHC(O)NR 1A R 1B , -N(O) m1 , -NR 1A R 1B , -C( O)R 1C , -C(O)-OR 1C , -C(O)NR 1A R 1B , -OR 1D , -NR 1A SO 2 R 1D , -NR 1A C(O)R 1C , -NR 1A C(O)OR 1C , -N R 1A OR 1C , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted
  • R 7 is independently halogen, -CX 7 3 , -CHX 7 2 , -CH 2 X 7 , -OCX 7 3 , - OCH 2 X 7 , -OCHX 7 2 , -CN, -SO n7 R 7D , -SO v7 NR 7A R 7B , -NHC(O)NR 7A R 7B , -N(O) m7 , -NR 7A R 7B , -C( O)R 7C , -C(O)-OR 7C , -C(O)NR 7A R 7B , -OR 7D , -NR 7A SO2R 7D , -NR 7A C(O)R 7C , -NR 7A C(O)OR 7C , -N R 7A OR 7C , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubsti
  • R 8 is independently hydrogen, halogen, -CX 8 3 , -CHX 8 2 , -CH 2 X 8 , -CN, -SO n8 R 8D , -SO v8 NR 8A R 8B , -C(O)R 8C , -C(O)OR 8C , -C(O)NR 8A R 8B , E, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
  • L 3 is a
  • E is an electrophilic moiety.
  • Each R 1A , R 1B , R 1C , R 1D , R 2A , R 2B , R 2C , R 2D , R 7A , R 7B , R 7C , R 7D , R 8A , R 8B , R 8C , and R 8D is independently hydrogen, -CX 3 , -CN, -COOH,
  • heterocycloalkyl substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl
  • R 1A and R 1B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl
  • R 2A and R 2B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl
  • R 7A and R 7B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl
  • R 8A and R 8B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubsti
  • z1 is an integer from 0 to 5.
  • z2 is an integer from 0 to 3.
  • z7 is an integer from 0 to 4.
  • Each X, X 1 , X 2 , X 7 , and X 8 is independently–F, -Cl, -Br, or–I.
  • n1, n2, n7, and n8 are independently an integer from 0 to 4.
  • m1, m2, m7, m8, v1, v2, v7, and v8 are independently 1 or 2.
  • a method of treating a disease in a patient in need of such treatment including administering a therapeutically effective amount of a compound as described herein to the patient.
  • a method of modulating the activity of a Ras protein e.g., K- Ras, H-Ras, N-Ras, human K-Ras, human H-Ras, or human N-Ras
  • the method including contacting the Ras protein (e.g., K-Ras, H-Ras, N-Ras, human K-Ras, human H-Ras, or human N-Ras) with an effective amount of a compound as described herein.
  • a method of modulating a Ras protein including contacting the Ras protein (e.g., K-Ras, H-Ras, N- Ras, human K-Ras, human H-Ras, or human N-Ras) with an effective amount of a compound as described herein.
  • a Ras protein e.g., K-Ras, H-Ras, N- Ras, human K-Ras, human H-Ras, or human N-Ras
  • the method including contacting the Ras protein (e.g., K-Ras, H-Ras, N-Ras, human K-Ras, human H-Ras, or human N-Ras) with an effective amount of a compound as described herein.
  • a Ras protein e.g., K-Ras, H-Ras, N-Ras, human K-Ras, human H-Ras, or human N-Ras
  • a cysteine residue of the Ras protein e.g., K-Ras, H-Ras, N-Ras, human K-Ras, human H-Ras, or human N-Ras.
  • a Ras protein e.g., K-Ras, H-Ras, N-Ras, human K-Ras, human H-Ras, or human N-Ras
  • a compound as described herein, wherein the compound is non-covalently bound to the Ras protein (e.g., K-Ras, H-Ras, N-Ras, human K-Ras, human H-Ras, or human N-Ras).
  • Typical non-covalent interactions include electrostatic interactions (e.g. ionic bond, hydrogen bond, halogen bond), van der Waals interactions (e.g.
  • a method of identifying an inhibitor (e.g., a covalent or non- covalent inhibitor) of Ras protein including: contacting a Ras protein (e.g., K-Ras, H-Ras, N-Ras, human K-Ras, human H-Ras, or human N-Ras) with a Ras (e.g., K-Ras, H-Ras, N-Ras, human K-Ras, human H-Ras, or human N-Ras) with a Ras (e.g., K-Ras, H-Ras, N-Ras, human K-Ras, human H-Ras, or human N-Ras) inhibitor test compound; allowing the Ras (e.g., K-Ras, H-Ras, N-Ras,
  • a method of selectively modulating a Ras protein including contacting the Ras protein (e.g., K-Ras, H-Ras, N-Ras, human K-Ras, human H-Ras, or human N-Ras), the method including contacting the Ras protein (e.g., K-Ras, H-Ras, N-Ras, human K-Ras, human H-Ras, or human N-Ras) with a compound which contacts at least one amino acid residue forming a Switch 2 binding pocket of the Ras protein (e.g., K-Ras, H-Ras, N-Ras, human K-Ras, human H-Ras, or human N-Ras), wherein the at least one amino acid residue is selected from an amino acid corresponding to V9, C72, E63, Y64, R68, H94, Y96, and Q99 of the human K-Ras, and wherein the compound covalently reacts with
  • FIGS.1A-1B The Ras-GTPase Effector Cycle is depicted in FIG.1A.
  • FIG.1B shows G12 and G13.
  • G12C– A disease relevant cysteine provides a chemical opportunity to target K-Ras*.
  • FIG.3. KRas-G12C GDP showing the switch 2 and switch 1 binding pockets.
  • FIG.4. Schematic overview of the tethering discovery method. The steps include identifying hits using mass spectrometry (% modification); find low affinity fragments, optimize leads using mass spectrometry along with biochemical assays; and finding active site or allosteric binders.
  • FIG.5. The figure summarizes the binding interactions of initial tethering hits DG01 and DG02 with H-Ras M72C ⁇ GDP and the non-hydrolyzable analog GppNHp. ⁇ ME50
  • FIG.6 iRAS148 binds behind Switch II.
  • FIGS.7A-7B The natural product inhibitoy of a GTPase (Gq).
  • FIG.7A shows YM- 254890 while FIG.7B depicts the interaction of YM-254890 with the protein.
  • FIG.8 The optimization of the reversible binding element and the cysteine reactive group.
  • FIG.9. Effects of the compound binding of the Ras-GTPase Effector cycle. When the compound binds, it inhibits GEF catalyzed nucleotide exchange.
  • FIGS.11A-11B The compound binding disrupts K-Ras G12C binding to GTP and thereby blocks effector binding.
  • FIGS.12A-12B Correlation between biochemical and cellular potency.
  • FIG.12B depicts the chemical structures of compounds 12, 10, and 17.
  • FIG.13 This blot shows the transient transfection of HEK 293s with various FLAG K-Ras constructs. This experiment indicates that M72C is a silent mutation that has no significant effect on MAPK signaling. It also does not interfere with known oncogenic mutations and their increased flux through the MAPK pathway (i.e. G12D).
  • FIG.14 Crystal structure of the Kras protein.
  • FIGS.15A-15B Glutamine 61 is involved in the catalysis of GTP hydrolysis.
  • FIG.16 A zoomed in view of the switch 2 binding pocket. The introduction of an unnatural cysteine in the switch II pocket to develop new probes. Residues M72 and V9 are marked and are proximal to the high affinity region of S-IIP’s binding pocket.
  • FIGS.17A-17B Tethering screen results for K-Ras M72C . Percent labeling at 1 mM ⁇ ME Vs.
  • FIG.17B Compound Number. Compounds are represented by a dot, and the line marks the 50% modification threshold for hit ID. Large dots are the top three hits shown in FIG.17B. Three fragments from the tethering screen are shown in FIG.17B, 2C07, 2B09, and 2B02 and their percent modification. [0035] FIG.18. Rendering of the protein showing that compound 2C07 occupies half of the switch II pocket and a new lipophilic channel. [0036] FIG.19. DG-3-95A (also referred to as compound 3 in FIG.34A) labeling kinetics at 20 ⁇ M (5X) drug. The kinetic curves demonstrate that DG-3-95A labeling is effected by the presence of other oncogenic mutations at position 61 in both the GDP and GNP states.
  • FIG.20 The switch II pocket is accessible in the GTP bound state.
  • DG-3-95A also referred to as compound 3 in FIG.34A labeling kinetics at 20 ⁇ M (5X) drug.
  • the kinetic curves demonstrate that DG-3-95A labeling is effected by the presence of other oncogenic mutations at position 61 in both the GDP and GNP states.
  • FIGS.21A-21B FIG.21A depicts the protein of H-Ras/GTP.
  • FIG.22B depicts the protein of H-Ras-switch-2 binder/GTP.
  • FIG.22A depicts the chemical structures of compound 079 and 083.
  • FIG.22B is a model of K-Ras inhibition by S-IIP inhibitors.
  • FIG.23A Top Left: K-Ras M72C ⁇ GDP bound to DG01 (1.486 ⁇ , R Work : .1780, R Free : .2073).
  • FIG.23B Top: H-Ras M72C ⁇ GNP bound to DG01 (2.200 ⁇ , RWork: .2109, RFree: .2547), Bottom: Comparison of Mg 2+ coordination between the GDP state, the two GNP states (State 1 and 2), and the new GNP DG01 structure.
  • FIG.23B H- Ras M72C DG01 SNP Structure (top) with specific portions zoomed in to show contacts. [0041] FIG.24.
  • FIG.25 Preliminary SAR results demonstrate improved binding to the S-IIP high affinity region and engagement with C72 with a variety of electrophilic moieties.
  • DG01/2 represents a compound moiety (e.g., a compound described herein).
  • FIGS.26A-26D Tethering at Cys 72 Yields New S-IIP Binder: FIG.26A: Surface and cartoon representation of the S-IIP formed by the binding of ARS-853 (5F2E).
  • FIG. 26B ⁇ ME50 values and percent labeling against various Ras constructs are reported for each tethering hit.
  • FIG.26C Co-crystal structure of 2C07 and K-Ras(M72C) with GDP and Mg2+. Close-up surface representation of 2C07’s binding site and FO - FC omit map (mesh 3 ⁇ ).
  • FIG.26D Differences between ARS-853 and 2C07 structures are mostly localized to Switch-II. Overlay of ARS-853’s binding pose on the surface representation of the co-crystal structure of 2C07 and K-Ras(M72C). [0044] FIGS.27A-27D. Compound 2C07 Binds and Engages With the S-IIP in Both
  • FIG.27A Co-crystal structure of 2C07 and H-Ras(M72C) with GDP and Mg2+.
  • FO - FC omit map (mesh 3 ⁇ ).
  • FIG. 27B Co-crystal structure of 2C07 and H-Ras(M72C) Chain C with GppNHp and Mg2+.
  • FO - FC omit map (mesh 3 ⁇ ).
  • FIG.27C Full cartoon structure comparison of 2C07 bound to both nucleotide states as well as a zoomed in view.2C07 induces a disordering of Switch II and a drastic movement of Switch I away from the nucleotide.
  • FIG.27D Distinct coordination states are representative of active (GppNHp State 2) and inactive forms of Ras (GDP and GppNHp State 1).2C07 induces a new Mg 2+ coordination network that compromises nucleotide coordination and stability.
  • FIGS.28A-28C Hydrogen Deuterium Exchange (HDX) Supports 2C07
  • FIG.28A Change in % deuterium between H-Ras(M72C) GDP and H-Ras(M72C) GppNHp displayed on HRas GppNHP (5P21).
  • FIG.28B Change in % deuterium between H-Ras(M72C) GDP and H-Ras(M72C) GDP 2C07 displayed on the H-Ras(M72C) GDP 2C07 crystal structure.
  • FIG.28C Change in % deuterium between H-Ras(M72C) GppNHp and H-Ras(M72C) GppNHP 2C07 displayed on Chain C of the H-Ras(M72C) GppNHp 2C07 crystal structure. All reported differences are the highest % deuterium difference across a 300 sec time course and are assigned a color based on the corresponding legend. All regions indicated as either an increase or decrease were tested for significance by a two-tailed T-test and had a p value ⁇ .05. The intensity key and legend in FIG. 28A may be used to understand the increase and decrease change in FIG.28B and FIG.28C. [0046] FIGS.29A-29D.
  • FIG.29A Raf-1-RBD pull-down of H-Ras(M72C) GppNHP and H-Ras(M72C) 2C07 GppNHp at various concentrations of H-Ras shows 2C07 does not inhibit Raf binding.
  • FIG.29B EDTA catalyed exchange and subsequent pull-down of H-Ras(M72C) GppNHp and H-Ras(M72C) GppNHp 2C07 by Raf-1-RBD demonstrates that 2C07 alters intrinsic Ras affinity for nucleotide towards GDP.
  • FIG.29C SOS cat pull-down of H- Ras(M72C) GDP and H-Ras(M72C) GDP at various concentrations of H-Ras demonstrates that 2C07 inhibits SOS binding.
  • FIG.29D Reconstruction of Ras cycle is achieved by inducing nucleotide exchange of 100 nM Ras by various concentrations of SOScat for either 1 or 2 hours and subsequent pull-down by Raf-1-RBD.2C07 inhibits activation of H-Ras by SOS cat and prevents pull-down by Raf-1-RBD.
  • FIG.30 Tethering screen hits 6H5 and 2E7 and their activity.
  • FIG.31 Tethering at 72 Yields New S-IIP Binder. Top hits from the tethering screen as well as two 2C07 derivatives with ⁇ ME 50 values reported.
  • FIG.32.2C07 Binds to H-Ras(M72C) GppNHp Causing Alternative Mg 2+ Coordination.
  • Percent labeling against H-Ras(M72C) GDP and GppNHp at the screening ⁇ ME concentration (1 mM) are graphed.
  • FIGS.33A-33D Percent labeling against H-Ras(M72C) GDP and GppNHp at the screening ⁇ ME concentration (1 mM) are graphed.
  • FIG. 33A Cartoon representation of pull down protocol. Raf-1-RBD pull-down of H-Ras(M72C) GppNHp and H-Ras(M72C) 2C07 GppNHp at various concentrations of H-Ras demonstrate 2C07 does not inhibit Raf binding.
  • FIG.33B Cartoon representation of pull down protocol. EDTA catalyzed exchange and subsequent pull down of H-Ras(M72C) GppNHp and H-Ras(M72C) GppNHp 2C07 by Raf- 1-RBD demonstrates that 2C07 alters Ras nucleotide preference.
  • FIG.33C Cartoon representation of pull down protocol. EDTA catalyzed exchange and subsequent pull down of H-Ras(M72C) GppNHp and H-Ras(M72C) GppNHp 2C07 by Raf- 1-RBD demonstrates that 2C07 alters Ras nucleotide preference.
  • FIG.33C Cartoon representation of pull down protocol. EDTA catalyzed exchange and subsequent pull down of H-Ras(M72C) GppNHp and H-Ras(M72C) GppNHp 2C07 by Raf- 1-RBD demonstrates that 2C07 alters Ras nucleotide preference.
  • FIG.33C Cartoon representation of pull
  • FIG.33D Cartoon representation of pull down protocol. Ras activation is achieved by catalyzing nucleotide exchange by SOS cat and indirectly reading out activated Ras by subsequent pull down by Raf-1- RBD. 2C07 inhibits SOS cat catalyzed nucleotide exchange.
  • FIGS.34A-34D Electrophiles Derived from the 2C07 Scaffold Readily Modify Ras(M72C) in both Nucleotide States.
  • FIG.34A Covalent modification of H-Ras(M72C) bound to GDP and GppNHp monitored by whole protein LC/MS.
  • FIG.34B Time-course of
  • FIG.34C Competition time course of Compound 3 labeling of H-Ras(M72C) GDP in the presence of varying concentrations of reversible Compound 4 with initial velocities, V 0 (%/h), calculated per condition.
  • FIG.35 The figure shows B-Factor Putty Cartoon Representation of H-Ras(G12C) GppNHp (PDB: 4L9W). The region of highest B-factor is still switch-II even in the GppNHp state where both switches form stabilizing polar contacts with the ⁇ -phosphate.
  • FIG.36 K-Ras(M72C) Full Tethering Screen Results. Percent modification for each member of the tethering screen library (screened at a ⁇ ME concentration of 1 mM) is plotted versus compound number. 50% modification was the cut-off for positive hits, and the hit rate was 1.6%.
  • FIG.37 Structure Comparison Between GDP Bound K and H-Ras 2C07 Co-crystal Structures. Overall secondary structure is identical between 2C07 bound isoforms (Left).2C07 binding is also consistent between isoforms (right).
  • FIGS.38A-38D The flexibility of switch-II implies the S-IIP should still be accessible even in the GTP state.
  • sequences are as follows, from top to bottom: YKLVVVGAGGVGKSAL (SEQ ID NO:7), KLVVVGAGGVGKSAL (SEQ ID NO:8), VVVGAGGVGKSAL (SEQ ID NO:9),
  • VVVGAGGVGKSALT (SEQ ID NO:10)
  • VVVGAGGVGKSALT (SEQ ID NO:10)
  • VDEYDPTIEDS (SEQ ID NO:16), YDPTIE (SEQ ID NO:17), YDPTIED (SEQ ID NO:18), YDPTIEDS (SEQ ID NO:19), DSYRKQVVIDGETCL (SEQ ID NO:20),
  • SYRKQVVIDGETCL (SEQ ID NO:22), YRKQVVIDG (SEQ ID NO:23), YRKQVVIDGET (SEQ ID NO:24), YRKQVVIDGETCL (SEQ ID NO:25), RKQVVIDGETCL (SEQ ID NO:26), LDILDTAGQE (SEQ ID NO:27), LDILDTAGQEE (SEQ ID NO:28), LDILDTAGQEEY (SEQ ID NO:29), DTAGQEE (SEQ ID NO:30), DTAGQEEY (SEQ ID NO:31), DTAGQEEYSA (SEQ ID NO:32), DTAGQEEYSAM (SEQ ID NO:33), YSAMRDQY (SEQ ID NO:34), RDQYCRTGEGF (SEQ ID NO:35), RDQYCRTGEGFL (SEQ ID NO:36), CRTGEGF (SEQ ID NO:37), CRTGEGFL (
  • AARTVESRQAQDL (SEQ ID NO:54), AARTVESRQAQDLARS (SEQ ID NO:55),
  • FIGS.39A-39D SRQAQDL (SEQ ID NO:56), LARSYGIPYIET (SEQ ID NO:57), ARSYGIPYIET (SEQ ID NO:58), ARSYGIPYIETSA (SEQ ID NO:59), ARSYGIPYIETSAKTRQGVEDAF (SEQ ID NO:60), YGIPYIET (SEQ ID NO:61), SAKTRQGVE (SEQ ID NO:62), SAKTRQGVEDA (SEQ ID NO:63), SAKTRQGVEDAF (SEQ ID NO:64), YTLVREIRQH (SEQ ID NO:65), VREIRQH (SEQ ID NO:66). [0056] FIGS.39A-39D.
  • FIG.39B Overlay of 2C07 bound H-Ras(M72C) GppNHp with Ras/Raf-1-RBD structure shows compound disruption of switch-II is likely tolerated.
  • FIG.39C Ras/PI3K- ⁇ structure shows interactions occur between PI3K- ⁇ and both switch regions.
  • FIG.39D Overlay of 2C07 bound H-Ras(M72C) GppNHp with the Ras/PI3K- ⁇ structure shows compound disruption of switch-II is not tolerated with significant clashes resulting between switch-II and PI3K- ⁇ .
  • FIG.40 Raf RBD Pull Down by H-Ras(M72C) GppNHp Pre-labeled With Compound 2,
  • FIGS.34A-34D Like 2C07, electrophile compounds based off the 2C07 fragment do not inhibit Raf RBD binding to activated Ras.
  • alkyl by itself or as part of another substituent, means, unless otherwise stated, a straight (i.e., unbranched) or branched carbon chain (or carbon), or combination thereof, which may be fully saturated, mono- or polyunsaturated and can include mono-, di- and multivalent radicals.
  • the alkyl may include a designated number of carbons (e.g., C 1 -C 10 means one to ten carbons).
  • Alkyl is an uncyclized chain.
  • saturated hydrocarbon radicals include, but are not limited to, groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, isobutyl, sec-butyl, methyl, homologs and isomers of, for example, n-pentyl, n-hexyl, n-heptyl, n-octyl, and the like.
  • An unsaturated alkyl group is one having one or more double bonds or triple bonds.
  • Examples of unsaturated alkyl groups include, but are not limited to, vinyl, 2- propenyl, crotyl, 2-isopentenyl, 2-(butadienyl), 2,4-pentadienyl, 3-(1,4-pentadienyl), ethynyl, 1- and 3-propynyl, 3-butynyl, and the higher homologs and isomers.
  • An alkoxy is an alkyl attached to the remainder of the molecule via an oxygen linker (-O-).
  • An alkyl moiety may be an alkenyl moiety.
  • An alkyl moiety may be an alkynyl moiety.
  • An alkyl moiety may be fully saturated.
  • alkenyl may include more than one double bond and/or one or more triple bonds in addition to the one or more double bonds.
  • An alkynyl may include more than one triple bond and/or one or more double bonds in addition to the one or more triple bonds.
  • alkylene by itself or as part of another substituent, means, unless otherwise stated, a divalent radical derived from an alkyl, as exemplified, but not limited by, - CH2CH2CH2CH2-.
  • an alkyl (or alkylene) group will have from 1 to 24 carbon atoms, with those groups having 10 or fewer carbon atoms being preferred herein.
  • A“lower alkyl” or “lower alkylene” is a shorter chain alkyl or alkylene group, generally having eight or fewer carbon atoms.
  • the term“alkenylene,” by itself or as part of another substituent, means, unless otherwise stated, a divalent radical derived from an alkene.
  • the term“heteroalkyl,” by itself or in combination with another term, means, unless otherwise stated, a stable straight or branched chain, or combinations thereof, including at least one carbon atom and at least one heteroatom (e.g., O, N, P, Si, and S, and wherein the nitrogen and sulfur atoms may optionally be oxidized, and the nitrogen heteroatom may optionally be quaternized).
  • heteroatom(s) e.g., N, S, Si, or P
  • the heteroatom(s) may be placed at any interior position of the heteroalkyl group or at the position at which the alkyl group is attached to the remainder of the molecule.
  • Heteroalkyl is an uncyclized chain.
  • Up to two or three heteroatoms may be consecutive, such as, for example, -CH2-NH-OCH3 and -CH2-O-Si(CH3)3.
  • a heteroalkyl moiety may include one heteroatom (e.g., O, N, S, Si, or P).
  • a heteroalkyl moiety may include two optionally different heteroatoms (e.g., O, N, S, Si, or P).
  • a heteroalkyl moiety may include three optionally different heteroatoms (e.g., O, N, S, Si, or P).
  • a heteroalkyl moiety may include four optionally different heteroatoms (e.g., O, N, S, Si, or P).
  • a heteroalkyl moiety may include five optionally different heteroatoms (e.g., O, N, S, Si, or P).
  • heteroalkyl moiety may include up to 8 optionally different heteroatoms (e.g., O, N, S, Si, or P).
  • heteroalkylene by itself or as part of another substituent, means, unless otherwise stated, a divalent radical derived from heteroalkyl, as exemplified, but not limited by, -CH 2 -CH 2 -S-CH 2 -CH 2 - and -CH 2 -S-CH 2 -CH 2 -NH-CH 2 -.
  • heteroatoms can also occupy either or both of the chain termini (e.g., alkyleneoxy,
  • heteroalkyl groups include those groups that are attached to the remainder of the molecule through a heteroatom, such as - C(O)R', -C(O)NR', -NR'R'', -OR', -SR', and/or -SO 2 R'.
  • heteroalkyl is recited, followed by recitations of specific heteroalkyl groups, such as -NR'R'' or the like, it will be understood that the terms heteroalkyl and -NR'R'' are not redundant or mutually exclusive. Rather, the specific heteroalkyl groups are recited to add clarity. Thus, the term“heteroalkyl” should not be interpreted herein as excluding specific heteroalkyl groups, such as -NR'R'' or the like. [0064]
  • a heterocycloalkyl a heteroatom can occupy the position at which the heterocycle is attached to the remainder of the molecule.
  • a cycloalkyl is a spirocyclic cycloalkyl, wherein the spirocyclic rings are cycloalkyl rings.
  • a cycloalkyl is a fused ring cycloalkyl, wherein the fused rings are cycloalkyl rings.
  • a cycloalkyl is a bridged ring cycloalkyl, wherein the bridged rings are cycloalkyl rings.
  • a cycloalkyl is monocyclic.
  • a cycloalkyl is two rings. In embodiments, a cycloalkyl is three rings. In embodiments, a cycloalkyl is four rings. In embodiments, a cycloalkyl is five rings. In embodiments, a cycloalkyl is polycyclic. In embodiments, a heterocycloalkyl is a spirocyclic heterocycloalkyl, wherein the spirocyclic rings are one or more heterocycloalkyl rings and optionally one or more cycloalkyl rings.
  • a heterocycloalkyl is a fused ring heterocycloalkyl, wherein the fused rings are one or more heterocycloalkyl rings and optionally one or more cycloalkyl rings.
  • a heterocycloalkyl is a bridged ring heterocycloalkyl, wherein the bridged rings are one or more heterocycloalkyl rings and optionally one or more cycloalkyl rings.
  • the rings of a spirocyclic, fused ring, or bridged ring heterocycloalkyl are heterocyclic rings.
  • a heterocycloalkyl is monocyclic. In embodiments, a heterocycloalkyl is two rings. In embodiments, a heterocycloalkyl is three rings. In embodiments, a heterocycloalkyl is four rings. In embodiments, a heterocycloalkyl is five rings. In embodiments, a
  • heterocycloalkyl is polycyclic.
  • cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 1-cyclohexenyl, 3-cyclohexenyl, cycloheptyl, and the like.
  • heterocycloalkyl examples include, but are not limited to, 1-(1,2,5,6- tetrahydropyridyl), 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-morpholinyl, 3-morpholinyl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydrothien-2-yl, tetrahydrothien-3-yl, 1- piperazinyl, 2-piperazinyl, and the like.
  • A“cycloalkylene” and a“heterocycloalkylene,” alone or as part of another substituent, means a divalent radical derived from a cycloalkyl and
  • halo or“halogen,” by themselves or as part of another substituent, mean, unless otherwise stated, a fluorine, chlorine, bromine, or iodine atom. Additionally, terms such as “haloalkyl” are meant to include monohaloalkyl and polyhaloalkyl.
  • halo(C1-C4)alkyl includes, but is not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, 2,2,2-trifluoroethyl, 4-chlorobutyl, 3-bromopropyl, and the like.
  • acyl means, unless otherwise stated, -C(O)R where R is a substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
  • aryl means, unless otherwise stated, a polyunsaturated, aromatic, hydrocarbon substituent, which can be a single ring or multiple rings (preferably from 1 to 3 rings) that are fused together (i.e., a fused ring aryl) or linked covalently.
  • a fused ring aryl refers to multiple rings fused together wherein at least one of the fused rings is an aryl ring.
  • heteroaryl refers to aryl groups (or rings) that contain at least one heteroatom such as N, O, or S, wherein the nitrogen and sulfur atoms are optionally oxidized, and the nitrogen atom(s) are optionally quaternized.
  • heteroaryl includes fused ring heteroaryl groups (i.e., multiple rings fused together wherein at least one of the fused rings is a heteroaromatic ring).
  • a 5,6-fused ring heteroarylene refers to two rings fused together, wherein one ring has 5 members and the other ring has 6 members, and wherein at least one ring is a heteroaryl ring.
  • a 6,6-fused ring heteroarylene refers to two rings fused together, wherein one ring has 6 members and the other ring has 6 members, and wherein at least one ring is a heteroaryl ring.
  • a 6,5- fused ring heteroarylene refers to two rings fused together, wherein one ring has 6 members and the other ring has 5 members, and wherein at least one ring is a heteroaryl ring.
  • a heteroaryl group can be attached to the remainder of the molecule through a carbon or heteroatom.
  • an aryl is a fused ring aryl, wherein the fused rings are one or more aryl rings and optionally one or more cycloalkyl and/or heterocycloalkyl rings.
  • an aryl is a bridged ring aryl, wherein the bridged rings are one or more aryl rings and optionally one or more cycloalkyl and/or heterocycloalkyl rings.
  • the rings of a fused ring aryl or bridged ring aryl are aryl rings.
  • an aryl is monocyclic.
  • an aryl is two rings.
  • an aryl is three rings.
  • an aryl is four rings.
  • an aryl is five rings.
  • an aryl is polycyclic.
  • a heteroaryl is a fused ring heteroaryl, wherein the fused rings are one or more heteroaryl rings and optionally one or more cycloalkyl, heterocycloalkyl, and/or aryl rings.
  • a heteroaryl is a bridged ring heteroaryl, wherein the bridged rings are one or more heteroaryl rings and optionally one or more cycloalkyl, heterocycloalkyl, and/or aryl rings.
  • the rings of a fused ring heteroaryl or bridged ring heteroaryl are heteroaryl rings.
  • a heteroaryl is monocyclic.
  • a heteroaryl is two rings.
  • a heteroaryl is three rings.
  • a heteroaryl is four rings.
  • a heteroaryl is five rings.
  • a heteroaryl is polycyclic.
  • Non-limiting examples of aryl and heteroaryl groups include phenyl, naphthyl, pyrrolyl, pyrazolyl, pyridazinyl, triazinyl, pyrimidinyl, imidazolyl, pyrazinyl, purinyl, oxazolyl, isoxazolyl, thiazolyl, furyl, thienyl, pyridyl, pyrimidyl, benzothiazolyl, benzoxazoyl benzimidazolyl, benzofuran, isobenzofuranyl, indolyl, isoindolyl, benzothiophenyl, isoquinolyl, quinoxalinyl, quinolyl, 1-naphthyl, 2-naphthyl, 4-biphenyl, 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 3-pyrazolyl, 2-imidazolyl, 4-imidazo
  • Substituents for each of the above noted aryl and heteroaryl ring systems are selected from the group of acceptable substituents described below.
  • An“arylene” and a“heteroarylene,” alone or as part of another substituent, mean a divalent radical derived from an aryl and heteroaryl, respectively.
  • a heteroaryl group substituent may be -O- bonded to a ring heteroatom nitrogen.
  • Spirocyclic rings are two or more rings wherein adjacent rings are attached through a single atom. The individual rings within spirocyclic rings may be identical or different.
  • Individual rings in spirocyclic rings may be substituted or unsubstituted and may have different substituents from other individual rings within a set of spirocyclic rings. Possible substituents for individual rings within spirocyclic rings are the possible substituents for the same ring when not part of spirocyclic rings (e.g. substituents for cycloalkyl or heterocycloalkyl rings).
  • Spirocylic rings may be substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heterocycloalkylene and individual rings within a spirocyclic ring group may be any of the immediately previous list, including having all rings of one type (e.g. all rings being substituted heterocycloalkylene wherein each ring may be the same or different substituted heterocycloalkylene).
  • heterocyclic spirocyclic rings means a spirocyclic rings wherein at least one ring is a heterocyclic ring and wherein each ring may be a different ring.
  • substituted spirocyclic rings means that at least one ring is substituted and each substituent may optionally be different.
  • alkylarylene as an arylene moiety covalently bonded to an alkylene moiety (also referred to herein as an alkylene linker).
  • the alkylarylene group has the formula: .
  • An alkylarylene moiety may be substituted (e.g. with a substituent group) on the alkylene moiety or the arylene linker (e.g.
  • alkylarylene is unsubstituted.
  • R, R', R'', R'', and R''' each preferably independently refer to hydrogen, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl (e.g., aryl substituted with 1-3 halogens), substituted or unsubstituted heteroaryl, substituted or
  • each of the R groups is independently selected as are each R', R'', R''', and R''' group when more than one of these groups is present.
  • R' and R'' are attached to the same nitrogen atom, they can be combined with the nitrogen atom to form a 4-, 5-, 6-, or 7-membered ring.
  • -NR'R'' includes, but is not limited to, 1-pyrrolidinyl and 4-morpholinyl.
  • alkyl is meant to include groups including carbon atoms bound to groups other than hydrogen groups, such as haloalkyl (e.g., -CF 3 and -CH 2 CF 3 ) and acyl (e.g., -C(O)CH 3 , -C(O)CF 3 , -C(O)CH 2 OCH 3 , and the like).
  • haloalkyl e.g., -CF 3 and -CH 2 CF 3
  • acyl e.g., -C(O)CH 3 , -C(O)CF 3 , -C(O)CH 2 OCH 3 , and the like.
  • each of the R groups is independently selected as are each R', R'', R'', and R''' groups when more than one of these groups is present.
  • Substituents for rings e.g. cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkylene, heterocycloalkylene, arylene, or heteroarylene
  • substituents on the ring may be depicted as substituents on the ring rather than on a specific atom of a ring (commonly referred to as a floating substituent).
  • the substituent may be attached to any of the ring atoms (obeying the rules of chemical valency) and in the case of fused rings, bridged rings, or spirocyclic rings, a substituent depicted as associated with one member of the fused rings, bridged rings, or spirocyclic rings (a floating substituent on a single ring), may be a substituent on any of the fused rings, bridged rings, or spirocyclic rings (a floating substituent on multiple rings).
  • the multiple substituents may be on the same atom, same ring, different atoms, different fused rings, different bridged rings, or different spirocyclic rings, and each substituent may optionally be different.
  • a point of attachment of a ring to the remainder of a molecule is not limited to a single atom (a floating substituent)
  • the attachment point may be any atom of the ring and in the case of fused rings, bridged rings, or spirocyclic rings, any atom of any of the fused rings, bridged rings, or spirocyclic rings while obeying the rules of chemical valency.
  • a ring, fused rings, bridged rings, or spirocyclic rings contain one or more ring heteroatoms and the ring, fused rings, bridged rings, or spirocyclic rings are shown with one or more floating substituents (including, but not limited to, points of attachment to the remainder of the molecule), the floating substituents may be bonded to the heteroatoms.
  • the ring heteroatoms are shown bound to one or more hydrogens (e.g. a ring nitrogen with two bonds to ring atoms and a third bond to a hydrogen) in the structure or formula with the floating substituent, when the heteroatom is bonded to the floating substituent, the substituent will be understood to replace the hydrogen, while obeying the rules of chemical valency.
  • Two or more substituents may optionally be joined to form aryl, heteroaryl, cycloalkyl, or heterocycloalkyl groups.
  • Such so-called ring-forming substituents are typically, though not necessarily, found attached to a cyclic base structure.
  • the ring-forming substituents are attached to adjacent members of the base structure.
  • two ring-forming substituents attached to adjacent members of a cyclic base structure create a fused ring structure.
  • the ring-forming substituents are attached to a single member of the base structure.
  • two ring-forming substituents attached to a single member of a cyclic base structure create a spirocyclic structure.
  • the ring- forming substituents are attached to non-adjacent members of the base structure and form a bridged ring structure.
  • Two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally form a ring of the formula -T-C(O)-(CRR') q -U-, wherein T and U are independently -NR-, -O-, - CRR'-, or a single bond, and q is an integer of from 0 to 3.
  • two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula -A-(CH 2 ) r -B-, wherein A and B are independently -CRR'-, -O-, -NR-, -S-, -S(O) -, - S(O)2-, -S(O)2NR'-, or a single bond, and r is an integer of from 1 to 4.
  • One of the single bonds of the new ring so formed may optionally be replaced with a double bond.
  • two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula -(CRR') s -X'- (C''R''R'') d -, where s and d are independently integers of from 0 to 3, and X' is -O-, -NR'-, -S-, -S(O)-, -S(O)2-, or -S(O)2NR'-.
  • R, R', R'', and R''' are preferably independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl.
  • the terms“heteroatom” or“ring heteroatom” are meant to include oxygen (O), nitrogen (N), sulfur (S), phosphorus (P), and silicon (Si).
  • A“substituent group,” as used herein, means a group selected from the following moieties: (A) oxo,
  • halogen -CCl3, -CBr3, -CF3, -CI3,-CN, -OH, -NH2, -COOH, -CONH2, -NO2, -SH, -SO3H , -SO 4 H, -SO 2 NH 2 , ⁇ NHNH 2 , ⁇ ONH 2 , ⁇ NHC(O)NHNH 2 , -NHC(O)NH 2 , -NHSO 2 H, -NHC(O)H, -NHC(O)OH, -NHOH, -OCCl 3 , -OCF 3 , -OCBr 3 , -OCI 3 ,-OCHCl 2 , -OCHBr 2 , -OCHI 2 , -OCHF 2 , unsubstituted alkyl (e.g., C 1 -C 8 alkyl, C 1 -C 6 alkyl, or C 1 -C 4 alkyl), unsubstituted heteroalkyl (e
  • halogen -CCl 3 , -CBr 3 , -CF 3 , -CI 3 ,-CN, -OH, -NH 2 , -COOH, -CONH 2 , -NO 2 , -SH, -SO 3 H, -SO4H, -SO2NH2, ⁇ NHNH2, ⁇ ONH2, ⁇ NHC(O)NHNH2, ⁇ NHC(O)NH2, -NHSO2H, -NHC(O)H, -NHC(O)OH, -NHOH, -OCCl3, -OCF3, -OCBr3, -OCI3,-OCHCl2, -OCHBr 2, -OCHI2, -OCHF2, unsubstituted alkyl (e.g., C1-C8 alkyl, C1-C6 alkyl, or C1-C4 alkyl), unsubstituted heteroalkyl (e.g., 2 to 8 membered heteroalkyl, 2 to 6
  • halogen -CCl 3 , -CBr 3 , -CF 3 , -CI 3 ,-CN, -OH, -NH 2 , -COOH, -CONH 2 , -NO 2 , -SH, -SO3H, -SO4H, -SO2NH2, ⁇ NHNH2, ⁇ ONH2, ⁇ NHC(O)NHNH2, ⁇ NHC(O)NH2, -NHSO 2 H, -NHC(O)H, -NHC(O)OH, -NHOH, -OCCl 3 , -OCF 3 , -OCBr 3 , -OCI 3 ,-OCH Cl2, -OCHBr2, -OCHI2, -OCHF2, unsubstituted alkyl (e.g., C1-C8 alkyl, C1-C6 alkyl, or C 1 -C 4 alkyl), unsubstituted heteroalkyl (e.g., 2 to 8 membere
  • unsubstituted alkyl e.g., C 1 -C 8 alkyl, C 1 -C 6 alkyl, or C 1 -C 4 alkyl
  • unsubstituted heteroalkyl e.g., 2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl
  • unsubstituted cycloalkyl e.g., C3-C8 cycloalkyl, C3-C6 cycloalkyl, or C5-C6 cycloalkyl
  • unsubstituted heterocycloalkyl e.g., 3 to 8 membered heterocycloalkyl, 3 to 6 membered heterocycloalkyl, or 5 to 6 membered heterocycloalkyl
  • unsubstituted aryl e.g., C6-C10 aryl, C10 aryl, or
  • A“size-limited substituent” or“ size-limited substituent group,” as used herein, means a group selected from all of the substituents described above for a“substituent group,” wherein each substituted or unsubstituted alkyl is a substituted or unsubstituted C 1 -C 20 alkyl, each substituted or unsubstituted heteroalkyl is a substituted or unsubstituted 2 to 20 membered heteroalkyl, each substituted or unsubstituted cycloalkyl is a substituted or unsubstituted C3-C8 cycloalkyl, each substituted or unsubstituted heterocycloalkyl is a substituted or unsubstituted 3 to 8 membered heterocycloalkyl, each substituted or unsubstituted aryl is a substituted or unsubstituted C6-C10 aryl, and each substituted or unsubstituted heteroaryl is
  • A“lower substituent” or“ lower substituent group,” as used herein, means a group selected from all of the substituents described above for a“substituent group,” wherein each substituted or unsubstituted alkyl is a substituted or unsubstituted C1-C8 alkyl, each substituted or unsubstituted heteroalkyl is a substituted or unsubstituted 2 to 8 membered heteroalkyl, each substituted or unsubstituted cycloalkyl is a substituted or unsubstituted C 3 -C 7 cycloalkyl, each substituted or unsubstituted heterocycloalkyl is a substituted or unsubstituted 3 to 7 membered heterocycloalkyl, each substituted or unsubstituted aryl is a substituted or unsubstituted C6-C10 aryl, and each substituted or unsubstituted heteroaryl is a substituted or un
  • each substituted group described in the compounds herein is substituted with at least one substituent group. More specifically, in some embodiments, each substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, substituted heteroaryl, substituted alkylene, substituted heteroalkylene, substituted cycloalkylene, substituted heterocycloalkylene, substituted arylene, and/or substituted heteroarylene described in the compounds herein are substituted with at least one substituent group. In other embodiments, at least one or all of these groups are substituted with at least one size-limited substituent group.
  • each substituted or unsubstituted alkyl may be a substituted or unsubstituted C 1 -C 20 alkyl
  • each substituted or unsubstituted heteroalkyl is a substituted or unsubstituted 2 to 20 membered heteroalkyl
  • each substituted or unsubstituted cycloalkyl is a substituted or unsubstituted C3-C8 cycloalkyl
  • each substituted or unsubstituted heterocycloalkyl is a substituted or unsubstituted 3 to 8 membered heterocycloalkyl
  • each substituted or unsubstituted aryl is a substituted or unsubstituted C6-C10 aryl
  • each substituted or unsubstituted heteroaryl is a substituted or unsubstituted or unsubstituted
  • each substituted or unsubstituted alkylene is a substituted or unsubstituted C 1 -C 20 alkylene
  • each substituted or unsubstituted heteroalkylene is a substituted or unsubstituted 2 to 20 membered heteroalkylene
  • each substituted or unsubstituted cycloalkylene is a substituted or unsubstituted C3-C8 cycloalkylene
  • each substituted or unsubstituted heterocycloalkylene is a substituted or unsubstituted 3 to 8 membered heterocycloalkylene
  • each substituted or unsubstituted arylene is a substituted or unsubstituted C6-C10 arylene
  • each substituted or unsubstituted heteroarylene is a substituted or unsubstituted 5 to 10 membered heteroarylene.
  • each substituted or unsubstituted alkyl is a substituted or unsubstituted C1-C8 alkyl
  • each substituted or unsubstituted heteroalkyl is a substituted or unsubstituted 2 to 8 membered heteroalkyl
  • each substituted or unsubstituted cycloalkyl is a substituted or unsubstituted C 3 -C 7 cycloalkyl
  • each substituted or unsubstituted heterocycloalkyl is a substituted or unsubstituted 3 to 7 membered heterocycloalkyl
  • each substituted or unsubstituted aryl is a substituted or unsubstituted C6-C10 aryl
  • each substituted or unsubstituted heteroaryl is a substituted or unsubstituted 5 to 9 membered heteroaryl.
  • each substituted or unsubstituted alkylene is a substituted or unsubstituted C1-C8 alkylene
  • each substituted or unsubstituted heteroalkylene is a substituted or unsubstituted 2 to 8 membered heteroalkylene
  • each substituted or unsubstituted cycloalkylene is a substituted or unsubstituted C3-C7 cycloalkylene
  • each substituted or unsubstituted heterocycloalkylene is a substituted or unsubstituted 3 to 7 membered heterocycloalkylene
  • each substituted or unsubstituted arylene is a substituted or unsubstituted C 6 -C 10 arylene
  • each substituted or unsubstituted heteroarylene is a substituted or unsubstituted 5 to 9 membered heteroarylene.
  • the compound is a chemical species set forth in the Examples section, figures, or tables below.
  • Certain compounds of the present disclosure possess asymmetric carbon atoms (optical or chiral centers) or double bonds; the enantiomers, racemates, diastereomers, tautomers, geometric isomers, stereoisometric forms that may be defined, in terms of absolute
  • the term“isomers” refers to compounds having the same number and kind of atoms, and hence the same molecular weight, but differing in respect to the structural arrangement or configuration of the atoms.
  • the term“tautomer,” as used herein, refers to one of two or more structural isomers which exist in equilibrium and which are readily converted from one isomeric form to another. [0089] It will be apparent to one skilled in the art that certain compounds of this disclosure may exist in tautomeric forms, all such tautomeric forms of the compounds being within the scope of the disclosure.
  • structures depicted herein are also meant to include all stereochemical forms of the structure; i.e., the R and S configurations for each asymmetric center. Therefore, single stereochemical isomers as well as enantiomeric and diastereomeric mixtures of the present compounds are within the scope of the disclosure.
  • structures depicted herein are also meant to include compounds which differ only in the presence of one or more isotopically enriched atoms. For example, compounds having the present structures except for the replacement of a hydrogen by a deuterium or tritium, or the replacement of a carbon by 13 C- or 14 C-enriched carbon are within the scope of this disclosure.
  • the compounds of the present disclosure may also contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds.
  • the compounds may be radiolabeled with radioactive isotopes, such as for example tritium ( 3 H), iodine-125 ( 125 I), or carbon-14 ( 14 C). All isotopic variations of the compounds of the present disclosure, whether radioactive or not, are encompassed within the scope of the present disclosure.
  • radioactive isotopes such as for example tritium ( 3 H), iodine-125 ( 125 I), or carbon-14 ( 14 C). All isotopic variations of the compounds of the present disclosure, whether radioactive or not, are encompassed within the scope of the present disclosure.
  • each member of the Markush group should be considered separately, thereby comprising another embodiment, and the Markush group is not to be read as a single unit.
  • “Analog,” or“analogue” is used in accordance with its plain ordinary meaning within Chemistry and Biology and refers to a chemical compound that is structurally similar to another compound (i.e., a so-called“reference” compound) but differs in composition, e.g., in the replacement of one atom by an atom of a different element, or in the presence of a particular functional group, or the replacement of one functional group by another functional group, or the absolute stereochemistry of one or more chiral centers of the reference compound.
  • an analog is a compound that is similar or comparable in function and appearance but not in structure or origin to a reference compound.
  • a or “an,” as used in herein means one or more.
  • substituted with a[n] means the specified group may be substituted with one or more of any or all of the named substituents.
  • a group such as an alkyl or heteroaryl group
  • the group may contain one or more unsubstituted C 1 -C 20 alkyls, and/or one or more unsubstituted 2 to 20 membered heteroalkyls.
  • a moiety is substituted (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, substituted heteroaryl, substituted alkylene, substituted heteroalkylene, substituted cycloalkylene, substituted heterocycloalkylene, substituted arylene, and/or substituted heteroarylene), the moiety is substituted with at least one substituent (e.g., a substituent group, a size-limited substituent group, or lower substituent group) and each substituent is optionally different.
  • substituent e.g., a substituent group, a size-limited substituent group, or lower substituent group
  • one or more moieties of a compound are substituted (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted
  • the one or more moieties are each independently substituted with at least one substituent (e.g., a substituent group, a size-limited substituent group, or lower substituent group) and each substituents on each of the one or more moieties is optionally different. Additionally, where multiple substituents are present on a moiety, each substituent may be optionally differently.
  • R-substituted where a moiety is substituted with an R substituent, the moiety may be referred to as“R-substituted.” Where a moiety is R-substituted, the moiety is substituted with at least one R substituent and each R substituent is optionally different. Where a particular R group is present in the description of a chemical genus, a Roman alphabetic symbol or number may be used to distinguish each appearance of that particular R group. For example, where multiple R 13 substituents are present, each R 13 substituent may be distinguished as R 13A , R 13B , R 13C , R 13D , etc., wherein each of R 13A , R 13B , R 13C , R 13D , etc.
  • A“covalent cysteine modifier moiety” as used herein refers to a subtituent that is capable of reacting with the sulfhydryl functional group of a cysteine amino acid (e.g.
  • A“detectable moiety” as used herein refers to a moiety that can be covalently or noncovalently attached to a compound or biomolecule that can be detected for instance, using techniques known in the art.
  • the detectable moiety is covalently attached.
  • the detectable moiety may provide for imaging of the attached compound or biomolecule.
  • the detectable moiety may indicate the contacting between two compounds.
  • Exemplary detectable moieties are fluorophores, antibodies, reactive dies, radio-labeled moieties, magnetic contrast agents, and quantum dots.
  • Exemplary fluorophores include fluorescein, rhodamine, GFP, coumarin, FITC, Alexa fluor, Cy3, Cy5, BODIPY, and cyanine dyes.
  • Exemplary radionuclides include Fluorine-18, Gallium-68, and Copper-64.
  • Exemplary magnetic contrast agents include gadolinium, iron oxide and iron platinum, and manganese.
  • a group may be substituted by one or more of a number of substituents
  • substitutions are selected so as to comply with principles of chemical bonding and to give compounds which are not inherently unstable and/or would be known to one of ordinary skill in the art as likely to be unstable under ambient conditions, such as aqueous, neutral, and several known physiological conditions.
  • a heterocycloalkyl or heteroaryl is attached to the remainder of the molecule via a ring heteroatom in compliance with principles of chemical bonding known to those skilled in the art thereby avoiding inherently unstable compounds.
  • salts are meant to include salts of the active compounds that are prepared with relatively nontoxic acids or bases, depending on the particular substituents found on the compounds described herein.
  • base addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired base, either neat or in a suitable inert solvent.
  • pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic amino, or magnesium salt, or a similar salt.
  • acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired acid, either neat or in a suitable inert solvent.
  • pharmaceutically acceptable acid addition salts include those derived from inorganic acids like hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric,
  • salts of amino acids such as arginate and the like, and salts of organic acids like glucuronic or galactunoric acids and the like (see, for example, Berge et al., “Pharmaceutical Salts”, Journal of Pharmaceutical Science, 1977, 66, 1-19).
  • Certain specific compounds of the present disclosure contain both basic and acidic functionalities that allow the compounds to be converted into either base or acid addition salts.
  • the compounds of the present disclosure may exist as salts, such as with pharmaceutically acceptable acids.
  • the present disclosure includes such salts.
  • Non-limiting examples of such salts include hydrochlorides, hydrobromides, phosphates, sulfates,
  • methanesulfonates nitrates, maleates, acetates, citrates, fumarates, proprionates, tartrates (e.g., (+)-tartrates, (-)-tartrates, or mixtures thereof including racemic mixtures), succinates, benzoates, and salts with amino acids such as glutamic acid, and quaternary ammonium salts (e.g. methyl iodide, ethyl iodide, and the like). These salts may be prepared by methods known to those skilled in the art. [0102] The neutral forms of the compounds are preferably regenerated by contacting the salt with a base or acid and isolating the parent compound in the conventional manner.
  • the parent form of the compound may differ from the various salt forms in certain physical properties, such as solubility in polar solvents.
  • the present disclosure provides compounds, which are in a prodrug form.
  • Prodrugs of the compounds described herein are those compounds that readily undergo chemical changes under physiological conditions to provide the compounds of the present disclosure.
  • Prodrugs of the compounds described herein may be converted in vivo after administration.
  • prodrugs can be converted to the compounds of the present disclosure by chemical or biochemical methods in an ex vivo environment, such as, for example, when contacted with a suitable enzyme or chemical reagent.
  • Certain compounds of the present disclosure can exist in unsolvated forms as well as solvated forms, including hydrated forms.
  • solvated forms are equivalent to unsolvated forms and are encompassed within the scope of the present disclosure.
  • Certain compounds of the present disclosure may exist in multiple crystalline or amorphous forms. In general, all physical forms are equivalent for the uses contemplated by the present disclosure and are intended to be within the scope of the present disclosure.
  • “Pharmaceutically acceptable excipient” and“pharmaceutically acceptable carrier” refer to a substance that aids the administration of an active agent to and absorption by a subject and can be included in the compositions of the present disclosure without causing a significant adverse toxicological effect on the patient.
  • Non-limiting examples of pharmaceutically acceptable excipients include water, NaCl, normal saline solutions, lactated Ringer’s, normal sucrose, normal glucose, binders, fillers, disintegrants, lubricants, coatings, sweeteners, flavors, salt solutions (such as Ringer's solution), alcohols, oils, gelatins, carbohydrates such as lactose, amylose or starch, fatty acid esters, hydroxymethycellulose, polyvinyl pyrrolidine, and colors, and the like.
  • Such preparations can be sterilized and, if desired, mixed with auxiliary agents such as lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, coloring, and/or aromatic substances and the like that do not deleteriously react with the compounds of the disclosure.
  • auxiliary agents such as lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, coloring, and/or aromatic substances and the like that do not deleteriously react with the compounds of the disclosure.
  • preparation is intended to include the formulation of the active compound with encapsulating material as a carrier providing a capsule in which the active component with or without other carriers, is surrounded by a carrier, which is thus in association with it.
  • A“Ras modulator” refers to a compound (e.g. a compound described herein) that modulates the activity of Ras (e.g., human Ras (a human Ras modulator), human K-Ras (a human K-Ras modulator), human H-Ras (a human H-Ras modulator)) when compared to a control, such as absence of the compound or a compound with known inactivity.
  • A“Ras inhibitor” refers to a compound (e.g.
  • a compound described herein that reduces the activity of Ras (e.g., human Ras (a human Ras inhibitor), human K-Ras (a human K-Ras inhibitor), human H-Ras (a human H-Ras inhibitor)) when compared to a control, such as absence of the compound or a compound with known inactivity.
  • Ras e.g., human Ras (a human Ras inhibitor), human K-Ras (a human K-Ras inhibitor), human H-Ras (a human H-Ras inhibitor)
  • a control such as absence of the compound or a compound with known inactivity.
  • a polypeptide, or a cell is“recombinant” when it is artificial or engineered, or derived from or contains an artificial or engineered protein or nucleic acid (e.g. non-natural or not wild type).
  • a polynucleotide that is inserted into a vector or any other heterologous location, e.g., in a genome of a recombinant organism, such that it is not associated with nucleotide sequences that normally flank the polynucleotide as it is found in nature is a recombinant polynucleotide.
  • a protein expressed in vitro or in vivo from a recombinant polynucleotide is an example of a recombinant polypeptide.
  • a polynucleotide sequence that does not appear in nature for example a variant of a naturally occurring gene, is recombinant.
  • an amino acid residue in a protein "corresponds" to a given residue when it occupies the same essential structural position within the protein as the given residue.
  • a selected residue in a selected protein corresponds to Cys12 of human Ras (e.g., K-Ras or H-Ras) protein when the selected residue occupies the same essential spatial or other structural relationship as Cys12 in human Ras (e.g., K-Ras or H-Ras) protein.
  • the position in the aligned selected protein aligning with Cys12 is said to correspond to Cys12.
  • a three dimensional structural alignment can also be used, e.g., where the structure of the selected protein is aligned for maximum correspondence with the human K-Ras protein and the overall structures compared.
  • an amino acid that occupies the same essential position as Cys12 in the structural model is said to correspond to the Cys12 residue.
  • a selected residue in a selected protein corresponds to Cys13 of human Ras (e.g., K-Ras or H-Ras) protein when the selected residue occupies the same essential spatial or other structural relationship as Cys13 in human Ras (e.g., K-Ras or H- Ras) protein.
  • a selected protein is aligned for maximum homology with the human Ras (e.g., K-Ras or H-Ras) protein
  • the position in the aligned selected protein aligning with Cys13 is said to correspond to Cys13.
  • a three dimensional structural alignment can also be used, e.g., where the structure of the selected protein is aligned for maximum correspondence with the human K-Ras protein and the overall structures compared.
  • an amino acid that occupies the same essential position as Cys13 in the structural model is said to correspond to the Cys13 residue.
  • the term“activation”,“activate”,“activating” and the like in reference to a protein refers to conversion of a protein into a biologically active derivative from an initial inactive or deactivated state.
  • the term“inhibition”,“inhibit”,“inhibiting” and the like in reference to a protein-inhibitor interaction means negatively affecting (e.g. decreasing) the activity or function of the protein relative to the activity or function of the protein in the absence of the inhibitor.
  • inhibition means negatively affecting (e.g. decreasing) the concentration or levels of the protein relative to the concentration or level of the protein in the absence of the inhibitor.
  • inhibition refers to reduction of a disease or symptoms of disease.
  • inhibition refers to a reduction in the activity of a particular protein target.
  • inhibition includes, at least in part, partially or totally blocking stimulation, decreasing, preventing, or delaying activation, or inactivating, desensitizing, or down-regulating signal transduction or enzymatic activity or the amount of a protein.
  • inhibition refers to a reduction of activity of a target protein resulting from a direct interaction (e.g. an inhibitor contacts the target protein).
  • inhibition refers to a reduction of activity of a target protein from an indirect interaction (e.g. an inhibitor contacts a protein that activates the target protein, thereby preventing target protein activation).
  • A“Ras inhibitor” e.g., human K-Ras inhibitor or human H-Ras inhibitor
  • is a compound that negatively affects e.g.
  • Ras e.g., human K-Ras or human H-Ras
  • Ras e.g., human K-Ras or human H-Ras
  • the term "expression” includes any step involved in the production of the polypeptide including, but not limited to, transcription, post-transcriptional modification, translation, post- translational modification, and secretion. Expression can be detected using conventional techniques for detecting protein (e.g., ELISA, Western blotting, flow cytometry,
  • the terms“treating”, or“treatment” refers to any indicia of success in the therapy or amelioration of an injury, disease, pathology or condition, including any objective or subjective parameter such as abatement; remission; diminishing of symptoms or making the injury, pathology or condition more tolerable to the patient; slowing in the rate of degeneration or decline; making the final point of degeneration less debilitating; improving a patient’s physical or mental well-being.
  • the treatment or amelioration of symptoms can be based on objective or subjective parameters; including the results of a physical examination, neuropsychiatric exams, and/or a psychiatric evaluation.
  • treating may include prevention of an injury, pathology, condition, or disease.
  • treating is preventing.
  • treating does not include preventing.
  • “Patient”,“subject”, or“subject in need thereof” refers to a living organism suffering from or prone to a disease or condition that can be treated by administration of a pharmaceutical composition as provided herein. Non-limiting examples include humans, other mammals, bovines, rats, mice, dogs, monkeys, goat, sheep, cows, deer, and other non-mammalian animals. In some embodiments, a patient is human.
  • administering means oral administration, administration as a suppository, topical contact, intravenous, intraperitoneal, intramuscular, intralesional, intrathecal, intranasal or subcutaneous administration, or the implantation of a slow-release device, e.g., a mini-osmotic pump, to a subject.
  • Administration is by any route, including parenteral and transmucosal (e.g., buccal, sublingual, palatal, gingival, nasal, vaginal, rectal, or transdermal) compatible with the preparation.
  • Parenteral administration includes, e.g., intravenous, intramuscular, intra-arteriole, intradermal, subcutaneous, intraperitoneal, intraventricular, and intracranial.
  • Other modes of delivery include, but are not limited to, the use of liposomal formulations, intravenous infusion, transdermal patches, etc.
  • "Co-administer” it is meant that a composition described herein is administered at the same time, just prior to, or just after the administration of one or more additional therapies.
  • the compounds of the disclosure can be administered alone or can be coadministered to the patient. Coadministration is meant to include simultaneous or sequential administration of the
  • compositions of the present disclosure can be delivered transdermally, by a topical route, or formulated as applicator sticks, solutions, suspensions, emulsions, gels, creams, ointments, pastes, jellies, paints, powders, and aerosols.
  • Anti-cancer agent or“anti-cancer drug” is used in accordance with its plain ordinary meaning and refers to a composition (e.g. compound, drug, antagonist, inhibitor, modulator) having antineoplastic properties or the ability to inhibit the growth or proliferation of cells.
  • an anti-cancer agent is a chemotherapeutic.
  • an anti- cancer agent is an agent approved by the FDA or similar regulatory agency of a country other than the USA, for treating cancer.
  • anti-cancer agents include, but are not limited to, anti-androgens (e.g., Casodex, Flutamide, MDV3100, or ARN-509), MEK (e.g. MEK1, MEK2, or MEK1 and MEK2) inhibitors (e.g.
  • alkylating agents e.g., XL518, CI-1040, PD035901, selumetinib/ AZD6244, GSK1120212/ trametinib, GDC-0973, ARRY-162, ARRY-300, AZD8330, PD0325901, U0126, PD98059, TAK-733, PD318088, AS703026, BAY 869766), alkylating agents (e.g.,
  • cyclophosphamide ifosfamide, chlorambucil, busulfan, melphalan, mechlorethamine, uramustine, thiotepa, nitrosoureas, nitrogen mustards (e.g., mechloroethamine,
  • cyclophosphamide chlorambucil, meiphalan
  • ethylenimine and methylmelamines e.g., hexamethlymelamine, thiotepa
  • alkyl sulfonates e.g., busulfan
  • nitrosoureas e.g., carmustine, lomusitne, semustine, streptozocin
  • triazenes decarbazine
  • anti-metabolites e.g., 5- azathioprine, leucovorin, capecitabine, fludarabine, gemcitabine, pemetrexed, raltitrexed, folic acid analog (e.g., methotrexate), pyrimidine analogs (e.g., fluorouracil, floxouridine,
  • Cytarabine purine analogs (e.g., mercaptopurine, thioguanine, pentostatin), etc.), plant alkaloids (e.g., vincristine, vinblastine, vinorelbine, vindesine, podophyllotoxin, paclitaxel, docetaxel, etc.), topoisomerase inhibitors (e.g., irinotecan, topotecan, amsacrine, etoposide (VP16), etoposide phosphate, teniposide, etc.), antitumor antibiotics (e.g., doxorubicin, adriamycin, daunorubicin, epirubicin, actinomycin, bleomycin, mitomycin, mitoxantrone, plicamycin, etc.), platinum-based compounds (e.g.
  • cisplatin oxaloplatin, carboplatin
  • anthracenedione e.g., mitoxantrone
  • substituted urea e.g., hydroxyurea
  • methyl hydrazine derivative e.g., procarbazine
  • adrenocortical suppressant e.g., mitotane, aminoglutethimide
  • epipodophyllotoxins e.g., etoposide
  • antibiotics e.g., daunorubicin, doxorubicin, bleomycin
  • enzymes e.g., L-asparaginase
  • inhibitors of mitogen-activated protein kinase signaling e.g.
  • BCR/ABL antagonists beta lactam derivatives; bFGF inhibitor; bicalutamide; camptothecin derivatives; casein kinase inhibitors (ICOS); clomifene analogues; cytarabine dacliximab;
  • dexamethasone dexamethasone; estrogen agonists; estrogen antagonists; etanidazole; etoposide phosphate;
  • exemestane fadrozole; finasteride; fludarabine; fluorodaunorunicin hydrochloride; gadolinium texaphyrin; gallium nitrate; gelatinase inhibitors; gemcitabine; glutathione inhibitors; hepsulfam; immunostimulant peptides; insulin-like growth factor-1 receptor inhibitor; interferon agonists; interferons; interleukins; letrozole; leukemia inhibiting factor; leukocyte alpha interferon;
  • leuprolide+estrogen+progesterone leuprorelin; matrilysin inhibitors; matrix metalloproteinase inhibitors; MIF inhibitor; mifepristone; mismatched double stranded RNA; monoclonal antibody,; mycobacterial cell wall extract; nitric oxide modulators; oxaliplatin; panomifene; pentrozole; phosphatase inhibitors; plasminogen activator inhibitor; platinum complex; platinum compounds; prednisone; proteasome inhibitors; protein A-based immune modulator; protein kinase C inhibitor; protein tyrosine phosphatase inhibitors; purine nucleoside phosphorylase inhibitors; ras farnesyl protein transferase inhibitors; ras inhibitors; ras-GAP inhibitor; ribozymes; signal transduction inhibitors; signal transduction modulators; single chain antigen- binding protein; stem cell inhibitor; stem-cell division inhibitors; stromelysin inhibitor
  • glycosaminoglycans synthetic glycosaminoglycans; tamoxifen methiodide; telomerase inhibitors; thyroid stimulating hormone; translation inhibitors; tyrosine kinase inhibitors; urokinase receptor antagonists;
  • steroids e.g., dexamethasone
  • finasteride aromatase inhibitors
  • gonadotropin-releasing hormone agonists GnRH
  • adrenocorticosteroids e.g., prednisone
  • progestins e.g., hydroxyprogesterone caproate, megestrol acetate
  • estrogens e.g., diethlystilbestrol, ethinyl estradiol
  • antiestrogen e.g., tamoxifen
  • androgens e.g., testosterone propionate, fluoxymesterone
  • antiandrogen e.g., flutamide
  • immunostimulants e.g., Bacillus Calmette-Guérin (BCG), levamisole, interleukin-2, alpha-interferon, etc.
  • monoclonal antibodies e.g., anti-CD20, anti-HER2, anti-CD52, anti- HLA-DR, and anti-VEGF monoclonal antibodies
  • immunotoxins e.g., anti-CD33 monoclonal antibody-calicheamicin conjugate, anti-CD22 monoclonal antibody-pseudomonas exotoxin conjugate, etc.
  • radioimmunotherapy e.g., anti-CD20 monoclonal antibody conjug
  • gefitinib IressaTM
  • erlotinib TarcevaTM
  • cetuximab ErbituxTM
  • lapatinib TykerbTM
  • panitumumab VectibixTM
  • vandetanib CaprelsaTM
  • afatinib/BIBW2992 CI- 1033/canertinib, neratinib/HKI-272, CP-724714, TAK-285, AST-1306, ARRY334543, ARRY- 380, AG-1478, dacomitinib/PF299804, OSI-420/desmethyl erlotinib, AZD8931, AEE788, pelitinib/EKB-569, CUDC-101, WZ8040, WZ4002, WZ3146, AG-490, XL647, PD153035, BMS-599626), sorafenib, imatinib, sunitinib,
  • tomaymycin carboplatin
  • CC-1065 and CC-1065 analogs including amino-CBIs, nitrogen mustards (such as chlorambucil and melphalan), dolastatin and dolastatin analogs (including auristatins: eg. monomethyl auristatin E), anthracycline antibiotics (such as doxorubicin, daunorubicin, etc.), duocarmycins and duocarmycin analogs, enediynes (such as neocarzinostatin and calicheamicins), leptomycin derivaties, maytansinoids and maytansinoid analogs (e.g.
  • A“cell” as used herein, refers to a cell carrying out metabolic or other function sufficient to preserve or replicate its genomic DNA.
  • a cell can be identified by well-known methods in the art including, for example, presence of an intact membrane, staining by a particular dye, ability to produce progeny or, in the case of a gamete, ability to combine with a second gamete to produce a viable offspring.
  • Cells may include prokaryotic and eukaroytic cells.
  • Prokaryotic cells include but are not limited to bacteria.
  • Eukaryotic cells include but are not limited to yeast cells and cells derived from plants and animals, for example mammalian, insect (e.g., spodoptera) and human cells. Cells may be useful when they are naturally nonadherent or have been treated not to adhere to surfaces, for example by trypsinization.
  • the term“signaling pathway” as used herein refers to a series of interactions between cellular and optionally extra-cellular components (e.g.
  • Ras e.g., human K-Ras or human H-Ras
  • a compound as described herein may reduce the interactions between the Ras (e.g., human K-Ras or human H-Ras) protein and effectors or signaling pathway
  • co-administration includes administering one active agent within 0.5, 1, 2, 4, 6, 8, 10, 12, 16, 20, or 24 hours of a second active agent.
  • Co-administration includes administering two active agents simultaneously, approximately simultaneously (e.g., within about 1, 5, 10, 15, 20, or 30 minutes of each other), or sequentially in any order.
  • co-administration can be accomplished by co-formulation, i.e., preparing a single pharmaceutical composition including both active agents.
  • the active agents can be formulated separately.
  • the active and/or adjunctive agents may be linked or conjugated to one another.
  • the compounds described herein can be co-administered with conventional chemotherapeutic agents including alkylating agents (e.g., cyclophosphamide, ifosfamide, chlorambucil, busulfan, melphalan, mechlorethamine, uramustine, thiotepa, nitrosoureas, etc.), anti-metabolites (e.g., 5-fluorouracil, azathioprine, methotrexate, leucovorin, capecitabine, cytarabine, floxuridine, fludarabine, gemcitabine, pemetrexed, raltitrexed, etc.), plant alkaloids (e.g., vincristine, vinblastine, vinorelbine, vindesine, podophyllotoxin, paclitaxel, docetaxel, etc.), topoisomerase inhibitors (e.g., iri
  • alkylating agents e.g
  • the compounds described herein can also be co-administered with conventional hormonal therapeutic agents including, but not limited to, steroids (e.g., dexamethasone), finasteride, aromatase inhibitors, tamoxifen, and gonadotropin-releasing hormone agonists (GnRH) such as goserelin.
  • steroids e.g., dexamethasone
  • finasteride e.g., fen
  • aromatase inhibitors e.g., tamoxifen
  • GnRH gonadotropin-releasing hormone agonists
  • goserelin goserelin.
  • the compounds described herein can be co-administered with gonadotropin-releasing hormone agonists
  • immunotherapeutic agents including, but not limited to, immunostimulants (e.g., Bacillus Calmette-Guérin (BCG), levamisole, interleukin-2, alpha-interferon, etc.), monoclonal antibodies (e.g., anti-CD20, anti-HER2, anti-CD52, anti-HLA-DR, and anti-VEGF monoclonal antibodies), immunotoxins (e.g., anti-CD33 monoclonal antibody-calicheamicin conjugate, anti- CD22 monoclonal antibody-pseudomonas exotoxin conjugate, etc.), and radioimmunotherapy (e.g., anti-CD20 monoclonal antibody conjugated to 111 In, 90 Y, or 131 I, etc.).
  • immunostimulants e.g., Bacillus Calmette-Guérin (BCG), levamisole, interleukin-2, alpha-interferon, etc.
  • monoclonal antibodies e.g.,
  • the compounds described herein can be co-administered with conventional radiotherapeutic agents including, but not limited to, radionuclides such as 47 Sc, 64 Cu, 67 Cu, 89 Sr, 86 Y, 87 Y, 90 Y, 105 Rh, 111 Ag, 111 In, 117m Sn, 149 Pm, 153 Sm, 166 Ho, 177 Lu, 186 Re, 188 Re, 211 At, and 212 Bi, optionally conjugated to antibodies directed against tumor antigens.
  • radionuclides such as 47 Sc, 64 Cu, 67 Cu, 89 Sr, 86 Y, 87 Y, 90 Y, 105 Rh, 111 Ag, 111 In, 117m Sn, 149 Pm, 153 Sm, 166 Ho, 177 Lu, 186 Re, 188 Re, 211 At, and 212 Bi, optionally conjugated to antibodies directed against tumor antigens.
  • compound utilized in the pharmaceutical compositions of the present disclosure may be administered at the initial dosage of
  • a daily dose range of about 0.01 mg/kg to about 500 mg/kg, or about 0.1 mg/kg to about 200 mg/kg, or about 1 mg/kg to about 100 mg/kg, or about 10 mg/kg to about 50 mg/kg, can be used.
  • the dosages may be varied depending upon the requirements of the patient, the severity of the condition being treated, and the compound or drug being employed. For example, dosages can be empirically determined considering the type and stage of cancer diagnosed in a particular patient.
  • the dose administered to a patient, in the context of the present disclosure, should be sufficient to affect a beneficial therapeutic response in the patient over time.
  • the size of the dose will also be determined by the existence, nature, and extent of any adverse side-effects that accompany the administration of a compound in a particular patient.
  • the compounds described herein can be used in combination with one another, with other active agents known to be useful in treating cancer or with adjunctive agents that may not be effective alone, but may contribute to the efficacy of the active agent.
  • the compounds of the disclosure can be administered alone or can be coadministered to the patient. Coadministration is meant to include simultaneous or sequential administration of the compounds individually or in combination (more than one compound).
  • the compounds of the present disclosure can be prepared and administered in a wide variety of oral, parenteral and topical dosage forms.
  • Oral preparations include tablets, pills, powder, dragees, capsules, liquids, lozenges, cachets, gels, syrups, slurries, suspensions, etc., suitable for ingestion by the patient.
  • the compounds of the present disclosure can also be administered by injection, that is, intravenously, intramuscularly, intracutaneously,
  • compositions comprising a pharmaceutically acceptable excipient and one or more compounds of the disclosure.
  • pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules.
  • a solid carrier can be one or more substances, that may also act as diluents, flavoring agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material.
  • the carrier is a finely divided solid in a mixture with the finely divided active component (e.g. a compound provided herein).
  • the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.
  • the powders and tablets preferably contain from 5% to 70% of the active compound.
  • Suitable solid excipients include, but are not limited to, magnesium carbonate;
  • magnesium stearate talc
  • pectin dextrin
  • starch tragacanth
  • a low melting wax cocoa butter
  • carbohydrates sugars including, but not limited to, lactose, sucrose, mannitol, or sorbitol, starch from corn, wheat, rice, potato, or other plants
  • cellulose such as methyl cellulose
  • Dragee cores are provided with suitable coatings such as concentrated sugar solutions, which may also contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures.
  • Dyestuffs or pigments may be added to the tablets or dragee coatings for product identification or to characterize the quantity of active compound (i.e., dosage).
  • Pharmaceutical preparations of the disclosure can also be used orally using, for example, push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a coating such as glycerol or sorbitol.
  • a low melting wax such as a mixture of fatty acid glycerides or cocoa butter, is first melted and the active component is dispersed homogeneously therein, as by stirring. The molten homogeneous mixture is then poured into convenient sized molds, allowed to cool, and thereby to solidify.
  • Liquid form preparations include solutions, suspensions, and emulsions, for example, water or water/propylene glycol solutions.
  • liquid preparations can be formulated in solution in aqueous polyethylene glycol solution.
  • particularly suitable admixtures for the compounds of the disclosure are injectable, sterile solutions, preferably oily or aqueous solutions, as well as suspensions, emulsions, or implants, including suppositories.
  • carriers for parenteral administration include aqueous solutions of dextrose, saline, pure water, ethanol, glycerol, propylene glycol, peanut oil, sesame oil, polyoxyethylene-block polymers, and the like.
  • Ampules are convenient unit dosages.
  • the compounds of the disclosure can also be incorporated into liposomes or administered via transdermal pumps or patches.
  • Pharmaceutical admixtures suitable for use in the present disclosure are well-known to those of skill in the art and are described, for example, in Pharmaceutical Sciences (17th Ed., Mack Pub. Co., Easton, PA) and WO 96/05309, the teachings of both of which are hereby incorporated by reference.
  • Aqueous solutions suitable for oral use can be prepared by dissolving the active component (e.g. compounds described herein) in water and adding suitable colorants, flavors, stabilizers, and thickening agents as desired.
  • Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose,
  • hydroxypropylmethylcellulose sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia, and dispersing or wetting agents such as a naturally occurring phosphatide (e.g., lecithin), a condensation product of an alkylene oxide with a fatty acid (e.g., polyoxyethylene stearate), a condensation product of ethylene oxide with a long chain aliphatic alcohol (e.g.,
  • aqueous suspension can also contain one or more preservatives such as ethyl or n-propyl p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents and one or more sweetening agents, such as sucrose, aspartame or saccharin.
  • preservatives such as ethyl or n-propyl p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents and one or more sweetening agents, such as sucrose, aspartame or saccharin.
  • Formulations can be adjusted for osmolarity.
  • solid form preparations that are intended to be converted, shortly before use, to liquid form preparations for oral administration.
  • Such liquid forms include solutions, suspensions, and emulsions.
  • These preparations may contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.
  • Oil suspensions can contain a thickening agent, such as beeswax, hard paraffin or cetyl alcohol.
  • Sweetening agents can be added to provide a palatable oral preparation, such as glycerol, sorbitol or sucrose.
  • These formulations can be preserved by the addition of an antioxidant such as ascorbic acid.
  • an injectable oil vehicle see Minto, J.
  • the pharmaceutical formulations of the disclosure can also be in the form of oil-in-water emulsions.
  • the oily phase can be a vegetable oil or a mineral oil, described above, or a mixture of these.
  • Suitable emulsifying agents include naturally-occurring gums, such as gum acacia and gum tragacanth, naturally occurring phosphatides, such as soybean lecithin, esters or partial esters derived from fatty acids and hexitol anhydrides, such as sorbitan mono-oleate, and condensation products of these partial esters with ethylene oxide, such as polyoxyethylene sorbitan mono-oleate.
  • the emulsion can also contain sweetening agents and flavoring agents, as in the formulation of syrups and elixirs. Such formulations can also contain a demulcent, a preservative, or a coloring agent.
  • the pharmaceutical preparation is preferably in unit dosage form. In such form the preparation is subdivided into unit doses containing appropriate quantities of the active component.
  • the unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules. Also, the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.
  • the quantity of active component in a unit dose preparation may be varied or adjusted from 0.1 mg to 10000 mg, more typically 1.0 mg to 1000 mg, most typically 10 mg to 500 mg, according to the particular application and the potency of the active component.
  • the composition can, if desired, also contain other compatible therapeutic agents.
  • Some compounds may have limited solubility in water and therefore may require a surfactant or other appropriate co-solvent in the composition.
  • Such co-solvents include:
  • Viscosity greater than that of simple aqueous solutions may be desirable to decrease variability in dispensing the formulations, to decrease physical separation of components of a suspension or emulsion of formulation and/or otherwise to improve the formulation.
  • Such viscosity building agents include, for example, polyvinyl alcohol, polyvinyl pyrrolidone, methyl cellulose, hydroxy propyl methylcellulose, hydroxyethyl cellulose, carboxymethyl cellulose, hydroxy propyl cellulose, chondroitin sulfate and salts thereof, hyaluronic acid and salts thereof, combinations of the foregoing, and other agents known to those skilled in the art. Such agents are typically employed at a level between about 0.01% and about 2% by weight. Determination of acceptable amounts of any of the above adjuvants is readily ascertained by one skilled in the art. [0146]
  • the compositions of the present disclosure may additionally include components to provide sustained release and/or comfort. Such components include high molecular weight, anionic mucomimetic polymers, gelling polysaccharides and finely-divided drug carrier substrates. These components are discussed in greater detail in U.S. Pat. Nos.4,911,920;
  • compositions provided by the present disclosure include compositions wherein the active ingredient is contained in a therapeutically effective amount, i.e., in an amount effective to achieve its intended purpose.
  • the actual amount effective for a particular application will depend, inter alia, on the condition being treated.
  • compositions When administered in methods to treat a disease, such compositions will contain an amount of active ingredient effective to achieve the desired result, e.g., modulating the activity of a target molecule (e.g.
  • a Ras K-Ras, K-Ras G12C, K-Ras G12D, K-Ras G12V, K-Ras G13C, K-Ras G13D, a mutant K- Ras, an activated K-Ras), and/or reducing, eliminating, or slowing the progression of disease symptoms (e.g. cancer growth or metastasis).
  • Determination of a therapeutically effective amount of a compound of the disclosure is well within the capabilities of those skilled in the art, especially in light of the detailed disclosure herein.
  • the dosage and frequency (single or multiple doses) administered to a mammal can vary depending upon a variety of factors, for example, whether the mammal suffers from another disease, and its route of administration; size, age, sex, health, body weight, body mass index, and diet of the recipient; nature and extent of symptoms of the disease being treated (e.g. lung cancer, NSCL cancer, colon cancer, colorectal cancer, breast cancer, pancreatic cancer, leukemia), kind of concurrent treatment, complications from the disease being treated or other health-related problems.
  • Other therapeutic regimens or agents can be used in conjunction with the methods and compounds of Applicants' disclosure. Adjustment and manipulation of established dosages (e.g., frequency and duration) are well within the ability of those skilled in the art.
  • the therapeutically effective amount can be initially determined from cell culture assays.
  • Target concentrations will be those concentrations of active compound(s) that are capable of achieving the methods described herein, as measured using the methods described herein or known in the art.
  • therapeutically effective amounts for use in humans can also be determined from animal models. For example, a dose for humans can be formulated to achieve a concentration that has been found to be effective in animals. The dosage in humans can be adjusted by monitoring compounds effectiveness and adjusting the dosage upwards or downwards, as described above. Adjusting the dose to achieve maximal efficacy in humans based on the methods described above and other methods is well within the capabilities of the ordinarily skilled artisan.
  • Dosages may be varied depending upon the requirements of the patient and the compound being employed.
  • the dose administered to a patient in the context of the present disclosure should be sufficient to effect a beneficial therapeutic response in the patient over time.
  • the size of the dose also will be determined by the existence, nature, and extent of any adverse side-effects. Determination of the proper dosage for a particular situation is within the skill of the practitioner. Generally, treatment is initiated with smaller dosages which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under circumstances is reached.
  • the dosage range is 0.001% to 10% w/v. In another embodiment, the dosage range is 0.1% to 5% w/v.
  • Dosage amounts and intervals can be adjusted individually to provide levels of the administered compound effective for the particular clinical indication being treated. This will provide a therapeutic regimen that is commensurate with the severity of the individual's disease state.
  • an effective prophylactic or therapeutic treatment regimen can be planned that does not cause substantial toxicity and yet is effective to treat the clinical symptoms demonstrated by the particular patient. This planning should involve the careful choice of active compound by considering factors such as compound potency, relative bioavailability, patient body weight, presence and severity of adverse side effects, preferred mode of administration and the toxicity profile of the selected agent.
  • the ratio between toxicity and therapeutic effect for a particular compound is its therapeutic index and can be expressed as the ratio between LD50 (the amount of compound lethal in 50% of the population) and ED50 (the amount of compound effective in 50% of the population).
  • LD50 the amount of compound lethal in 50% of the population
  • ED50 the amount of compound effective in 50% of the population.
  • Compounds that exhibit high therapeutic indices are preferred.
  • Therapeutic index data obtained from cell culture assays and/or animal studies can be used in formulating a range of dosages for use in humans.
  • the dosage of such compounds preferably lies within a range of plasma concentrations that include the ED 50 with little or no toxicity.
  • the dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. See, e.g.
  • a combinatorial chemical library is a collection of diverse chemical compounds generated by either chemical synthesis or biological synthesis, by combining a number of chemical“building blocks” such as reagents.
  • a linear combinatorial chemical library such as a polypeptide library is formed by combining a set of chemical building blocks (amino acids) in every possible way for a given compound length (i.e., the number of amino acids in a polypeptide compound).
  • combinatorial chemical libraries include, but are not limited to, peptide libraries (see, e.g., U.S. Patent 5,010,175, Furka, Int. J. Pept. Prot. Res.37:487-493 (1991) and Houghton et al., Nature 354:84-88 (1991)).
  • chemistries for generating chemical diversity libraries can also be used. Such chemistries include, but are not limited to: peptoids (e.g., PCT Publication No.
  • An“effective amount” is an amount sufficient for a compound to accomplish a stated purpose relative to the absence of the compound (e.g. achieve the effect for which it is administered, treat a disease, reduce enzyme activity, increase enzyme activity, reduce signaling pathway, reduce one or more symptoms of a disease or condition (e.g. reduce GTPase activity in a cell, increase GTPase activity, reduce signaling pathway stimulated by GTP bound Ras (e.g.
  • K- Ras reduce the signaling pathway activity of Ras, reduce the signaling pathway activity of K- Ras, reduce the signaling pathway activity of K-Ras4A, reduce the signaling pathway activity of K-Ras4B, reduce the signaling pathway activity of H-Ras, reduce the signaling pathway activity of N-Ras, reduce the signaling pathway activity of K-Ras G12C, reduce the signaling pathway activity of K-Ras G12V, reduce the signaling pathway activity of K-Ras G13C, reduce the signaling pathway activity of K-Ras G13D, reduce the signaling pathway activity of K-Ras G12D, reduce the signaling pathway activity of a mutant K-Ras, increase the activity of Ras, increase the activity of K-Ras, increase the activity of K-Ras4A, increase the activity of K- Ras4B, increase the activity of H-Ras, increase the activity of N-Ras, increase the activity of K- Ras G12C, increase the activity of K-Ras G
  • an“effective amount” is an amount sufficient to contribute to the treatment, prevention, or reduction of a symptom or symptoms of a disease, which could also be referred to as a“therapeutically effective amount.”
  • A“reduction” of a symptom or symptoms means decreasing of the severity or frequency of the symptom(s), or elimination of the symptom(s).
  • A“prophylactically effective amount” of a drug is an amount of a drug that, when administered to a subject, will have the intended prophylactic effect, e.g., preventing or delaying the onset (or reoccurrence) of an injury, disease, pathology or condition, or reducing the likelihood of the onset (or
  • an“activity decreasing amount,” as used herein, refers to an amount of antagonist required to decrease the activity of an enzyme relative to the absence of the antagonist.
  • A“function disrupting amount,” as used herein, refers to the amount of antagonist required to disrupt the function of an enzyme or protein relative to the absence of the antagonist (e.g.
  • Control or“control experiment” is used in accordance with its plain ordinary meaning and refers to an experiment in which the subjects or reagents of the experiment are treated as in a parallel experiment except for omission of a procedure, reagent, or variable of the experiment.
  • the control is used as a standard of comparison in evaluating experimental effects.
  • a control is the measurement of the activity (e.g. GTPase activity, protein-protein interaction, signaling pathway) of a protein (e.g.
  • Contacting is used in accordance with its plain ordinary meaning and refers to the process of allowing at least two distinct species (e.g. chemical compounds including
  • the term“contacting” or“binding”, which may be used interchangeably, may include allowing two species to react, interact, or physically touch, wherein the two species may be a compound as described herein and a protein or enzyme (e.g.
  • the protein may be K-Ras. In some embodiments, the protein may be a mutant K-Ras (e.g. K-Ras G12C, K-Ras G12V, K-Ras G13C, K-Ras G12D, K-Ras G13D). In some embodiments, the protein may be K-Ras4A.
  • the protein may be K-Ras4B. In some embodiments, the protein may be human K-Ras. In some embodiments contacting or binding includes allowing a compound described herein to interact with a protein or enzyme that is involved in a signaling pathway. In some embodiments contacting or binding includes allowing a compound described herein to interact with a Switch 2 – Binding Pocket. In some embodiments contacting or binding includes allowing a compound described herein to interact with a Switch 2 Groove. [0161] As defined herein, the term“inhibition”,“inhibit”,“inhibiting” and the like in reference to a protein-inhibitor interaction means negatively affecting (e.g. decreasing) the activity or function of the protein (e.g.
  • GTP bound Ras e.g. K-Ras, K-Ras G12C, K-Ras G12V, K-Ras G13C, K-Ras G12D, K-Ras G13D
  • nucleotide exchange effector protein binding, effector protein activation, guanine exchange factor (GEF) binding, SOS binding, GEF-facilitated nucleotide exchange, phosphate release, nucleotide release, nucleotide binding
  • inhibition refers to reduction of a disease or symptoms of disease.
  • inhibition refers to a reduction in the activity of a signal transduction pathway or signaling pathway (e.g. reduction of a pathway involving GTP bound Ras (e.g. K-Ras, K-Ras G12C, K- Ras G12V, K-Ras G13C, K-Ras G12D, K-Ras G13D), reduction of a pathway involving mutant K-Ras (e.g. K-Ras G12C, K-Ras G12V, K-Ras G13C, K-Ras G12D, K-Ras G13D)).
  • a signal transduction pathway or signaling pathway e.g. reduction of a pathway involving GTP bound Ras (e.g. K-Ras, K-Ras G12C, K- Ras G12V, K-Ras G13C, K-Ras G12D, K-Ras G13D)).
  • a pathway involving GTP bound Ras e.g.
  • inhibition includes, at least in part, partially or totally blocking stimulation, decreasing, preventing, or delaying activation, or inactivating, desensitizing, or down-regulating the signaling pathway or enzymatic activity or the amount of a protein (e.g. K-Ras, K-Ras G12C, K- Ras G12V, K-Ras G13C, K-Ras G12D, K-Ras G13D).
  • inhibition refers to inhibition of binding of Ras (K-Ras, K-Ras G12C, K-Ras G12V, K-Ras G13C, K-Ras G12D, K-Ras G13D) with signaling pathway binding partners (e.g.
  • inhibition refers to inhibition of binding of Ras with a GEF (e.g. SOS).
  • GEF e.g. SOS
  • modulator refers to a composition that increases or decreases the level of a target molecule or the function (e.g. GTPase activity, nucleotide exchange, effector protein binding, effector protein activation, guanine exchange factor (GEF) binding, SOS binding, GEF- facilitated nucleotide exchange, phosphate release, nucleotide release, nucleotide binding) of a target molecule or the physical state (e.g.
  • a target may be K-Ras and the function may be to hydrolyze GTP or activate a signaling pathway that is activated by GTP bound K-Ras, binding of K-Ras with protein binding partners (e.g. PI3K, SOS, Raf)).
  • a GTPase modulator is a compound that reduces the activity of a GTPase in a cell.
  • a GTPase modulator is a compound that increases the activity of a GTPase in a cell.
  • a GTPase modulator is a compound that reduces the signaling pathway in a cell that is activated by the GTP bound form of Ras. In some embodiments, a GTPase modulator is a compound that increases the signaling pathway in a cell that is activated by the GTP bound form of Ras. In some embodiments, a K-Ras disease modulator is a compound that reduces the severity of one or more symptoms of a disease associated with K-Ras (e.g. cancer, metastatic cancer). A K-Ras modulator is a compound that increases or decreases the activity or function or level of activity or level of function of K-Ras or level of K-Ras or level of K-Ras in a particular physical state.
  • a mutant K-Ras modulator is a compound that that increases or decreases the activity or function or level of activity or level of function of mutant K-Ras or level of mutant K-Ras or level of mutant K-Ras in a particular physical state.
  • a K-Ras G12C modulator, K-Ras G12V modulator, K-Ras G12D modulator, K- Ras G13C modulator, or K-Ras G13D modulator is a compound that increases or decreases the activity or function or level of activity or level of function of that particular mutant K-Ras or level of that particular mutant K-Ras or level of that particular mutant K-Ras in a particular physical state.
  • a K-Ras inhibitor is a compound that decreases the activity or function or level of activity or level of function of K-Ras or level of K-Ras or level of K-Ras in a particular physical state.
  • a mutant K-Ras inhibitor is a compound that that decreases the activity or function or level of activity or level of function of mutant K-Ras or level of mutant K-Ras or level of mutant K-Ras in a particular physical state.
  • a K-Ras G12C inhibitor, K-Ras G12V inhibitor, K-Ras G12D inhibitor, K-Ras G13C inhibitor, or K-Ras G13D inhibitor is a compound that decreases the activity or function or level of activity or level of function of that particular mutant K-Ras or level of that particular mutant K-Ras or level of that particular mutant K-Ras in a particular physical state.
  • a Ras (e.g., human K-Ras or human H-Ras) associated disease modulator is a compound that reduces the severity of one or more symptoms of a disease associated with Ras (e.g., human K-Ras or human H-Ras) (e.g. cancer).
  • a Ras (e.g., human K-Ras or human H-Ras) modulator is a compound that increases or decreases the activity or function or level of activity or level of function of Ras (e.g., human K-Ras or human H-Ras).
  • the term“modulate” is used in accordance with its plain ordinary meaning and refers to the act of changing or varying one or more properties.“Modulation” refers to the process of changing or varying one or more properties. For example, as applied to the effects of a modulator on a target protein, to modulate means to change by increasing or decreasing a property or function of the target molecule or the amount of the target molecule.
  • “Disease” or“condition” refer to a state of being or health status of a patient or subject capable of being treated with the compounds or methods provided herein. In some
  • the disease is a disease related to (e.g. caused by) a mutant Ras.
  • the disease is a disease related to (e.g. caused by) a mutant K-Ras (e.g. K-Ras G12C, G12V, G13C, G12D, or G13D) or aberrant K-Ras signaling pathway activity (e.g. lung cancer, breast cancer, colon cancer, colorectal cancer, pancreatic cancer, leukemia).
  • K-Ras e.g. K-Ras G12C, G12V, G13C, G12D, or G13D
  • aberrant K-Ras signaling pathway activity e.g. lung cancer, breast cancer, colon cancer, colorectal cancer, pancreatic cancer, leukemia.
  • diseases, disorders, or conditions include, but are not limited to cancer.
  • diseases, disorders, or conditions include, but are not limited to MYH-associated polyposis.
  • “disease” or“condition” refers to cancer
  • “disease” or“condition” refers to MYH-associated polyposis.
  • “cancer” refers to human cancers and carcinomas, sarcomas, adenocarcinomas, lymphomas, leukemias, etc., including solid and lymphoid cancers, kidney, breast, lung (NSCLC), bladder, colon, ovarian, prostate, pancreas, stomach, brain, head and neck, skin, uterine, testicular, glioma, esophagus, and liver cancer, including hepatocarcinoma, lymphoma, including B-acute lymphoblastic lymphoma, non-Hodgkin’s lymphomas (e.g., Burkitt’s, Small Cell, and Large Cell lymphomas), Hodgkin’s lymphoma, leukemia (including AML, ALL, and CML), or multiple myeloma.
  • NSCLC non-acute lymphoblastic lymphoma
  • cancer refers to all types of cancer, neoplasm or malignant tumors found in mammals (e.g. humans), including leukemia, lymphomas, carcinomas and sarcomas.
  • exemplary cancers that may be treated with a compound or method provided herein include cancer of the thyroid, endocrine system, brain, breast, cervix, colon, head & neck, liver, kidney, lung, non-small cell lung, melanoma, mesothelioma, ovary, sarcoma, stomach, uterus, Medulloblastoma, colorectal cancer, pancreatic cancer.
  • Additional examples include, Hodgkin's Disease, Non-Hodgkin's Lymphoma, multiple myeloma, neuroblastoma, glioma, glioblastoma multiforme, ovarian cancer, rhabdomyosarcoma, primary thrombocytosis, primary
  • macroglobulinemia primary brain tumors, cancer, malignant pancreatic insulanoma, malignant carcinoid, urinary bladder cancer, premalignant skin lesions, testicular cancer, lymphomas, thyroid cancer, neuroblastoma, esophageal cancer, genitourinary tract cancer, malignant hypercalcemia, endometrial cancer, adrenal cortical cancer, neoplasms of the endocrine or exocrine pancreas, medullary thyroid cancer, medullary thyroid carcinoma, melanoma, colorectal cancer, papillary thyroid cancer, hepatocellular carcinoma, or prostate cancer.
  • leukemia refers broadly to progressive, malignant diseases of the blood- forming organs and is generally characterized by a distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemia is generally clinically classified on the basis of (1) the duration and character of the disease-acute or chronic; (2) the type of cell involved; myeloid (myelogenous), lymphoid (lymphogenous), or monocytic; and (3) the increase or non-increase in the number abnormal cells in the blood-leukemic or aleukemic (subleukemic).
  • Exemplary leukemias that may be treated with a compound or method provided herein include, for example, acute nonlymphocytic leukemia, chronic lymphocytic leukemia, acute granulocytic leukemia, chronic granulocytic leukemia, acute promyelocytic leukemia, adult T-cell leukemia, aleukemic leukemia, a leukocythemic leukemia, basophylic leukemia, blast cell leukemia, bovine leukemia, chronic myelocytic leukemia, leukemia cutis, embryonal leukemia, eosinophilic leukemia, Gross' leukemia, hairy-cell leukemia, hemoblastic leukemia,
  • hemocytoblastic leukemia histiocytic leukemia, stem cell leukemia, acute monocytic leukemia, leukopenic leukemia, lymphatic leukemia, lymphoblastic leukemia, lymphocytic leukemia, lymphogenous leukemia, lymphoid leukemia, lymphosarcoma cell leukemia, mast cell leukemia, megakaryocytic leukemia, micromyeloblastic leukemia, monocytic leukemia, myeloblastic leukemia, myelocytic leukemia, myeloid granulocytic leukemia, myelomonocytic leukemia, Naegeli leukemia, plasma cell leukemia, multiple myeloma, plasmacytic leukemia,
  • the term“lymphoma” refers to a group of cancers affecting
  • lymphoma the blood cells that are found primarily in lymph nodes, spleen, thymus, and bone marrow.
  • lymphoma Two main types of lymphoma are non-Hodgkin lymphoma and Hodgkin’s disease.
  • Hodgkin’s disease represents approximately 15% of all diagnosed lymphomas. This is a cancer associated with Reed-Sternberg malignant B lymphocytes.
  • Non-Hodgkin’s lymphomas (NHL) can be classified based on the rate at which cancer grows and the type of cells involved. There are aggressive (high grade) and indolent (low grade) types of NHL. Based on the type of cells involved, there are B-cell and T-cell NHLs.
  • Exemplary B-cell lymphomas that may be treated with a compound or method provided herein include, but are not limited to, small lymphocytic lymphoma, Mantle cell lymphoma, follicular lymphoma, marginal zone lymphoma, extranodal (MALT) lymphoma, nodal (monocytoid B- cell) lymphoma, splenic lymphoma, diffuse large cell B-lymphoma, Burkitt’s lymphoma, lymphoblastic lymphoma, immunoblastic large cell lymphoma, or precursor B-lymphoblastic lymphoma.
  • Exemplary T-cell lymphomas that may be treated with a compound or method provided herein include, but are not limited to, cunateous T-cell lymphoma, peripheral T-cell lymphoma, anaplastic large cell lymphoma, mycosis fungoides, and precursor T-lymphoblastic lymphoma.
  • the term "sarcoma” generally refers to a tumor which is made up of a substance like the embryonic connective tissue and is generally composed of closely packed cells embedded in a fibrillar or homogeneous substance.
  • Sarcomas that may be treated with a compound or method provided herein include a chondrosarcoma, fibrosarcoma, lymphosarcoma, melanosarcoma, myxosarcoma, osteosarcoma, Abemethy's sarcoma, adipose sarcoma, liposarcoma, alveolar soft part sarcoma, ameloblastic sarcoma, botryoid sarcoma, chloroma sarcoma, chorio carcinoma, embryonal sarcoma, Wilms' tumor sarcoma, endometrial sarcoma, stromal sarcoma, Ewing's sarcoma, fascial sarcoma, fibroblastic sarcoma, giant cell sarcoma, granulocytic sarcoma, Hodgkin's sarcoma, idiopathic multiple pigmented hemo
  • melanoma is taken to mean a tumor arising from the melanocytic system of the skin and other organs.
  • Melanomas that may be treated with a compound or method provided herein include, for example, acral-lentiginous melanoma, amelanotic melanoma, benign juvenile melanoma, Cloudman's melanoma, S91 melanoma, Harding-Passey melanoma, juvenile melanoma, lentigo maligna melanoma, malignant melanoma, nodular melanoma, subungal melanoma, or superficial spreading melanoma.
  • carcinoma refers to a malignant new growth made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases.
  • exemplary carcinomas that may be treated with a compound or method provided herein include, for example, medullary thyroid carcinoma, familial medullary thyroid carcinoma, acinar carcinoma, acinous carcinoma, adenocystic carcinoma, adenoid cystic carcinoma, carcinoma adenomatosum, carcinoma of adrenal cortex, alveolar carcinoma, alveolar cell carcinoma, basal cell carcinoma, carcinoma basocellulare, basaloid carcinoma, basosquamous cell carcinoma, bronchioalveolar carcinoma, bronchiolar carcinoma, bronchogenic carcinoma, cerebriform carcinoma, cholangiocellular carcinoma, chorionic carcinoma, colloid carcinoma, comedo carcinoma, corpus carcinoma, cribriform carcinoma, carcinoma en cuirasse, carcinoma cutaneum, cylindrical carcinoma, cylindrical cell carcinoma, duct carcinoma, carcinoma durum, embryonal carcinoma,
  • encephaloid carcinoma epiermoid carcinoma, carcinoma epitheliale adenoides, exophytic carcinoma, carcinoma ex ulcere, carcinoma fibrosum, gelatiniforni carcinoma, gelatinous carcinoma, giant cell carcinoma, carcinoma gigantocellulare, glandular carcinoma, granulosa cell carcinoma, hair-matrix carcinoma, hematoid carcinoma, hepatocellular carcinoma, Hurthle cell carcinoma, hyaline carcinoma, hypernephroid carcinoma, infantile embryonal carcinoma, carcinoma in situ, intraepidermal carcinoma, intraepithelial carcinoma, Krompecher's carcinoma, Kulchitzky-cell carcinoma, large-cell carcinoma, lenticular carcinoma, carcinoma lenticulare, lipomatous carcinoma, lymphoepithelial carcinoma, carcinoma medullare, medullary carcinoma, melanotic carcinoma, carcinoma molle, mucinous carcinoma, carcinoma muciparum, carcinoma mucocellulare, mucoepidermoid carcinoma, carcinoma mucosum, mucous carcinoma, carcinoma myxomatodes
  • Ras associated cancer refers to a cancer caused by aberrant Ras activity or signaling.
  • A“cancer associated with aberrant K-Ras activity” is a cancer caused by aberrant K-Ras activity or signaling (e.g. a mutant K-Ras).
  • K-Ras related cancers may include lung cancer, non- small cell lung cancer, breast cancer, leukemia, pancreatic cancer, colon cancer, colorectal cancer.
  • Ras Ras, K-Ras, H- Ras, N-Ras, mutant K-Ras (including K-Ras G12C, K-Ras G12V, K-Ras G13C, K-Ras G12D, K-Ras G13D mutants), mutant N-Ras, and mutant H-Ras are well known in the art and determining such cancers are within the skill of a person of skill in the art.
  • administering) a Ras inhibitor means administering a compound that inhibits the activity or level (e.g. amount) or level of a signaling pathway of one or more Ras proteins (e.g.
  • a Ras inhibitor K-Ras inhibitor, N-Ras inhibitor, H-Ras inhibitor, mutant K-Ras inhibitor, K-Ras G12C inhibitor, K-Ras G12V inhibitor, K-Ras G13C inhibitor, K-Ras G12D inhibitor, K-Ras G13D inhibitor) to a subject.
  • Administration may include, without being limited by mechanism, allowing sufficient time for the Ras inhibitor to reduce the activity of one or more Ras proteins or for the Ras inhibitor to reduce one or more symptoms of a disease (e.g. cancer, wherein the Ras inhibitor may arrest the cell cycle, slow the cell cycle, reduce DNA replication, reduce cell replication, reduce cell growth, reduce metastasis, or cause cell death).
  • administering means administering a compound that inhibits the activity or level (e.g. amount) or level of a signaling pathway of one or more K-Ras proteins (K-Ras, mutant K-Ras, K-Ras G12C, K-Ras G12V, K-Ras G12D, K-Ras G13C, K-Ras G13D).
  • the administering does not include administration of any active agent other than the recited active agent.
  • the term“associated” or“associated with” in the context of a substance or substance activity or function associated with a disease e.g.
  • Ras e.g., human K-Ras or human H-Ras activity, a protein associated disease, a cancer associated with aberrant Ras activity, K-Ras associated cancer, mutant K-Ras associated cancer, activated K-Ras associated cancer, K-Ras G12C associated cancer, K-Ras G12V associated cancer, K-Ras G13C associated cancer, K-Ras G12D associated cancer, K-Ras G13D associated cancer) means that the disease (e.g. cancer) is caused by (in whole or in part), or a symptom of the disease is caused by (in whole or inpart) the substance or substance activity or function.
  • the disease e.g. cancer
  • a symptom of the disease is caused by (in whole or inpart) the substance or substance activity or function.
  • a cancer associated with aberrant Ras activity or function may be a cancer that results (entirely or partially) from aberrant Ras activity or function (e.g. enzyme activity, protein-protein binding, signaling pathway) or a cancer wherein a particular symptom of the disease is caused (entirely or partially) by aberrant Ras activity or function.
  • aberrant Ras activity or function e.g. enzyme activity, protein-protein binding, signaling pathway
  • a cancer associated with aberrant Ras activity or function or a Ras associated cancer may be treated with a Ras modulator or Ras inhibitor, in the instance where increased Ras activity or function (e.g.
  • a cancer associated with K-Ras G12C may be a cancer that a subject with K-Ras G12C is at higher risk of developing as compared to a subject without K-Ras G12C.
  • a cancer associated with K-Ras G12V may be a cancer that a subject with K-Ras G12V is at higher risk of developing as compared to a subject without K-Ras G12V.
  • the term“aberrant” as used herein refers to different from normal. When used to describe enzymatic activity, aberrant refers to activity that is greater or less than a normal control or the average of normal non-diseased control samples.
  • Aberrant activity may refer to an amount of activity that results in a disease, wherein returning the aberrant activity to a normal or non- disease-associated amount (e.g. by administering a compound or using a method as described herein), results in reduction of the disease or one or more disease symptoms.
  • the term“electrophilic chemical moiety” is used in accordance with its plain ordinary chemical meaning and refers to a monovalent chemical group that is electrophilic.
  • the term“Ras” refers to one or more of the family of human Ras GTPase proteins (e.g. K-Ras, H-Ras, N-Ras).
  • K-Ras refers to the nucleotide sequences or proteins of human K-Ras (e.g. human K-Ras4A (NP_203524.1), human K-Ras4B (NP_004976.2), or both K-Ras4A and K-Ras4B).
  • the term“K-Ras” includes both the wild-type form of the nucleotide sequences or proteins as well as any mutants thereof.
  • “K-Ras” is wild- type K-Ras.
  • “K-Ras” is one or more mutant forms.
  • K-Ras XYZ refers to a nucleotide sequence or protein of a mutant K-Ras wherein the Y numbered amino acid of K-Ras that has an X amino acid in the wildtype instead has a Z amino acid in the mutant (e.g. K-Ras G12C has a G in wildtype protein but a C in the K-Ras G12C mutant protein).
  • K-Ras refers to K-Ras4A and K-Ras4B.
  • K-Ras refers to K-Ras4A.
  • K-Ras refers to K-Ras4B (e.g., NM_004985.4 or NP_004976.2).
  • K-Ras refers to the protein including (e.g., consisting of) the amino acid sequence below or including the sequence below with one or more mutations (e.g., G12C, G12V, or G13C):
  • K-Ras refers to the protein including (e.g., consisting of) the amino acid sequence below or including (e.g., consisting of) the sequence below with one or more mutations (e.g., G12C, G12V, or G13C):
  • “H-Ras” is wild-type H-Ras. In some embodiments,“H-Ras” is one or more mutant forms.
  • the term“H-Ras” XYZ refers to a nucleotide sequence or protein of a mutant H-Ras wherein the Y numbered amino acid of H-Ras that has an X amino acid in the wildtype instead has a Z amino acid in the mutant (e.g. H-Ras G12C has a G in wildtype protein but a C in the H-Ras G12C mutant protein).
  • H-Ras refers to the protein NP_005334.1.
  • H-Ras refers to the protein including (e.g., consisting of) the amino acid sequence below or including (e.g., consisting of) the sequence below with one or more mutations (e.g., G12C, G12V, or G13C): MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQ YMRTGEGFLCVFAINNTKSFEDIHQYREQIKRVKDSDDVPMVLVGNKCDLAARTVESRQAQDLARSYGIP YIETSAKTRQGVEDAFYTLVREIRQH (SEQ ID NO:4) [0179]
  • H-Ras refers to the protein including (e.g., consisting of) the amino acid sequence below or including (e.g., consisting of) the sequence below with one or more mutations (e.g., G12C, G12V, or G13C): MTEYK
  • Ras inhibitor test compound refers to a compound that is being characterized in an assay for the ability to inhibit an activity, function, or level (e.g.
  • K-Ras inhibitor test compound refers to a compound that is being characterized in an assay for the ability to inhibit an activity, function, or level (e.g. amount) of K-Ras protein.
  • A“Switch 2 - Binding Pocket covalent inhibitor test compound” is a Ras inhibitor test compound that binds to a Ras Switch 2– Binding Pocket and is being tested for the ability to covalently inhibit an activity, function, or level (e.g. amount) of a Ras protein.
  • a substituted form of one of the named groups may be substituted with one or more of any of the substituent groups described herein while obeying the rules of chemical valency.
  • “Switch 2,” as used herein, refers to a protein domain of a Ras protein (e.g. K-Ras) formed at least in part by residues corresponding to residues 60-76 of K-Ras (e.g. K-Ras Switch 2 refers to residues 60-76 of K-Ras).
  • A“Switch 2 Binding Region” is a region of a Ras protein (e.g. K-Ras) that is formed by amino acid residues that contact at least a portion of Switch 2 when Ras is bound to GTP.
  • A“Switch 2 - Binding Pocket” or“S2BP” or“switch-II pocket” or “S-IIP” is a cavity bound (the limits or boundaries of which are made), at least in part, by the amino acid residues that form Switch 2 and the Switch 2 Binding Region, which may also include adjacent (e.g., through space in the folded protein structure) amino acid residues (e.g., V9, E63, Y64, R68, M72, H94, Y96, and/or Q99; amino acids binding or contacting 2C07 in FIG.18, 21A-B, 23A-B, 24, 26A-E, 27A-D, or 28A-C, A59, Y64, D69, R73, F78, K88, E91, D92, H94, H95, R97, R102, and/or V103; V7, V9, G10, P34, T58, A59, G60, Q61, E62, E63, Y64, R68,
  • a“Switch 2 - Binding Pocket” or“S2BP” is a cavity, in the GDP bound form of Ras (e.g. K-Ras), bound (the limits or boundaries of which are made), at least in part, by the amino acid residues that form Switch 2 and the Switch 2 Binding Region which may also include adjacent (e.g., through space in the folded protein structure) amino acid residues (e.g., V9, E63, Y64, R68, M72, H94, Y96, and/or Q99; amino acids binding or contacting 2C07 in FIG.18, 21A-B, 23A-B, 24, 26A-E, 27A-D, or 28A-C; V7, V9, G10, P34, T58, A59, G60, Q61, E62, E63, Y64, R68, D69, Y71, M72, R73, F78, K88, E91, D92, H94, H95, Y96, R97
  • a“Switch 2 - Binding Pocket” or“S2BP” is a cavity, in the GTP bound form of Ras (e.g. K-Ras), bound (the limits or boundaries of which are made), at least in part, by the amino acid residues that form Switch 2 and the Switch 2 Binding Region, which may also include adjacent (e.g., through space in the folded protein structure) amino acid residues (e.g., V9, E63, Y64, R68, M72, H94, Y96, and/or Q99 of K-Ras or amino acid residues corresponding to V9, E63, Y64, R68, M72, H94, Y96, and/or Q99 of K-Ras; amino acids binding or contacting 2C07 in FIG.18, 21A-B, 23A-B, 24, 26A-E, 27A-D, or 28A-C or amino acid residues corresponding to amino acids binding or contacting 2C07 in FIG.18
  • the“Switch 2 - Binding Pocket” or“S2BP” is a cavity bound (the limits or boundaries of which are made), at least in part, by the amino acid residues binding or contacting 2C07 in FIG.18, 21A-B, 23A-B, 24, 26A- E, 27A-D, or 28A-C or amino acid residues corresponding to amino acids binding or contacting 2C07 in FIG.18, 21A-B, 23A-B, 24, 26A-E, 27A-D, or 28A-C).
  • the“Switch 2 - Binding Pocket” or“S2BP” is a cavity bound (the limits or boundaries of which are made), at least in part, by the amino acid residues V9, E63, Y64, R68, M72, H94, Y96, and/or Q99 or amino acids corresponding thereto.
  • the“Switch 2 - Binding Pocket” or“S2BP” is a cavity bound (the limits or boundaries of which are made), at least in part, by the amino acid residues V7, V9, T58, A59, G60, E63, Y64, R68, D69, Y71, M72, R73, F78, K88, E91, D92, H94, H95, Y96, R97, Q99, I100, R102, and/or V103 (these amino acids may collectively be termed the“Switch 2 Groove”) or amino acids corresponding thereto.
  • the “Switch 2 - Binding Pocket” or“S2BP” is a cavity bound (the limits or boundaries of which are made), at least in part, by the amino acid residues V7, V9, G10, P34, T58, A59, G60, Q61, E62, E63, Y64, R68, D69, Y71, M72, R73, F78, K88, E91, D92, H94, H95, Y96, R97, Q99, I100, R102, and/or V103 or amino acids corresponding thereto.
  • the“Switch 2 - Binding Pocket” or“S2BP” is a cavity bound (the limits or boundaries of which are made), at least in part, by the amino acid residues V9, A59, E63, Y64, R68, D69, M72, R73, F78, K88, E91, D92, H94, H95, Y96, R97, Q99, R102, and/or V103, or amino acids corresponding thereto.
  • the“Switch 2 - Binding Pocket” or“S2BP” is a cavity bound (the limits or boundaries of which are made), at least in part, by the amino acid residues A59, Y64, D69, R73, F78, K88, E91, D92, H94, H95, R97, R102, and/or V103 or amino acids corresponding thereto.
  • the“Switch 2 - Binding Pocket” or“S2BP” is a cavity bound (the limits or boundaries of which are made), at least in part, by the amino acid residues V9, E63, Y64, R68, M72, H94, Y96, and/or Q99 or amino acids corresponding thereto.
  • the“Switch 2 - Binding Pocket” or“S2BP” is a cavity bound (the limits or boundaries of which are made), by the amino acid residues V9, E63, Y64, R68, M72, H94, Y96, and/or Q99 of K-Ras or amino acids corresponding thereto.
  • the“Switch 2 - Binding Pocket” or“S2BP” is a cavity bound (the limits or boundaries of which are made), by the amino acid residues V7, V9, T58, A59, G60, E63, Y64, R68, D69, Y71, M72, R73, F78, K88, E91, D92, H94, H95, Y96, R97, Q99, I100, R102, and/or V103 of K-Ras or amino acids corresponding thereto.
  • the“Switch 2 - Binding Pocket” or“S2BP” is a cavity bound (the limits or boundaries of which are made), by the amino acid residues V7, V9, G10, P34, T58, A59, G60, Q61, E62, E63, Y64, R68, D69, Y71, M72, R73, F78, K88, E91, D92, H94, H95, Y96, R97, Q99, I100, R102, and/or V103 of K-Ras or amino acids corresponding thereto.
  • the“Switch 2 - Binding Pocket” or“S2BP” is a cavity bound (the limits or boundaries of which are made), by the amino acid residues V9, A59, E63, Y64, R68, D69, M72, R73, F78, K88, E91, D92, H94, H95, Y96, R97, Q99, R102, and/or V103 of K-Ras or amino acids corresponding thereto.
  • the“Switch 2 - Binding Pocket” or“S2BP” is a cavity bound (the limits or boundaries of which are made), by the amino acid residues A59, Y64, D69, R73, F78, K88, E91, D92, H94, H95, R97, R102, and/or V103 of K-Ras or amino acids corresponding thereto.
  • the“Switch 2 - Binding Pocket” or“S2BP” is a cavity bound (the limits or boundaries of which are made), by the amino acid residues V9, E63, Y64, R68, M72, H94, Y96, and/or Q99 of K-Ras or amino acids corresponding thereto.
  • the “Switch 2 - Binding Pocket” or“S2BP” is a cavity bound (the limits or boundaries of which are made), at least in part, by the amino acid residues corresponding to V9, E63, Y64, R68, M72, H94, Y96, and/or Q99 of K-Ras.
  • the“Switch 2 - Binding Pocket” or“S2BP” is a cavity bound (the limits or boundaries of which are made), at least in part, by the amino acid residues corresponding to V7, V9, T58, A59, G60, E63, Y64, R68, D69, Y71, M72, R73, F78, K88, E91, D92, H94, H95, Y96, R97, Q99, I100, R102, and/or V103 of K-Ras.
  • the“Switch 2 - Binding Pocket” or“S2BP” is a cavity bound (the limits or boundaries of which are made), at least in part, by the amino acid residues corresponding to V7, V9, G10, P34, T58, A59, G60, Q61, E62, E63, Y64, R68, D69, Y71, M72, R73, F78, K88, E91, D92, H94, H95, Y96, R97, Q99, I100, R102, and/or V103 of K-Ras.
  • the “Switch 2 - Binding Pocket” or“S2BP” is a cavity bound (the limits or boundaries of which are made), at least in part, by the amino acid residues corresponding to V9, A59, E63, Y64, R68, D69, M72, R73, F78, K88, E91, D92, H94, H95, Y96, R97, Q99, R102, and/or V103 of K-Ras.
  • the“Switch 2 - Binding Pocket” or“S2BP” is a cavity bound (the limits or boundaries of which are made), at least in part, by the amino acid residues corresponding to A59, Y64, D69, R73, F78, K88, E91, D92, H94, H95, R97, R102, and/or V103 of K-Ras.
  • the“Switch 2 - Binding Pocket” or“S2BP” is a cavity bound (the limits or boundaries of which are made), at least in part, by the amino acid residues corresponding to V9, E63, Y64, R68, M72, H94, Y96, and/or Q99 of K-Ras.
  • the Switch 2 - Binding Pocket is bound at least in part by one or more of V7, V9, G10, P34, T58, G60, Q61, E62, E63, Y64, R68, Y71, M72, H94, Y96, Q99, and/or I100 of K-Ras or equivalent residues in homologous, related (e.g. H-Ras, N-Ras), or mutant Ras proteins.
  • the Switch 2 - Binding Pocket is bound at least in part by one or more of V7, V9, G10, P34, T58, A59, G60, Q61, E62, E63, Y64, R68, D69, Y71, M72, R73, F78, K88, E91, D92, H94, H95, Y96, R97, Q99, I100, R102, or V103 of K-Ras or equivalent residues in homologous, related (e.g. H-Ras, N-Ras), or mutant Ras proteins.
  • the Switch 2 - Binding Pocket is bound at least in part by one or more of V9, A59, E63, Y64, R68, D69, M72, R73, F78, K88, E91, D92, H94, H95, Y96, R97, Q99, R102, or V103 of K-Ras or equivalent residues in homologous, related (e.g. H-Ras, N-Ras), or mutant Ras proteins.
  • the Switch 2 - Binding Pocket is bound at least in part by one or more of V9, E63, Y64, R68, M72, H94, Y96, and/or Q99 of K-Ras or equivalent residues in homologous, related (e.g. H-Ras, N-Ras), or mutant Ras proteins.
  • the Switch 2 - Binding Pocket is bound at least in part by one or more of V7, V9, T58, A59, G60, E63, Y64, R68, D69, Y71, M72, R73, F78, K88, E91, D92, H94, H95, Y96, R97, Q99, I100, R102, or V103 of K-Ras or equivalent residues in homologous, related (e.g. H-Ras, N-Ras), or mutant Ras proteins.
  • the Switch 2 - Binding Pocket is bound at least in part by one or more of V7, V9, G10, P34, T58, A59, G60, Q61, E62, E63, Y64, R68, D69, Y71, M72, R73, F78, K88, E91, D92, H94, H95, Y96, R97, Q99, I100, R102, or V103 of K-Ras or equivalent residues in homologous, related (e.g. H-Ras, N-Ras), or mutant Ras proteins.
  • the Switch 2 - Binding Pocket is bound at least in part by one or more of V9, A59, E63, Y64, R68, D69, M72, R73, F78, K88, E91, D92, H94, H95, Y96, R97, Q99, R102, and/or V103, of K-Ras or equivalent residues in homologous, related (e.g. H-Ras, N-Ras), or mutant Ras proteins.
  • the Switch 2 - Binding Pocket is bound at least in part by one or more of A59, Y64, D69, R73, F78, K88, E91, D92, H94, H95, R97, R102, or V103 of K- Ras or equivalent residues in homologous, related (e.g. H-Ras, N-Ras), or mutant Ras proteins.
  • the Switch 2 - Binding Pocket is bound at least in part by one or more of V9, E63, Y64, R68, M72, H94, Y96, or Q99 of K-Ras or equivalent residues in homologous, related (e.g. H-Ras, N-Ras), or mutant Ras proteins.
  • a compound as described herein, which binds to amino acids that form or contacts amino acids that form the Switch 2 - Binding Pocket is a“Switch 2 - Binding Pocket binding compound” and a moiety of a compound that binds to amino acids that form or contacts amino acids that form the Switch 2 - Binding Pocket is a “Switch 2 - Binding Pocket binding moiety”.
  • a compound as described herein, which binds to amino acids that form or contacts amino acids that form the Switch 2 Groove is a“Switch 2 Groove binding compound” and a moiety of a compound that binds to amino acids that form or contacts amino acids that form the Switch 2 Groove is a“Switch 2 Groove binding moiety”.
  • a Switch 2 - Binding Pocket binding compound or Switch 2 - Binding Pocket binding moiety binds or contacts at least one amino acid that forms the Switch 2 - Binding Pocket. In some embodiments, a Switch 2 - Binding Pocket binding compound or Switch 2 - Binding Pocket binding moiety binds or contacts multiple amino acids that form the Switch 2 - Binding Pocket. In some embodiments, a Switch 2 Groove binding compound or Switch 2 Groove binding moiety binds or contacts at least one amino acid that forms the Switch 2 Groove. In some embodiments, a Switch 2 Groove binding compound or Switch 2 Groove binding moiety binds or contacts multiple amino acids that form the Switch 2 Groove.
  • a Switch 2 - Binding Pocket binding compound or Switch 2 - Binding Pocket binding moiety binds or contacts at least one K-Ras amino acid selected from V7, V9, G10, P34, T58, G60, Q61, E62, E63, Y64, R68, Y71, M72, H94, Y96, Q99, and I100 or amino acids corresponding thereto.
  • a Switch 2 - Binding Pocket binding compound or Switch 2 - Binding Pocket binding moiety binds or contacts multiple (e.g, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15) K-Ras amino acids selected from V7, V9, G10, P34, T58, G60, Q61, E62, E63, Y64, R68, Y71, M72, H94, Y96, Q99, and I100 or amino acids
  • a Switch 2 - Binding Pocket binding compound or Switch 2 - Binding Pocket binding moiety binds or contacts one K-Ras amino acid selected from V9, E63, Y64, R68, M72, H94, Y96, and Q99 or amino acids corresponding thereto.
  • a Switch 2 - Binding Pocket binding compound or Switch 2 - Binding Pocket binding moiety binds or contacts multiple (e.g, 2, 3, 4, 5, 6, 7, or 8) K-Ras amino acids selected from V9, E63, Y64, R68, M72, H94, Y96, and Q99 or amino acids corresponding thereto.
  • a Switch 2 - Binding Pocket binding compound or Switch 2 - Binding Pocket binding moiety binds or contacts at least one K-Ras amino acid selected from V7, V9, T58, A59, G60, E63, Y64, R68, D69, Y71, M72, R73, F78, K88, E91, D92, H94, H95, Y96, R97, Q99, I100, R102, and V103 or amino acids corresponding thereto.
  • a Switch 2 - Binding Pocket binding compound or Switch 2 - Binding Pocket binding moiety binds or contacts at least one K-Ras amino acid selected from V7, V9, G10, P34, T58, A59, G60, Q61, E62, E63, Y64, R68, D69, Y71, M72, R73, F78, K88, E91, D92, H94, H95, Y96, R97, Q99, I100, R102, and V103 or amino acids corresponding thereto.
  • a Switch 2 - Binding Pocket binding compound or Switch 2 - Binding Pocket binding moiety binds or contacts at least one K-Ras amino acid selected from V9, A59, E63, Y64, R68, D69, M72, R73, F78, K88, E91, D92, H94, H95, Y96, R97, Q99, R102, and V103, or amino acids corresponding thereto.
  • a Switch 2 - Binding Pocket binding compound or Switch 2 - Binding Pocket binding moiety binds or contacts multiple (e.g, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24) K-Ras amino acids selected from V7, V9, T58, A59, G60, E63, Y64, R68, D69, Y71, M72, R73, F78, K88, E91, D92, H94, H95, Y96, R97, Q99, I100, R102, and V103 or amino acids corresponding thereto.
  • K-Ras amino acids selected from V7, V9, T58, A59, G60, E63, Y64, R68, D69, Y71, M72, R73, F78, K88, E91, D92, H94, H95, Y96, R97, Q99, I100, R102, and V103 or amino acids corresponding thereto.
  • a Switch 2 - Binding Pocket binding compound or Switch 2 - Binding Pocket binding moiety binds or contacts multiple (e.g, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, or 28) K-Ras amino acids selected from V7, V9, G10, P34, T58, A59, G60, Q61, E62, E63, Y64, R68, D69, Y71, M72, R73, F78, K88, E91, D92, H94, H95, Y96, R97, Q99, I100, R102, and V103 or amino acids corresponding thereto.
  • K-Ras amino acids selected from V7, V9, G10, P34, T58, A59, G60, Q61, E62, E63, Y64, R68, D69, Y71, M72, R73, F78, K88, E91, D92, H94, H95, Y96, R97,
  • a Switch 2 - Binding Pocket binding compound or Switch 2 - Binding Pocket binding moiety binds or contacts multiple (e.g, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, or 19) K-Ras amino acids selected from V9, A59, E63, Y64, R68, D69, M72, R73, F78, K88, E91, D92, H94, H95, Y96, R97, Q99, R102, and V103, or amino acids corresponding thereto.
  • a Switch 2 - Binding Pocket binding compound or Switch 2 - Binding Pocket binding moiety binds or contacts at least one K-Ras amino acid selected from A59, Y64, D69, R73, F78, K88, E91, D92, H94, H95, R97, R102, or V103 or amino acids corresponding thereto.
  • a Switch 2 - Binding Pocket binding compound or Switch 2 - Binding Pocket binding moiety binds or contacts multiple (e.g, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or 13) K-Ras amino acids selected from A59, Y64, D69, R73, F78, K88, E91, D92, H94, H95, R97, R102, or V103 or amino acids corresponding thereto.
  • K-Ras amino acids selected from A59, Y64, D69, R73, F78, K88, E91, D92, H94, H95, R97, R102, or V103 or amino acids corresponding thereto.
  • a Switch 2 - Binding Pocket binding compound or Switch 2 - Binding Pocket binding moiety binds or contacts at least one amino acid selected from amino acids in a mutant K-Ras, related Ras (H-Ras, N-Ras), or homolog of K-Ras corresponding to K- Ras residues V7, V9, G10, P34, T58, G60, Q61, E62, E63, Y64, R68, Y71, M72, H94, Y96, Q99, and I100 or amino acids corresponding thereto.
  • a Switch 2 - Binding Pocket binding compound or Switch 2 - Binding Pocket binding moiety binds or contacts multiple (e.g, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15) K-Ras amino acids selected from amino acids in a mutant K-Ras, related Ras (H-Ras, N-Ras), or homolog of K-Ras corresponding to K-Ras residues V7, V9, G10, P34, T58, G60, Q61, E62, E63, Y64, R68, Y71, M72, H94, Y96, Q99, and I100 or amino acids corresponding thereto.
  • K-Ras amino acids selected from amino acids in a mutant K-Ras, related Ras (H-Ras, N-Ras), or homolog of K-Ras corresponding to K-Ras residues V7, V9, G10, P34, T58, G60, Q61, E62, E63, Y
  • a Switch 2 - Binding Pocket binding compound or Switch 2 - Binding Pocket binding moiety binds or contacts one amino acid selected from amino acids in a mutant K-Ras, related Ras (H-Ras, N- Ras), or homolog of K-Ras corresponding to K-Ras residues V9, E63, Y64, R68, M72, H94, Y96, and Q99 or amino acids corresponding thereto.
  • a Switch 2 - Binding Pocket binding compound or Switch 2 - Binding Pocket binding moiety binds or contacts multiple (e.g, 2, 3, 4, 5, 6, 7, or 8) K-Ras amino acids selected from amino acids in a mutant K-Ras, related Ras (H-Ras, N-Ras), or homolog of K-Ras corresponding to K-Ras residues V9, E63, Y64, R68, M72, H94, Y96, and Q99 or amino acids corresponding thereto.
  • a Switch 2 - Binding Pocket binding compound or Switch 2 - Binding Pocket binding moiety binds or contacts at least one amino acid selected from amino acids in a mutant K-Ras, related Ras (H-Ras, N-Ras), or homolog of K-Ras corresponding to K-Ras residues V7, V9, T58, A59, G60, E63, Y64, R68, D69, Y71, M72, R73, F78, K88, E91, D92, H94, H95, Y96, R97, Q99, I100, R102, or V103 or amino acids corresponding thereto.
  • a Switch 2 - Binding Pocket binding compound or Switch 2 - Binding Pocket binding moiety binds or contacts at least one amino acid selected from amino acids in a mutant K-Ras, related Ras (H-Ras, N-Ras), or homolog of K-Ras corresponding to K-Ras residues V7, V9, G10, P34, T58, A59, G60, Q61, E62, E63, Y64, R68, D69, Y71, M72, R73, F78, K88, E91, D92, H94, H95, Y96, R97, Q99, I100, R102, or V103 or amino acids corresponding thereto.
  • a Switch 2 - Binding Pocket binding compound or Switch 2 - Binding Pocket binding moiety binds or contacts at least one amino acid selected from amino acids in a mutant K-Ras, related Ras (H-Ras, N-Ras), or homolog of K-Ras corresponding to K-Ras residues V9, A59, E63, Y64, R68, D69, M72, R73, F78, K88, E91, D92, H94, H95, Y96, R97, Q99, R102, or V103, or amino acids corresponding thereto.
  • a Switch 2 - Binding Pocket binding compound or Switch 2 - Binding Pocket binding moiety binds or contacts multiple (e.g, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24) K-Ras amino acids selected from amino acids in a mutant K-Ras, related Ras (H-Ras, N- Ras), or homolog of K-Ras corresponding to K-Ras residues V7, V9, T58, A59, G60, E63, Y64, R68, D69, Y71, M72, R73, F78, K88, E91, D92, H94, H95, Y96, R97, Q99, I100, R102, or V103 or amino acids corresponding thereto.
  • K-Ras amino acids selected from amino acids in a mutant K-Ras, related Ras (H-Ras, N- Ras), or homolog of K-Ras corresponding to K-Ras residues V7,
  • a Switch 2 - Binding Pocket binding compound or Switch 2 - Binding Pocket binding moiety binds or contacts multiple (e.g, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, or 28) K- Ras amino acids selected from amino acids in a mutant K-Ras, related Ras (H-Ras, N-Ras), or homolog of K-Ras corresponding to K-Ras residues V7, V9, G10, P34, T58, A59, G60, Q61, E62, E63, Y64, R68, D69, Y71, M72, R73, F78, K88, E91, D92, H94, H95, Y96, R97, Q99, I100, R102, or V103 or amino acids corresponding thereto.
  • K- Ras amino acids selected from amino acids in a mutant K-Ras, related Ras (H-Ras, N-Ras), or homolog of K-
  • a Switch 2 - Binding Pocket binding compound or Switch 2 - Binding Pocket binding moiety binds or contacts multiple (e.g, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, or 19) K-Ras amino acids selected from amino acids in a mutant K-Ras, related Ras (H-Ras, N-Ras), or homolog of K-Ras corresponding to K-Ras residues V9, A59, E63, Y64, R68, D69, M72, R73, F78, K88, E91, D92, H94, H95, Y96, R97, Q99, R102, or V103, or amino acids corresponding thereto.
  • K-Ras amino acids selected from amino acids in a mutant K-Ras, related Ras (H-Ras, N-Ras), or homolog of K-Ras corresponding to K-Ras residues V9, A59, E63, Y64, R68, D69,
  • a Switch 2 - Binding Pocket binding compound or Switch 2 - Binding Pocket binding moiety binds or contacts at least one amino acid selected from amino acids in a mutant K-Ras, related Ras (H-Ras, N-Ras), or homolog of K-Ras corresponding to K-Ras residues A59, Y64, D69, R73, F78, K88, E91, D92, H94, H95, R97, R102, or V103 or amino acids corresponding thereto.
  • a Switch 2 - Binding Pocket binding compound or Switch 2 - Binding Pocket binding moiety binds or contacts multiple (e.g, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or 13) K-Ras amino acids selected from amino acids in a mutant K-Ras, related Ras (H-Ras, N-Ras), or homolog of K-Ras corresponding to K-Ras residues A59, Y64, D69, R73, F78, K88, E91, D92, H94, H95, R97, R102, or V103 or amino acids corresponding thereto.
  • multiple e.g, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or 13
  • K-Ras amino acids selected from amino acids in a mutant K-Ras, related Ras (H-Ras, N-Ras), or homolog of K-Ras corresponding to K-Ras residues A59, Y64, D69, R73, F78, K88, E91, D92
  • a substituted or unsubstituted moiety e.g., substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, and/or substituted or unsubstituted heteroarylene) is unsubstituted (e.g., is an unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted
  • a substituted or unsubstituted moiety e.g., substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, and/or substituted or unsubstituted heteroarylene) is substituted (e.g., is a substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, substituted heteroaryl, substituted alky
  • a substituted moiety e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, substituted heteroaryl, substituted alkylene, substituted heteroalkylene, substituted cycloalkylene, substituted heterocycloalkylene, substituted arylene, and/or substituted heteroarylene
  • is substituted with at least one substituent group wherein if the substituted moiety is substituted with a plurality of substituent groups, each substituent group may optionally be different. In embodiments, if the substituted moiety is substituted with a plurality of substituent groups, each substituent group is different.
  • a substituted moiety e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, substituted heteroaryl, substituted alkylene, substituted heteroalkylene, substituted cycloalkylene, substituted heterocycloalkylene, substituted arylene, and/or substituted heteroarylene
  • is substituted with at least one size-limited substituent group wherein if the substituted moiety is substituted with a plurality of size-limited substituent groups, each size-limited substituent group may optionally be different.
  • each size-limited substituent group is different.
  • a substituted moiety e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, substituted heteroaryl, substituted alkylene, substituted heteroalkylene, substituted cycloalkylene, substituted heterocycloalkylene, substituted arylene, and/or substituted heteroarylene
  • each lower substituent group is different.
  • a substituted moiety e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, substituted heteroaryl, substituted alkylene, substituted heteroalkylene, substituted cycloalkylene, substituted heterocycloalkylene, substituted arylene, and/or substituted heteroarylene
  • a compound e.g., Switch 2 - Binding Pocket binding compound, Switch 2 Groove binding compound
  • a Ras protein e.g., K-Ras, N-Ras, H-Ras, human K-Ras, human N-Ras and/or human H-Ras protein
  • the compound may contact a residue of a Ras protein Switch 2 binding pocket.
  • the compound e.g., Switch 2 - Binding Pocket binding compound, Switch 2 Groove binding compound
  • a Ras protein e.g., K-Ras, N-Ras, H-Ras, human K-Ras, human N-Ras and/or human H-Ras protein.
  • the compound may contact a plurality of residues of a Ras protein Switch 2 binding pocket.
  • the residue of the Switch 2 binding pocket that contacts the compound may be V7, V9, G10, P34, T58, G60, Q61, E62, E63, Y64, R68, Y71, M72, H94, Y96, Q99, or I100 or amino acids corresponding thereto.
  • the residue of the Switch 2 binding pocket that contacts the compound may be V7, V9, T58, A59, G60, E63, Y64, R68, D69, Y71, M72, R73, F78, K88, E91, D92, H94, H95, Y96, R97, Q99, I100, R102, or V103 or amino acids corresponding thereto.
  • the residue of the Switch 2 binding pocket that contacts the compound may be V7, V9, G10, P34, T58, A59, G60, Q61, E62, E63, Y64, R68, D69, Y71, M72, R73, F78, K88, E91, D92, H94, H95, Y96, R97, Q99, I100, R102, or V103 or amino acids corresponding thereto.
  • the residue of the Switch 2 binding pocket that contacts the compound may be V9, A59, E63, Y64, R68, D69, M72, R73, F78, K88, E91, D92, H94, H95, Y96, R97, Q99, R102, or V103, or amino acids corresponding thereto.
  • the residue of the Switch 2 binding pocket that contacts the compound may be A59, Y64, D69, R73, F78, K88, E91, D92, H94, H95, R97, R102, or V103 or amino acids corresponding thereto.
  • the residue of the Switch 2 binding pocket that contacts the compound may be V9, E63, Y64, R68, M72, H94, Y96, or Q99 or amino acids corresponding thereto. In embodiments, the residue of the Switch 2 binding pocket that contacts the compound may be V7, V9, G10, P34, T58, G60, Q61, E62, E63, R68, Y71, M72, Y96, Q99, or I100 or amino acids corresponding thereto. In embodiments, the residue of the Switch 2 binding pocket that contacts the compound may be V9, E63, Y64, R68, M72, H94, Y96, or Q99 or amino acids corresponding thereto.
  • the compound contacts at least one of V7, V9, T58, A59, G60, E63, Y64, R68, D69, Y71, M72, R73, F78, K88, E91, D92, H94, H95, Y96, R97, Q99, I100, R102, or V103 or amino acids corresponding thereto.
  • the compound contacts at least one of V7, V9, G10, P34, T58, A59, G60, Q61, E62, E63, Y64, R68, D69, Y71, M72, R73, F78, K88, E91, D92, H94, H95, Y96, R97, Q99, I100, R102, or V103 or amino acids corresponding thereto.
  • the compound contacts at least one of V9, A59, E63, Y64, R68, D69, M72, R73, F78, K88, E91, D92, H94, H95, Y96, R97, Q99, R102, or V103, or amino acids corresponding thereto. In some embodiments, the compound contacts at least one of A59, Y64, D69, R73, F78, K88, E91, D92, H94, H95, R97, R102, or V103 or amino acids corresponding thereto. In some embodiments, the compound contacts at least one of V9, E63, Y64, R68, M72, H94, Y96, or Q99 or amino acids corresponding thereto.
  • the compound contacts at least one of V9, E63, Y64, R68, M72, H94, Y96, or Q99 or amino acids corresponding thereto. In some embodiments, the compound contacts at least one of Y64 and H94 or amino acids corresponding thereto. In some embodiments, the compound contacts at least one of G60, E62, or E63 or amino acids corresponding thereto.
  • the compound is a Ras modulator (e.g., Ras inhibitor, K-Ras modulator, H-Ras modulator, K-Ras inhibitor, H-Ras inhibitor, human Ras modulator, human Ras inhibitor, human K-Ras modulator, human H-Ras modulator, human K-Ras inhibitor, or human H-Ras inhibitor).
  • the amino acid numbering used above is human K-Ras amino acid numbering.
  • the compound covalently reacts with an amino acid residue of the Ras protein to form a covalent bond (e.g. reversible or irreversible).
  • the amino acid residue is a cysteine, aspartate, lysine, tyrosine or glutamate residue of the Ras protein.
  • the amino acid residue is a cysteine residue, for example a G12C or G13C residue of a K-Ras protein.
  • the amino acid residue is an aspartate residue, for example a G12D or G13D residue of a K-Ras protein.
  • a novel Ras modulator e.g., Ras inhibitor, K-Ras modulator, H-Ras modulator, K-Ras inhibitor, H-Ras inhibitor, human Ras modulator, human Ras inhibitor, human K-Ras modulator, human H-Ras modulator, human K-Ras inhibitor, or human H-Ras inhibitor.
  • the Ras modulator may be a Switch 2 - Binding Pocket binding compound or a compound described herein.
  • the Ras modulator may be a Switch 2 Groove binding compound or a compound described herein.
  • the Switch 2 - Binding Pocket binding compounds of the present disclosure are compounds containing a Switch 2 - Binding Pocket binding moiety.
  • the compound may contact a residue of a Ras protein Switch 2 binding pocket.
  • the residue of the Switch 2 binding pocket that contacts the compound may be V7, V9, T58, A59, G60, E63, Y64, R68, D69, Y71, M72, R73, F78, K88, E91, D92, H94, H95, Y96, R97, Q99, I100, R102, or V103 or amino acids corresponding thereto.
  • the residue of the Switch 2 binding pocket that contacts the compound may be V7, V9, G10, P34, T58, A59, G60, Q61, E62, E63, Y64, R68, D69, Y71, M72, R73, F78, K88, E91, D92, H94, H95, Y96, R97, Q99, I100, R102, or V103 or amino acids corresponding thereto.
  • the residue of the Switch 2 binding pocket that contacts the compound may be V9, A59, E63, Y64, R68, D69, M72, R73, F78, K88, E91, D92, H94, H95, Y96, R97, Q99, R102, or V103, or amino acids corresponding thereto.
  • the residue of the Switch 2 binding pocket that contacts the compound may be A59, Y64, D69, R73, F78, K88, E91, D92, H94, H95, R97, R102, or V103 or amino acids corresponding thereto.
  • the residue of the Switch 2 binding pocket that contacts the compound may be V9, E63, Y64, R68, M72, H94, Y96, or Q99 or amino acids corresponding thereto. In embodiments, the residue of the Switch 2 binding pocket that contacts the compound may be V7, V9, G10, P34, T58, G60, Q61, E62, E63, Y64, R68, Y71, M72, H94, Y96, Q99, or I100 or amino acids corresponding thereto.
  • the residue of the Switch 2 binding pocket that contacts the compound may be V7, V9, G10, P34, T58, G60, Q61, E62, E63, R68, Y71, M72, Y96, Q99, or I100 or amino acids corresponding thereto. In embodiments, the residue of the Switch 2 binding pocket that contacts the compound may be V9, E63, Y64, R68, M72, H94, Y96, or Q99 or amino acids corresponding thereto. In some embodiments, the compound contacts at least one of V9, E63, Y64, R68, M72, H94, Y96, or Q99 or amino acids corresponding thereto. In some embodiments,
  • the compound contacts at least one of Y64 and H94 or amino acids corresponding thereto. In some embodiments, the compound contacts at least one of G60, E62, or E63 or amino acids corresponding thereto. In some embodiments, the compound contacts at least one of V7, V9, T58, A59, G60, E63, Y64, R68, D69, Y71, M72, R73, F78, K88, E91, D92, H94, H95, Y96, R97, Q99, I100, R102, or V103 or amino acids corresponding thereto. In some embodiments, the compound contacts at least one of Y64 and H94 or amino acids corresponding thereto. In some embodiments, the compound contacts at least one of G60, E62, or E63 or amino acids corresponding thereto. In some embodiments, the compound contacts at least one of V7, V9, T58, A59, G60, E63, Y64, R68, D69, Y71, M72, R73, F78, K
  • the compound contacts at least one of V7, V9, G10, P34, T58, A59, G60, Q61, E62, E63, Y64, R68, D69, Y71, M72, R73, F78, K88, E91, D92, H94, H95, Y96, R97, Q99, I100, R102, or V103 or amino acids corresponding thereto.
  • the compound contacts at least one of V9, A59, E63, Y64, R68, D69, M72, R73, F78, K88, E91, D92, H94, H95, Y96, R97, Q99, R102, or V103, or amino acids corresponding thereto.
  • the compound contacts at least one of A59, Y64, D69, R73, F78, K88, E91, D92, H94, H95, R97, R102, or V103 or amino acids corresponding thereto. In some embodiments, the compound contacts at least one of V9, E63, Y64, R68, M72, H94, Y96, or Q99 or amino acids corresponding thereto.
  • the amino acid numbering used above is human K-Ras amino acid numbering.
  • the Switch 2 - Binding Pocket binding moiety displaces at least one water molecule within the Switch 2 - Binding Pocket.
  • the Switch 2 - Binding Pocket binding moiety may also contact one or more amino acids that from part of the Switch 2 - Binding Pocket.
  • a description of the Switch 2 - Binding Pocket and methods of determining whether a substituent fills space within the Switch 2 - Binding Pocket are set forth herein. [0196] In an aspect is provided a compound having the formula:
  • R 1 is independently halogen, -CX 1 3, -CHX 1 2, -CH2X 1 , -OCX 1 3, - OCH 2 X 1 , -OCHX 1 2 , -CN, -SO n1 R 1D , -SO v1 NR 1A R 1B , -NHC(O)NR 1A R 1B , -N(O) m1 , -NR 1A R 1B , -C( O)R 1C , -C(O)-OR 1C , -C(O)NR 1A R 1B , -OR 1D , -NR 1A SO 2 R 1D , -NR 1A C(O)R 1C , -NR 1A C(O)OR 1C , -N R 1A OR 1C , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted
  • unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroarylR 2 is independently halogen, -CX 2 3 , -CHX 2 2 , -CH 2 X 2 , -OCX 2 3 , - OCH 2 X 2 , -OCHX 2 2 , -CN, -SO n2 R 2D , -SO v2 NR 2A R 2B , -NHC(O)NR 2A R 2B , -N(O) m2 , -NR 2A R 2B , -C( O)R 2C , -C(O)-OR 2C , -C(O)NR 2A R 2B , -OR 2D , -NR 2A SO2R 2D , -NR 2A C(O)R 2C , -NR 2A C(O)OR 2C , -N R 2
  • R 8 is independently hydrogen, halogen, -CX 8 3, -CHX 8 2, -CH2X 8 , -OCX 8 3, - OCH2X 8 , -OCHX 8 2, -CN, -SOn8R 8D , -SOv8NR 8A R 8B , -NHC(O)NR 8A R 8B , -N(O)m8, -NR 8A R 8B , -C( O)R 8C , -C(O)-OR 8C , -C(O)NR 8A R 8B , -OR 8D , -NR 8A SO 2 R 8D , -NR 8A C(O)R 8C , -NR 8A C(O)OR 8C , -N R 8A OR 8C , E, substituted or unsubsti
  • E is an electrophilic moiety.
  • Each R 1A , R 1B , R 1C , R 1D , R 2A , R 2B , R 2C , R 2D , R 7A , R 7B , R 7C , R 7D , R 8A , R 8B , R 8C , and R 8D is independently hydrogen, -CX 3 , -CN, -COOH, -CONH 2 , -CHX 2 , -CH 2 X, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R 1A and R 1B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or un
  • z1 is an integer from 0 to 5.
  • z2 is an integer from 0 to 3.
  • z7 is an integer from 0 to 4.
  • Each X, X 1 , X 2 , X 7 , and X 8 is independently– F, -Cl, -Br, or–I.
  • n1, n2, n7, and n8 are independently an integer from 0 to 4.
  • m1, m2, m7, m8, v1, v2, v7, and v8 are independently 1 or 2.
  • the compound has the formula: wherein R 8 , L 3 , R 2 , and R 1 are as described herein, including embodiments.
  • the compound has the formula:
  • R 8 , L 3 , R 7 , z7, R 2 , and R 1 are as described herein, including embodiments.
  • the compound has the formula:
  • the compound has the formula: [0202] In embodiments, the compound has the formula:
  • R 1 is independently halogen, -CX 1 3, -CHX 1 2, -CH2X 1 , -OCX 1 3, - OCH2X 1 , -OCHX 1 2, -CN, -SOn1R 1D , -SOv1NR 1A R 1B , -NHC(O)NR 1A R 1B , -N(O)m1, -NR 1A R 1B , -C( O)R 1C , -C(O)-OR 1C , -C(O)NR 1A R 1B , -OR 1D , -NR 1A SO 2 R 1D , -NR 1A C(O)R 1C , -NR 1A C(O)OR 1C , -N R 1A OR 1C , substituted or unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2),
  • R 1 is independently halogen, -CX 1 3, -CHX 1 2, -CH2X 1 , -OCX 1 3, - OCH2X 1 , -OCHX 1 2, substituted or unsubstituted alkyl, or substituted or unsubstituted
  • R 1 is independently halogen, -CX 1 3 , -CHX 1 2 , -CH 2 X 1 , -OCX 1 3 , - OCH2X 1 , -OCHX 1 2, substituted or unsubstituted (C1-C4) alkyl, or substituted or unsubstituted 2 to 4 membered heteroalkyl.
  • R 1 is
  • R 1 is halogen, -CH3, -CH2CH3, -CF3, or -OCH3. In embodiments, R 1 is -CH3, -CH2CH3, or -OCH3. In embodiments, R 1 is -OCH3.
  • R 1 is independently halogen, -CX 1 3 , -CHX 1 2 , -CH 2 X 1 , -OCX 1 3 , - OCH 2 X 1 , -OCHX 1 2 , -CN, substituted or unsubstituted alkyl, or substituted or unsubstituted heteroalkyl.
  • R 1 is independently halogen, -CX 1 3, -CHX 1 2, -CH2X 1 , -OCX 1 3, - OCH2X 1 , -OCHX 1 2, -CN, substituted or unsubstituted (C1-C4) alkyl, or substituted or unsubstituted 2 to 4 membered heteroalkyl.
  • R 1 is
  • R 1 is halogen, -CN, -CH3, -CF3, or -OCH 3 .
  • R 1 is halogen or -CH 3 .
  • R 1 is -Cl or -CH 3 .
  • R 1 is -CH3.
  • R 1 is -CH3 or -CH2CH3. [0205] In embodiments, R 1 is independently
  • R 1 is independently
  • R 1 is independently halogen. In embodiments, R 1 is
  • R 1 is independently -CX 1 3 .
  • R 1 is independently -CHX 1 2 .
  • R 1 is independently -CH2X 1 .
  • R 1 is independently -OCX 1 3.
  • R 1 is independently -OCH 2 X 1 .
  • R 1 is independently -OCHX 1 2 .
  • R 1 is independently -CN.
  • R 1 is independently -SO n1 R 1D .
  • R 1 is independently -SOv1NR 1A R 1B .
  • R 1 is independently -NHC(O)NR 1A R 1B .
  • R 1 is independently -N(O)m1.
  • R 1 is independently -NR 1A R 1B . In embodiments, R 1 is independently -C(O)R 1C . In embodiments, R 1 is independently -C(O)-OR 1C . In embodiments, R 1 is independently -C(O)NR 1A R 1B . In embodiments, R 1 is
  • R 1 independently -OR 1D . In embodiments, R 1 is independently -SR 1D . In embodiments, R 1 is independently -NR 1A SO 2 R 1D . In embodiments, R 1 is independently -NR 1A C(O)R 1C . In embodiments, R 1 is independently -NR 1A C(O)OR 1C . In embodiments, R 1 is
  • R 1 is independently -NR 1A OR 1C .
  • R 1 is independently -OH.
  • R 1 is independently -NH 2 .
  • R 1 is independently -COOH.
  • R 1 is independently -CONH 2 .
  • R 1 is independently -NO 2 .
  • R 1 is independently -SH.
  • R 1 is independently -CF3.
  • R 1 is independently -CHF2.
  • R 1 is independently -CH2F.
  • R 1 is independently -OCF 3 .
  • R 1 is independently -OCH 2 F.
  • R 1 is independently -OCHF2.
  • R 1 is independently–OCH3.
  • R 1 is independently–OCH2CH3. In embodiments, R 1 is independently–OCH2CH2CH3. In embodiments, R 1 is independently–OCH(CH 3 ) 2 . In embodiments, R 1 is independently– OC(CH 3 ) 3 . In embodiments, R 1 is independently–SCH 3 . In embodiments, R 1 is independently –SCH2CH3. In embodiments, R 1 is independently–SCH2CH2CH3. In embodiments, R 1 is independently–SCH(CH 3 ) 2 . In embodiments, R 1 is independently–SC(CH 3 ) 3 . In embodiments, R 1 is independently–CH 3 . In embodiments, R 1 is independently–CH 2 CH 3 . In embodiments, R 1 is independently–CH2CH2CH3.
  • R 1 is independently–CH(CH3)2. In embodiments, R 1 is independently–C(CH3)3. In embodiments, R 1 is independently–F. In embodiments, R 1 is independently–Cl. In embodiments, R 1 is independently–Br. In
  • R 1 is independently–I. In embodiments, X 1 is independently–F. In
  • X 1 is independently–Cl. In embodiments, X 1 is independently–Br. In embodiments, X 1 is independently–I. [0207] In embodiments, R 1 is independently substituted or unsubstituted alkyl (e.g., C 1 -C 8 , C 1 - C 6 , C 1 -C 4 , or C 1 -C 2 ). In embodiments, R 1 is independently substituted alkyl (e.g., C 1 -C 8 , C 1 -C 6 , C1-C4, or C1-C2).
  • R 1 is independently unsubstituted alkyl (e.g., C1-C8, C1-C6, C 1 -C 4 , or C 1 -C 2 ). In embodiments, R 1 is independently unsubstituted methyl. In embodiments, R 1 is independently unsubstituted ethyl. In embodiments, R 1 is independently unsubstituted propyl. In embodiments, R 1 is independently unsubstituted isopropyl. In embodiments, R 1 is independently unsubstituted tert-butyl.
  • R 1 is independently substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered). In embodiments, R 1 is independently substituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered). In embodiments, R 1 is independently unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered).
  • R 1 is independently substituted or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4- C 6 , or C 5 -C 6 ). In embodiments, R 1 is independently substituted cycloalkyl (e.g., C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ). In embodiments, R 1 is independently unsubstituted cycloalkyl (e.g., C 3 -C 8 , C 3 - C6, C4-C6, or C5-C6).
  • R 1 is independently substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered). In embodiments, R 1 is independently substituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered). In embodiments, R 1 is independently unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • R 1 is independently substituted or unsubstituted aryl (e.g., C6-C10 or phenyl). In embodiments, R 1 is independently substituted aryl (e.g., C6-C10 or phenyl). In embodiments, R 1 is independently unsubstituted aryl (e.g., C 6 -C 10 or phenyl). In embodiments, R 1 is independently substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). In embodiments, R 1 is independently substituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
  • R 1 is independently unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). [0208] In embodiments, R 1 is independently halogen, -CX 1 3, -CHX 1 2, -CH2X 1 , -OCX 1 3, - OCH2X 1 , -OCHX 1 2, -CN, -SOn1R 1D , -SOv1NR 1A R 1B , -NHC(O)NR 1A R 1B , -N(O)m1, -NR 1A R 1B , -C(O)R 1C , -C(O)-OR 1C , -C(O)NR 1A R 1B , -OR 1D , -NR 1A SO 2 R 1D , -NR 1A C(O)R 1C , -NR 1A C(O)OR 1C , -NR 1A OR 1C
  • R 1 is independently -OR 1D , substituted or unsubstituted alkyl, or substituted or unsubstituted heteroalkyl. In embodiments, R 1 is independently -OR 1D , wherein R 1D is substituted or unsubstituted alkyl. In embodiments, R 1 is independently -OR 1D , wherein R 1D is substituted or unsubstituted C1-C6 alkyl. In embodiments, R 1 is independently -OR 1D , wherein R 1D is substituted or unsubstituted C 1 -C 4 alkyl. In embodiments, R 1 is
  • R 1D is independently -OR 1D , wherein R 1D is unsubstituted C 1 -C 4 alkyl.
  • R 1 is independently–OCH3.
  • R 1A is independently hydrogen. In embodiments, R 1A is
  • R 1A is independently -CX 1A 3 .
  • R 1A is independently -CHX 1A 2 .
  • R 1A is independently -CH2X 1A .
  • R 1A is independently -CN.
  • R 1A is independently -COOH.
  • R 1A is independently -CONH2.
  • X 1A is independently–F, -Cl, -Br, or -I.
  • R 1A is independently substituted or unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2).
  • R 1A is independently substituted alkyl (e.g., C1-C8, C1- C 6 , C 1 -C 4 , or C 1 -C 2 ). In embodiments, R 1A is independently unsubstituted alkyl (e.g., C 1 -C 8 , C 1 - C 6 , C 1 -C 4 , or C 1 -C 2 ). In embodiments, R 1A is independently unsubstituted methyl. In
  • R 1A is independently unsubstituted ethyl. In embodiments, R 1A is independently unsubstituted propyl. In embodiments, R 1A is independently unsubstituted isopropyl. In embodiments, R 1A is independently unsubstituted tert-butyl. In embodiments, R 1A is
  • R 1A is independently substituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered).
  • R 1A is independently substituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered).
  • R 1A is independently unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered).
  • R 1A is independently substituted or unsubstituted cycloalkyl (e.g., C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ). In embodiments, R 1A is independently substituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6). In embodiments, R 1A is independently unsubstituted cycloalkyl (e.g., C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ).
  • R 1A is independently substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered). In embodiments, R 1A is independently substituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered). In embodiments, R 1A is independently unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • R 1A is independently substituted or unsubstituted aryl (e.g., C 6 -C 10 or phenyl). In embodiments, R 1A is independently substituted aryl (e.g., C6-C10 or phenyl). In embodiments, R 1A is independently unsubstituted aryl (e.g., C6- C10 or phenyl). In embodiments, R 1A is independently substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
  • R 1A is independently substituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). In embodiments, R 1A is independently unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). [0212] In embodiments, R 1B is independently hydrogen. In embodiments, R 1B is
  • R 1B is independently -CX 1B 3.
  • R 1B is independently -CHX 1B 2.
  • R 1B is independently -CH2X 1B .
  • R 1B is independently -CN.
  • R 1B is independently -COOH.
  • R 1B is independently -CONH 2 .
  • X 1B is independently–F, -Cl, -Br, or -I.
  • R 1B is independently substituted or unsubstituted alkyl (e.g., C1-C8, C 1 -C 6 , C 1 -C 4 , or C 1 -C 2 ).
  • R 1B is independently substituted alkyl (e.g., C 1 -C 8 , C 1 - C 6 , C 1 -C 4 , or C 1 -C 2 ). In embodiments, R 1B is independently unsubstituted alkyl (e.g., C 1 -C 8 , C 1 - C6, C1-C4, or C1-C2). In embodiments, R 1B is independently unsubstituted methyl. In
  • R 1B is independently unsubstituted ethyl. In embodiments, R 1B is independently unsubstituted propyl. In embodiments, R 1B is independently unsubstituted isopropyl. In embodiments, R 1B is independently unsubstituted tert-butyl. In embodiments, R 1B is
  • R 1B is independently substituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered).
  • R 1B is independently substituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered).
  • R 1B is independently unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered).
  • R 1B is independently substituted or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6). In embodiments, R 1B is independently substituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6). In embodiments, R 1B is independently unsubstituted cycloalkyl (e.g., C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ).
  • R 1B is independently substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • R 1B is independently substituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • R 1B is independently unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • R 1B is independently substituted or unsubstituted aryl (e.g., C6-C10 or phenyl). In embodiments, R 1B is independently substituted aryl (e.g., C6-C10 or phenyl). In embodiments, R 1B is independently unsubstituted aryl (e.g., C6- C 10 or phenyl). In embodiments, R 1B is independently substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
  • R 1B is independently substituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). In embodiments, R 1B is independently unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). [0214] In embodiments, R 1A and R 1B substituents bonded to the same nitrogen atom may be joined to form a substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • a substituted or unsubstituted heterocycloalkyl e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered.
  • R 1A and R 1B substituents bonded to the same nitrogen atom may be joined to form a substituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • R 1A and R 1B substituents bonded to the same nitrogen atom may be joined to form an unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • R 1A and R 1B substituents bonded to the same nitrogen atom may be joined to form a substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
  • R 1A and R 1B substituents bonded to the same nitrogen atom may be joined to form a substituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
  • R 1A and R 1B substituents bonded to the same nitrogen atom may be joined to form an unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
  • R 1C is independently hydrogen. In embodiments, R 1C is
  • R 1C is independently -CX 1C 3 .
  • R 1C is independently -CHX 1C 2 .
  • R 1C is independently -CH2X 1C .
  • R 1C is independently -CN.
  • R 1C is independently -COOH.
  • R 1C is independently -CONH 2 .
  • X 1C is independently–F, -Cl, -Br, or -I.
  • R 1C is independently substituted or unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2).
  • R 1C is independently substituted alkyl (e.g., C1-C8, C1- C 6 , C 1 -C 4 , or C 1 -C 2 ). In embodiments, R 1C is independently unsubstituted alkyl (e.g., C 1 -C 8 , C 1 - C6, C1-C4, or C1-C2). In embodiments, R 1C is independently unsubstituted methyl. In
  • R 1C is independently unsubstituted ethyl. In embodiments, R 1C is independently unsubstituted propyl. In embodiments, R 1C is independently unsubstituted isopropyl. In embodiments, R 1C is independently unsubstituted tert-butyl. In embodiments, R 1C is
  • R 1C is independently substituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered).
  • R 1C is independently substituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered).
  • R 1C is independently unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered).
  • R 1C is independently substituted or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6). In embodiments, R 1C is independently substituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6). In embodiments, R 1C is independently unsubstituted cycloalkyl (e.g., C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ).
  • R 1C is independently substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered). In embodiments, R 1C is independently substituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered). In embodiments, R 1C is independently unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • R 1C is independently substituted or unsubstituted aryl (e.g., C 6 -C 10 or phenyl). In embodiments, R 1C is independently substituted aryl (e.g., C6-C10 or phenyl). In embodiments, R 1C is independently unsubstituted aryl (e.g., C6- C10 or phenyl). In embodiments, R 1C is independently substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
  • R 1C is independently substituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). In embodiments, R 1C is independently unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). [0218] In embodiments, R 1D is independently hydrogen. In embodiments, R 1D is
  • R 1D is independently -CX 1D 3.
  • R 1D is independently -CHX 1D 2.
  • R 1D is independently -CH 2 X 1D .
  • R 1D is independently -CN.
  • R 1D is independently -COOH.
  • R 1D is independently -CONH 2 .
  • X 1D is independently–F, -Cl, -Br, or -I. [0219] In embodiments, R 1D is independently substituted or unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2).
  • R 1D is independently substituted alkyl (e.g., C1-C8, C1- C 6 , C 1 -C 4 , or C 1 -C 2 ). In embodiments, R 1D is independently unsubstituted alkyl (e.g., C 1 -C 8 , C 1 - C6, C1-C4, or C1-C2). In embodiments, R 1D is independently unsubstituted methyl. In
  • R 1D is independently unsubstituted ethyl. In embodiments, R 1D is independently unsubstituted propyl. In embodiments, R 1D is independently unsubstituted isopropyl. In embodiments, R 1D is independently unsubstituted tert-butyl. In embodiments, R 1D is
  • R 1D is independently substituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered).
  • R 1D is independently substituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered).
  • R 1D is independently unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered).
  • R 1D is independently substituted or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6). In embodiments, R 1D is independently substituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6). In embodiments, R 1D is independently unsubstituted cycloalkyl (e.g., C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ).
  • R 1D is independently substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered). In embodiments, R 1D is independently substituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered). In embodiments, R 1D is independently unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • R 1D is independently substituted or unsubstituted aryl (e.g., C 6 -C 10 or phenyl). In embodiments, R 1D is independently substituted aryl (e.g., C6-C10 or phenyl). In embodiments, R 1D is independently unsubstituted aryl (e.g., C6- C10 or phenyl). In embodiments, R 1D is independently substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
  • R 1D is independently substituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). In embodiments, R 1D is independently unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). [0220] In embodiments, R 1 is independently substituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). [0220] In embodiments, R 1 is independently substituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). [0220] In embodiments, R 1 is independently
  • X 1 is independently–F, -Cl, -Br, or–I. In embodiments, R 1 is independently unsubstituted methyl. In embodiments, R 1 is independently unsubstituted ethyl. [0221] R 20 is independently oxo,
  • unsubstituted alkyl e.g., C1-C8, C1-C6, C1-C4, or C1-C2
  • R 21 -substituted or unsubstituted heteroalkyl e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered
  • R 21 -substituted or unsubstituted cycloalkyl e.g., C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6
  • R 21 -substituted or unsubstituted heterocycloalkyl e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered
  • R 21 -substituted or unsubstituted aryl e.g., C6
  • X 20 is independently–F, -Cl, -Br, or–I.
  • R 20 is independently unsubstituted methyl.
  • R 20 is independently unsubstituted ethyl.
  • R 21 is independently oxo,
  • X 21 is independently–F, -Cl, -Br, or–I. In embodiments, R 21 is independently unsubstituted methyl. In embodiments, R 21 is independently unsubstituted ethyl. [0223] R 22 is independently oxo,
  • X 22 is independently–F, -Cl, -Br, or–I. In embodiments, R 22 is independently unsubstituted methyl. In embodiments, R 22 is independently unsubstituted ethyl. [0224] In embodiments, R 1A is independently
  • R 20A -substituted or unsubstituted alkyl e.g., C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2
  • R 20A -substituted or unsubstituted heteroalkyl e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered
  • R 20A -substituted or unsubstituted cycloalkyl e.g., C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6
  • R 20A - substituted or unsubstituted heterocycloalkyl e.g.
  • unsubstituted alkyl e.g., C1-C8, C1-C6, C1-C4, or C1-C2
  • unsubstituted heteroalkyl e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered
  • unsubstituted cycloalkyl e.g., C 3 -C 8 , C 3 - C 6 , C 4 -C 6 , or C 5 -C 6
  • unsubstituted heterocycloalkyl e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered
  • unsubstituted aryl e.g., C6-C10 or
  • X 1A is independently–F, -Cl, -Br, or–I.
  • R 1A is independently hydrogen.
  • R 1A is independently unsubstituted methyl.
  • R 1A is independently unsubstituted ethyl.
  • R 1A and R 1B substituents bonded to the same nitrogen atom may optionally be joined to form a R 20A -substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered) or R 20A - substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
  • a R 20A -substituted or unsubstituted heterocycloalkyl e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered
  • R 20A - substituted or unsubstituted heteroaryl e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered
  • R 1A and R 1B substituents bonded to the same nitrogen atom may optionally be joined to form an unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered) or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
  • an unsubstituted heterocycloalkyl e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered
  • unsubstituted heteroaryl e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered.
  • R 1A and R 1B substituents bonded to the same nitrogen atom may optionally be joined to form a R 20A - substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • R 1A and R 1B substituents bonded to the same nitrogen atom may optionally be joined to form an unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • R 20A is independently oxo
  • X 20A is independently–F, -Cl, -Br, or–I.
  • R 20A is independently unsubstituted methyl.
  • R 20A is independently unsubstituted ethyl.
  • R 1B is independently
  • R 20B -substituted or unsubstituted alkyl e.g., C1-C8, C1-C6, C1-C4, or C1-C2
  • R 20B -substituted or unsubstituted heteroalkyl e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered
  • R 20B -substituted or unsubstituted cycloalkyl e.g., C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6
  • R 20B - substituted or unsubstituted heterocycloalkyl e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6
  • unsubstituted alkyl e.g., C1-C8, C 1 -C 6 , C 1 -C 4 , or C 1 -C 2
  • unsubstituted heteroalkyl e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered
  • unsubstituted cycloalkyl e.g., C3-C8, C3- C6, C4-C6, or C5-C6
  • unsubstituted heterocycloalkyl e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered
  • unsubstituted aryl e.g., C 6 -C 10 or pheny
  • X 1B is independently–F, -Cl, -Br, or–I.
  • R 1B is independently hydrogen.
  • R 1B is independently unsubstituted methyl.
  • R 1B is independently unsubstituted ethyl.
  • R 1A and R 1B substituents bonded to the same nitrogen atom may optionally be joined to form a R 20B -substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered) or R 20B - substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
  • a R 20B -substituted or unsubstituted heterocycloalkyl e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered
  • R 20B - substituted or unsubstituted heteroaryl e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered
  • R 1A and R 1B substituents bonded to the same nitrogen atom may optionally be joined to form an unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered) or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
  • an unsubstituted heterocycloalkyl e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered
  • unsubstituted heteroaryl e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered.
  • R 1A and R 1B substituents bonded to the same nitrogen atom may optionally be joined to form a R 20B - substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • R 1A and R 1B substituents bonded to the same nitrogen atom may optionally be joined to form an unsubstituted
  • R 20B is independently oxo
  • X 20B is independently–F, -Cl, -Br, or–I.
  • R 20B is independently unsubstituted methyl.
  • R 20B is independently unsubstituted ethyl.
  • R 1C is independently
  • R 20C -substituted or unsubstituted alkyl e.g., C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2
  • R 20C -substituted or unsubstituted heteroalkyl e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered
  • R 20C -substituted or unsubstituted cycloalkyl e.g., C3-C8, C3-C6, C4-C6, or C5-C6
  • R 20C - substituted or unsubstituted heterocycloalkyl e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6
  • unsubstituted alkyl e.g., C1-C8, C 1 -C 6 , C 1 -C 4 , or C 1 -C 2
  • unsubstituted heteroalkyl e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered
  • unsubstituted cycloalkyl e.g., C3-C8, C3- C6, C4-C6, or C5-C6
  • unsubstituted heterocycloalkyl e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered
  • unsubstituted aryl e.g., C 6 -C 10 or pheny
  • X 1C is independently–F, -Cl, -Br, or–I.
  • R 1C is independently hydrogen.
  • R 1C is independently unsubstituted methyl.
  • R 1C is independently unsubstituted ethyl.
  • R 20C is independently oxo,
  • X 20C is independently–F, -Cl, -Br, or–I.
  • R 20C is independently unsubstituted methyl.
  • R 20C is independently unsubstituted ethyl.
  • R 1D is independently
  • R 20D -substituted or unsubstituted alkyl e.g., C1-C8, C1-C6, C1-C4, or C1-C2
  • R 20D -substituted or unsubstituted heteroalkyl e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered
  • R 20D -substituted or unsubstituted cycloalkyl e.g., C3-C8, C3-C6, C4-C6, or C5-C6
  • R 20D - substituted or unsubstituted heterocycloalkyl e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered
  • unsubstituted alkyl e.g., C1-C8, C 1 -C 6 , C 1 -C 4 , or C 1 -C 2
  • unsubstituted heteroalkyl e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered
  • unsubstituted cycloalkyl e.g., C3-C8, C3- C6, C4-C6, or C5-C6
  • unsubstituted heterocycloalkyl e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered
  • unsubstituted aryl e.g., C6-C10 or phenyl
  • X 1D is independently–F, -Cl, -Br, or–I.
  • R 1D is independently hydrogen.
  • R 1D is independently unsubstituted methyl.
  • R 1D is independently unsubstituted ethyl.
  • R 20D is independently oxo,
  • X 20D is independently–F, -Cl, -Br, or–I.
  • R 20D is independently unsubstituted methyl.
  • R 20D is independently unsubstituted ethyl.
  • R 2 is independently halogen, -CX 2 3 , -CHX 2 2 , -CH 2 X 2 , -OCX 2 3 , - OCH 2 X 2 , -OCHX 2 2 , -CN, -SO n2 R 2D , -SO v2 NR 2A R 2B , -NHC(O)NR 2A R 2B ,
  • R 2 is independently halogen, -CX 2 3 , -CHX 2 2 , -CH 2 X 2 , -OCX 2 3 , - OCH 2 X 2 , -OCHX 2 2 , substituted or unsubstituted alkyl, or substituted or unsubstituted
  • R 2 is independently halogen, -CX 2 3, -CHX 2 2, -CH2X 2 , -OCX 2 3, - OCH 2 X 2 , -OCHX 2 2 , substituted or unsubstituted (C 1 -C 4 ) alkyl, or substituted or unsubstituted 2 to 4 membered heteroalkyl.
  • R 2 is
  • R 2 is halogen, -CH3, -CH2CH3, -CX 2 3, -CHX 2 2, -CH2X 2 , -OCH3, -OCX 2 3, -OCH2X 2 , -OCHX 2 2, -SCH3 , -SCX 2 3, -SCH2X 2 , or -SCHX 2 2.
  • R 2 is halogen, -CH3, -CH2CH3, -CF3, or -OCH3.
  • R 2 is -CH3, -CH2CH3, or -OCH3.
  • R 2 is -OCH3.
  • R 2 is independently halogen, -CX 2 3 , -CHX 2 2 , -CH 2 X 2 , -OCX 2 3 , - OCH2X 2 , -OCHX 2 2, -CN, substituted or unsubstituted alkyl, or substituted or unsubstituted heteroalkyl.
  • R 2 is independently halogen, -CX 2 3, -CHX 2 2, -CH2X 2 , -OCX 2 3, - OCH 2 X 2 , -OCHX 2 2 , -CN, substituted or unsubstituted (C 1 -C 4 ) alkyl, or substituted or unsubstituted 2 to 4 membered heteroalkyl.
  • R 2 is
  • R 2 is halogen, -CN, -CH 3 , -CF 3 , or -OCH 3 .
  • R 2 is halogen or -CH 3 .
  • R 2 is -Cl or -CH 3 .
  • R 2 is -CH3.
  • R 2 is -CH3 or -CH2CH3. [0236] In embodiments, R 2 is independently
  • R 2 is independently
  • R 2 is independently halogen. In embodiments, R 2 is
  • R 2 is independently -CX 2 3. In embodiments, R 2 is independently -CHX 2 2. In embodiments, R 2 is independently -CH2X 2 . In embodiments, R 2 is independently -OCX 2 3. In embodiments, R 2 is independently -OCH 2 X 2 . In embodiments, R 2 is independently -OCHX 2 2 . In embodiments, R 2 is independently -CN. In embodiments, R 2 is independently -SOn2R 2D . In embodiments, R 2 is independently -SOv2NR 2A R 2B . In embodiments, R 2 is independently -NHC(O)NR 2A R 2B . In embodiments, R 2 is independently -N(O) m2 .
  • R 2 is independently -NR 2A R 2B . In embodiments, R 2 is independently -C(O)R 2C . In embodiments, R 2 is independently -C(O)-OR 2C . In embodiments, R 2 is independently -C(O)NR 2A R 2B . In embodiments, R 2 is
  • R 2 independently -OR 2D .
  • R 2 is independently -SR 2D .
  • R 2 is independently -NR 2A SO 2 R 2D .
  • R 2 is independently -NR 2A C(O)R 2C .
  • R 2 is independently -NR 2A C(O)OR 2C .
  • R 2 is
  • R 2 is independently -NR 2A OR 2C .
  • R 2 is independently -OH.
  • R 2 is independently -NH 2 .
  • R 2 is independently -COOH.
  • R 2 is independently -CONH2.
  • R 2 is independently -NO2.
  • R 2 is independently -SH.
  • R 2 is independently -CF3.
  • R 2 is independently -CHF 2 .
  • R 2 is independently -CH 2 F.
  • R 2 is independently -OCF3.
  • R 2 is independently -OCH2F.
  • R 2 is independently -OCHF2.
  • R 2 is independently–OCH3.
  • R 2 is independently–OCH 2 CH 3 . In embodiments, R 2 is independently–OCH 2 CH 2 CH 3 . In embodiments, R 2 is independently–OCH(CH3)2. In embodiments, R 2 is independently– OC(CH3)3. In embodiments, R 2 is independently–SCH3. In embodiments, R 2 is independently –SCH 2 CH 3 . In embodiments, R 2 is independently–SCH 2 CH 2 CH 3 . In embodiments, R 2 is independently–SCH(CH 3 ) 2 . In embodiments, R 2 is independently–SC(CH 3 ) 3 . In embodiments, R 2 is independently–CH3. In embodiments, R 2 is independently–CH2CH3. In embodiments, R 2 is independently–CH2CH2CH3.
  • R 2 is independently–CH(CH3)2. In embodiments, R 2 is independently–C(CH 3 ) 3 . In embodiments, R 2 is independently–F. In embodiments, R 2 is independently–Cl. In embodiments, R 2 is independently–Br. In
  • R 2 is independently–I. In embodiments, X 2 is independently–F. In
  • X 2 is independently–Cl. In embodiments, X 2 is independently–Br. In embodiments, X 2 is independently–I. [0238] In embodiments, R 2 is independently substituted or unsubstituted alkyl (e.g., C1-C8, C1- C 6 , C 1 -C 4 , or C 1 -C 2 ). In embodiments, R 2 is independently substituted alkyl (e.g., C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2 ).
  • R 2 is independently unsubstituted alkyl (e.g., C 1 -C 8 , C 1 -C 6 , C1-C4, or C1-C2). In embodiments, R 2 is independently unsubstituted methyl. In embodiments, R 2 is independently unsubstituted ethyl. In embodiments, R 2 is independently unsubstituted propyl. In embodiments, R 2 is independently unsubstituted isopropyl. In embodiments, R 2 is independently unsubstituted tert-butyl.
  • R 2 is independently substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered).
  • R 2 is independently substituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered).
  • R 2 is independently unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered).
  • R 2 is independently substituted or unsubstituted cycloalkyl (e.g., C 3 -C 8 , C 3 -C 6 , C 4 - C6, or C5-C6). In embodiments, R 2 is independently substituted cycloalkyl (e.g., C3-C8, C3-C6, C 4 -C 6 , or C 5 -C 6 ). In embodiments, R 2 is independently unsubstituted cycloalkyl (e.g., C 3 -C 8 , C 3 - C 6 , C 4 -C 6 , or C 5 -C 6 ).
  • R 2 is independently substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • R 2 is independently substituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • R 2 is independently unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • R 2 is independently substituted or unsubstituted aryl (e.g., C6-C10 or phenyl). In embodiments, R 2 is independently substituted aryl (e.g., C 6 -C 10 or phenyl). In embodiments, R 2 is independently unsubstituted aryl (e.g., C6-C10 or phenyl). In embodiments, R 2 is independently substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). In embodiments, R 2 is independently substituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
  • R 2 is independently unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). [0239] In embodiments, R 2 is independently halogen, -CX 2 3 , -CHX 2 2 , -CH 2 X 2 , -OCX 2 3 , - OCH 2 X 2 , -OCHX 2 2 , substituted or unsubstituted alkyl, or substituted or unsubstituted
  • R 2 is independently halogen, -CX 2 3, -CHX 2 2, or -CH2X 2 . In embodiments, R 2 is independently -CX 2 3. In embodiments, R 2 is independently -CF3. [0240] In embodiments, R 2A is independently hydrogen. In embodiments, R 2A is
  • R 2A is independently -CX 2A 3.
  • R 2A is independently -CHX 2A 2.
  • R 2A is independently -CH2X 2A .
  • R 2A is independently -CN.
  • R 2A is independently -COOH.
  • R 2A is independently -CONH 2 .
  • X 2A is independently–F, -Cl, -Br, or -I.
  • R 2A is independently substituted or unsubstituted alkyl (e.g., C1-C8, C 1 -C 6 , C 1 -C 4 , or C 1 -C 2 ).
  • R 2A is independently substituted alkyl (e.g., C 1 -C 8 , C 1 - C 6 , C 1 -C 4 , or C 1 -C 2 ). In embodiments, R 2A is independently unsubstituted alkyl (e.g., C 1 -C 8 , C 1 - C6, C1-C4, or C1-C2). In embodiments, R 2A is independently unsubstituted methyl. In
  • R 2A is independently unsubstituted ethyl. In embodiments, R 2A is independently unsubstituted propyl. In embodiments, R 2A is independently unsubstituted isopropyl. In embodiments, R 2A is independently unsubstituted tert-butyl. In embodiments, R 2A is
  • R 2A is independently substituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered).
  • R 2A is independently substituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered).
  • R 2A is independently unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered).
  • R 2A is independently substituted or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6). In embodiments, R 2A is independently substituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6). In embodiments, R 2A is independently unsubstituted cycloalkyl (e.g., C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ).
  • R 2A is independently substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • R 2A is independently substituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • R 2A is independently unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • R 2A is independently substituted or unsubstituted aryl (e.g., C 6 -C 10 or phenyl). In embodiments, R 2A is independently substituted aryl (e.g., C6-C10 or phenyl). In embodiments, R 2A is independently unsubstituted aryl (e.g., C6- C10 or phenyl). In embodiments, R 2A is independently substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
  • R 2A is independently substituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). In embodiments, R 2A is independently unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). [0242] In embodiments, R 2B is independently hydrogen. In embodiments, R 2B is
  • R 2B is independently -CX 2B 3.
  • R 2B is independently -CHX 2B 2.
  • R 2B is independently -CH 2 X 2B .
  • R 2B is independently -CN.
  • R 2B is independently -COOH.
  • R 2B is independently -CONH 2 .
  • X 2B is independently–F, -Cl, -Br, or -I.
  • R 2B is independently substituted or unsubstituted alkyl (e.g., C1-C8, C 1 -C 6 , C 1 -C 4 , or C 1 -C 2 ).
  • R 2B is independently substituted alkyl (e.g., C 1 -C 8 , C 1 - C6, C1-C4, or C1-C2). In embodiments, R 2B is independently unsubstituted alkyl (e.g., C1-C8, C1- C6, C1-C4, or C1-C2). In embodiments, R 2B is independently unsubstituted methyl. In embodiments, R 2B is independently substituted alkyl (e.g., C 1 -C 8 , C 1 - C6, C1-C4, or C1-C2). In embodiments, R 2B is independently unsubstituted alkyl (e.g., C1-C8, C1- C6, C1-C4, or C1-C2). In embodiments, R 2B is independently unsubstituted methyl. In
  • R 2B is independently unsubstituted ethyl. In embodiments, R 2B is independently unsubstituted propyl. In embodiments, R 2B is independently unsubstituted isopropyl. In embodiments, R 2B is independently unsubstituted tert-butyl. In embodiments, R 2B is
  • R 2B is independently substituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered).
  • R 2B is independently substituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered).
  • R 2B is independently unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered).
  • R 2B is independently substituted or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6). In embodiments, R 2B is independently substituted cycloalkyl (e.g., C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ). In embodiments, R 2B is independently unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6).
  • R 2B is independently substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • R 2B is independently substituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • R 2B is independently unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • R 2B is independently substituted or unsubstituted aryl (e.g., C6-C10 or phenyl). In embodiments, R 2B is independently substituted aryl (e.g., C6-C10 or phenyl). In embodiments, R 2B is independently unsubstituted aryl (e.g., C6- C 10 or phenyl). In embodiments, R 2B is independently substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
  • R 2B is independently substituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). In embodiments, R 2B is independently unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). [0244] In embodiments, R 2A and R 2B substituents bonded to the same nitrogen atom may be joined to form a substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • a substituted or unsubstituted heterocycloalkyl e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered.
  • R 2A and R 2B substituents bonded to the same nitrogen atom may be joined to form a substituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • R 2A and R 2B substituents bonded to the same nitrogen atom may be joined to form an unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • R 2A and R 2B substituents bonded to the same nitrogen atom may be joined to form a substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
  • R 2A and R 2B substituents bonded to the same nitrogen atom may be joined to form a substituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
  • R 2A and R 2B substituents bonded to the same nitrogen atom may be joined to form an unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
  • R 2C is independently hydrogen.
  • R 2C is independently -CX 2C 3.
  • R 2C is independently -CHX 2C 2.
  • R 2C is independently -CH 2 X 2C .
  • R 2C is independently -CN.
  • R 2C is independently -COOH.
  • R 2C is independently -CONH2.
  • X 2C is independently–F, -Cl, -Br, or -I.
  • R 2C is independently substituted or unsubstituted alkyl (e.g., C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2 ).
  • R 2C is independently substituted alkyl (e.g., C 1 -C 8 , C 1 - C6, C1-C4, or C1-C2).
  • R 2C is independently unsubstituted alkyl (e.g., C1-C8, C1- C 6 , C 1 -C 4 , or C 1 -C 2 ).
  • R 2C is independently unsubstituted methyl.
  • R 2C is independently unsubstituted ethyl. In embodiments, R 2C is independently unsubstituted propyl. In embodiments, R 2C is independently unsubstituted isopropyl. In embodiments, R 2C is independently unsubstituted tert-butyl. In embodiments, R 2C is
  • R 2C is independently substituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered).
  • R 2C is independently substituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered).
  • R 2C is independently unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered).
  • R 2C is independently substituted or unsubstituted cycloalkyl (e.g., C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ). In embodiments, R 2C is independently substituted cycloalkyl (e.g., C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ). In embodiments, R 2C is independently unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6).
  • R 2C is independently substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • R 2C is independently substituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • R 2C is independently unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • R 2C is independently substituted or unsubstituted aryl (e.g., C6-C10 or phenyl). In embodiments, R 2C is independently substituted aryl (e.g., C 6 -C 10 or phenyl). In embodiments, R 2C is independently unsubstituted aryl (e.g., C 6 - C 10 or phenyl). In embodiments, R 2C is independently substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
  • R 2C is independently substituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). In embodiments, R 2C is independently unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
  • R 2D is independently hydrogen. In embodiments, R 2D is independently -CX 2D 3. In embodiments, R 2D is independently -CHX 2D 2. In embodiments, R 2D is independently -CH 2 X 2D . In embodiments, R 2D is independently -CN. In embodiments, R 2D is independently -COOH.
  • R 2D is independently -CONH2.
  • X 2D is independently–F, -Cl, -Br, or -I.
  • R 2D is independently substituted or unsubstituted alkyl (e.g., C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2 ).
  • R 2D is independently substituted alkyl (e.g., C 1 -C 8 , C 1 - C6, C1-C4, or C1-C2).
  • R 2D is independently unsubstituted alkyl (e.g., C1-C8, C1- C 6 , C 1 -C 4 , or C 1 -C 2 ). In embodiments, R 2D is independently unsubstituted methyl. In
  • R 2D is independently unsubstituted ethyl. In embodiments, R 2D is independently unsubstituted propyl. In embodiments, R 2D is independently unsubstituted isopropyl. In embodiments, R 2D is independently unsubstituted tert-butyl. In embodiments, R 2D is
  • R 2D is independently substituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered).
  • R 2D is independently substituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered).
  • R 2D is independently unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered).
  • R 2D is independently substituted or unsubstituted cycloalkyl (e.g., C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ). In embodiments, R 2D is independently substituted cycloalkyl (e.g., C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ). In embodiments, R 2D is independently unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6).
  • R 2D is independently substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • R 2D is independently substituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • R 2D is independently unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • R 2D is independently substituted or unsubstituted aryl (e.g., C6-C10 or phenyl). In embodiments, R 2D is independently substituted aryl (e.g., C 6 -C 10 or phenyl). In embodiments, R 2D is independently unsubstituted aryl (e.g., C 6 - C 10 or phenyl). In embodiments, R 2D is independently substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
  • R 2D is independently substituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). In embodiments, R 2D is independently unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). [0250] In embodiments, R 2 is independently substituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). [0250] In embodiments, R 2 is independently substituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). [0250] In embodiments, R 2 is independently
  • X 2 is independently–F, -Cl, -Br, or–I.
  • R 2 is independently unsubstituted methyl.
  • R 2 is independently unsubstituted ethyl.
  • R 23 is independently oxo,
  • X 23 is independently–F, -Cl, -Br, or–I. In embodiments, R 23 is independently unsubstituted methyl. In embodiments, R 23 is independently unsubstituted ethyl. [0252] R 24 is independently oxo,
  • X 24 is independently–F, -Cl, -Br, or–I. In embodiments, R 24 is independently unsubstituted methyl. In embodiments, R 24 is independently unsubstituted ethyl. [0253] R 25 is independently oxo,
  • X 25 is independently–F, -Cl, -Br, or–I.
  • R 25 is independently unsubstituted methyl.
  • R 25 is independently unsubstituted ethyl.
  • R 2A is independently
  • R 23A -substituted or unsubstituted alkyl e.g., C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2
  • R 23A -substituted or unsubstituted heteroalkyl e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered
  • R 23A -substituted or unsubstituted cycloalkyl e.g., C3-C8, C3-C6, C4-C6, or C5-C6)
  • R 23A - substituted or unsubstituted heterocycloalkyl e.g., 3 to 8 membered, 3 to 6
  • unsubstituted alkyl e.g., C1-C8, C1-C6, C1-C4, or C1-C2
  • unsubstituted heteroalkyl e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered
  • unsubstituted cycloalkyl e.g., C 3 -C 8 , C 3 - C 6 , C 4 -C 6 , or C 5 -C 6
  • unsubstituted heterocycloalkyl e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered
  • unsubstituted aryl e.g., C6-C10 or
  • X 2A is independently–F, -Cl, -Br, or–I.
  • R 2A is independently hydrogen.
  • R 2A is independently unsubstituted methyl.
  • R 2A is independently unsubstituted ethyl.
  • R 2A and R 2B substituents bonded to the same nitrogen atom may optionally be joined to form a R 23A -substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered) or R 23A - substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
  • a R 23A -substituted or unsubstituted heterocycloalkyl e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered
  • R 23A - substituted or unsubstituted heteroaryl e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered
  • R 2A and R 2B substituents bonded to the same nitrogen atom may optionally be joined to form an unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered) or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
  • an unsubstituted heterocycloalkyl e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered
  • unsubstituted heteroaryl e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered.
  • R 2A and R 2B substituents bonded to the same nitrogen atom may optionally be joined to form a R 23A - substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • R 2A and R 2B substituents bonded to the same nitrogen atom may optionally be joined to form an unsubstituted
  • R 23A is independently oxo
  • X 23A is independently–F, -Cl, -Br, or–I.
  • R 23A is independently unsubstituted methyl.
  • R 23A is independently unsubstituted ethyl.
  • R 2B is independently
  • R 23B -substituted or unsubstituted alkyl e.g., C1-C8, C1-C6, C1-C4, or C1-C2
  • R 23B -substituted or unsubstituted heteroalkyl e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered
  • R 23B -substituted or unsubstituted cycloalkyl e.g., C3-C8, C3-C6, C4-C6, or C5-C6
  • R 23B - substituted or unsubstituted heterocycloalkyl e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered
  • unsubstituted alkyl e.g., C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2
  • unsubstituted heteroalkyl e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered
  • unsubstituted cycloalkyl e.g., C3-C8, C3- C6, C4-C6, or C5-C6
  • unsubstituted heterocycloalkyl e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered
  • unsubstituted aryl e.g.,
  • X 2B is independently–F, -Cl, -Br, or–I.
  • R 2B is independently hydrogen.
  • R 2B is independently unsubstituted methyl.
  • R 2B is independently unsubstituted ethyl.
  • R 2A and R 2B substituents bonded to the same nitrogen atom may optionally be joined to form a R 23B -substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered) or R 23B - substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
  • a R 23B -substituted or unsubstituted heterocycloalkyl e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered
  • R 23B - substituted or unsubstituted heteroaryl e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered
  • R 2A and R 2B substituents bonded to the same nitrogen atom may optionally be joined to form an unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered) or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
  • an unsubstituted heterocycloalkyl e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered
  • unsubstituted heteroaryl e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered.
  • R 2A and R 2B substituents bonded to the same nitrogen atom may optionally be joined to form a R 23B - substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • R 2A and R 2B substituents bonded to the same nitrogen atom may optionally be joined to form an unsubstituted
  • R 23B is independently oxo
  • X 23B is independently–F, -Cl, -Br, or–I.
  • R 23B is independently unsubstituted methyl.
  • R 23B is independently unsubstituted ethyl.
  • R 2C is independently
  • R 23C -substituted or unsubstituted alkyl e.g., C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2
  • R 23C -substituted or unsubstituted heteroalkyl e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered
  • R 23C -substituted or unsubstituted cycloalkyl e.g., C3-C8, C3-C6, C4-C6, or C5-C6
  • R 23C - substituted or unsubstituted heterocycloalkyl e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6
  • unsubstituted alkyl e.g., C1-C8, C 1 -C 6 , C 1 -C 4 , or C 1 -C 2
  • unsubstituted heteroalkyl e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered
  • unsubstituted cycloalkyl e.g., C3-C8, C3- C6, C4-C6, or C5-C6
  • unsubstituted heterocycloalkyl e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered
  • unsubstituted aryl e.g., C 6 -C 10 or pheny
  • X 2C is independently–F, -Cl, -Br, or–I.
  • R 2C is independently hydrogen.
  • R 2C is independently unsubstituted methyl.
  • R 2C is independently unsubstituted ethyl.
  • R 23C is independently oxo,
  • X 23C is independently–F, -Cl, -Br, or–I.
  • R 23C is independently unsubstituted methyl.
  • R 23C is independently unsubstituted ethyl.
  • R 2D is independently
  • R 23D -substituted or unsubstituted alkyl e.g., C1-C8, C1-C6, C1-C4, or C1-C2
  • R 23D -substituted or unsubstituted heteroalkyl e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered
  • R 23D -substituted or unsubstituted cycloalkyl e.g., C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6
  • R 23D - substituted or unsubstituted heterocycloalkyl e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6
  • R 2D is independently hydrogen, -CX 2D 3, -CHX 2D 2, -CH2X 2D , -CN, -COOH, -CONH2, unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), unsubstituted cycloalkyl (e.g., C 3 -C 8 , C 3 - C6, C4-C6, or C5-C6), unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), unsubstituted aryl (e.g., C6-C10
  • X 2D is independently–F, -Cl, -Br, or–I.
  • R 2D is independently hydrogen.
  • R 2D is independently unsubstituted methyl.
  • R 2D is independently unsubstituted ethyl.
  • R 23D is independently oxo,
  • X 23D is independently–F, -Cl, -Br, or–I. In embodiments, R 23D is independently unsubstituted methyl. In embodiments, R 23D is independently unsubstituted ethyl. [0264] L 3 is a
  • L 3 is a
  • L 3 is a
  • L 3 is a bond.
  • L 3 is -O-. In embodiments, L 3 is -S-. In embodiments, L 3 is -C(O)-. In
  • L 3 is -NH-. In embodiments, L 3 is -C(O)NH-. In embodiments, L 3 is -NHC(O)-. In embodiments, L 3 is -N(CH3)-. In embodiments, L 3 is -C(O)N(CH3)-. In embodiments, L 3 is -N(CH 2 CH 3 )-. In embodiments, L 3 is -C(O)N(CH 2 CH 3 )-. In embodiments, L 3
  • L 3 is independently substituted or unsubstituted alkylene (e.g., C1-C8, C1-C6, C1-C4, or C1-C2). In embodiments, L 3 is independently substituted alkylene (e.g., C1-C8, C 1 -C 6 , C 1 -C 4 , or C 1 -C 2 ). In embodiments, L 3 is independently unsubstituted alkylene (e.g., C 1 - C8, C1-C6, C1-C4, or C1-C2). In embodiments, L 3 is independently unsubstituted methylene.
  • L 3 is independently unsubstituted ethylene. In embodiments, L 3 is independently unsubstituted propylene. In embodiments, L 3 is independently unsubstituted isopropylene. In embodiments, L 3 is independently unsubstituted tert-butylene. In embodiments, L 3 is independently substituted or unsubstituted heteroalkylene (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered).
  • heteroalkylene e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered.
  • L 3 is independently substituted heteroalkylene (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered). In embodiments, L 3 is independently unsubstituted heteroalkylene (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered). [0266] In embodiments, L 3 is independently
  • R 44 -substituted or unsubstituted alkylene e.g., C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2
  • R 44 -substituted or unsubstituted heteroalkylene e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered.
  • L 3 is independently
  • L 3 is independently a
  • L 3 is independently -N(H)-, -C(O)N(H)-, or -N(H)C(O)-. In embodiments, L 3 is independently -N(H)-. [0268] R 44 is independently oxo,
  • X 44 is independently–F, -Cl, -Br, or–I. In embodiments, R 44 is independently unsubstituted methyl. In embodiments, R 44 is independently unsubstituted ethyl. [0269] R 45 is independently oxo,
  • X 45 is independently–F, -Cl, -Br, or–I. In embodiments, R 45 is independently unsubstituted methyl. In embodiments, R 45 is independently unsubstituted ethyl. [0270] R 46 is independently oxo,
  • X 46 is independently–F, -Cl, -Br, or–I. In embodiments, R 46 is independently unsubstituted methyl. In embodiments, R 46 is independently unsubstituted ethyl. [0271] In embodiments, R 7 is independently halogen, -CX 7 3 , -CHX 7 2 , -CH 2 X 7 , -OCX 7 3 , - OCH2X 7 , -OCHX 7 2, -CN, -SOn7R 7D , -SOv7NR 7A R 7B , -NHC(O)NR 7A R 7B , -N(O)m7, -NR 7A R 7B , -C( O)R 7C , -C(O)-OR 7C , -C(O)NR 7A R 7B , -OR 7D , -NR 7A SO2R 7D , -NR 7A C(O)R 7C
  • R 7 is independently halogen, -CX 7 3 , -CHX 7 2 , -CH 2 X 7 , -OCX 7 3 , - OCH2X 7 , -OCHX 7 2, substituted or unsubstituted alkyl, or substituted or unsubstituted
  • R 7 is independently halogen, -CX 7 3, -CHX 7 2, -CH2X 7 , -OCX 7 3, - OCH 2 X 7 , -OCHX 7 2 , substituted or unsubstituted (C 1 -C 4 ) alkyl, or substituted or unsubstituted 2 to 4 membered heteroalkyl.
  • R 7 is independently halogen, -CX 7 3, -CHX 7 2, -CH2X 7 , -OCX 7 3, - OCH 2 X 7 , -OCHX 7 2 , substituted or unsubstituted (C 1 -C 4 ) alkyl, or substituted or unsubstituted 2 to 4 membered heteroalkyl.
  • R 7 is independently halogen, -CX 7 3, -CHX 7 2, -CH2X 7 , -OCX 7 3, - OCH 2 X 7 , -OCHX 7 2 , substituted or unsub
  • R 7 is independently
  • R 7 is
  • R 7 is independently -CH3, -CH2CH3, or -OCH3.
  • R 7 is independently -OCH3.
  • R 7 is independently halogen, -CX 7 3, -CHX 7 2, -CH2X 7 , -OCX 7 3, - OCH2X 7 , -OCHX 7 2, -CN, substituted or unsubstituted alkyl, or substituted or unsubstituted heteroalkyl.
  • R 7 is independently halogen, -CX 7 3 , -CHX 7 2 , -CH 2 X 7 , -OCX 7 3 , - OCH2X 7 , -OCHX 7 2, -CN, substituted or unsubstituted (C1-C4) alkyl, or substituted or unsubstituted 2 to 4 membered heteroalkyl.
  • R 7 is independently halogen, -CX 7 3 , -CHX 7 2 , -CH 2 X 7 , -OCX 7 3 , - OCH2X 7 , -OCHX 7 2, -CN, substituted or unsubstituted (C1-C4) alkyl, or substituted or unsubstituted 2 to 4 membered heteroalkyl.
  • R 7 is independently halogen, -CX 7 3 , -CHX 7 2 , -CH 2 X 7 , -OCX 7 3 , - OCH2X 7
  • R 7 is independently
  • R 7 is independently halogen or -CH3. In embodiments, R 7 is independently -Cl or -CH 3 . In embodiments, R 7 is independently -CH 3 . In embodiments, R 7 is independently -Cl. In embodiments, R 7 is independently -F. In
  • R 7 is independently -Br. In embodiments, R 7 is independently -I. In
  • R 7 is independently -CH3 or -CH2CH3.
  • X 7 is independently -Cl.
  • X 7 is independently -F.
  • X 7 is independently -Br.
  • X 7 is independently -I. [0273] In embodiments, R 7 is independently
  • R 7 is independently
  • R 7 is independently halogen. In embodiments, R 7 is
  • R 7 is independently -CX 7 3. In embodiments, R 7 is independently -CHX 7 2. In embodiments, R 7 is independently -CH2X 7 . In embodiments, R 7 is independently -OCX 7 3. In embodiments, R 7 is independently -OCH 2 X 7 . In embodiments, R 7 is independently -OCHX 7 2 . In embodiments, R 7 is independently -CN. In embodiments, R 7 is independently -SOn7R 7D . In embodiments, R 7 is independently -SOv7NR 7A R 7B . In embodiments, R 7 is independently -NHC(O)NR 7A R 7B . In embodiments, R 7 is independently -N(O) m7 .
  • R 7 is independently -NR 7A R 7B . In embodiments, R 7 is independently -C(O)R 7C . In embodiments, R 7 is independently -C(O)-OR 7C . In embodiments, R 7 is independently -C(O)NR 7A R 7B . In embodiments, R 7 is
  • R 7 independently -OR 7D .
  • R 7 is independently -SR 7D .
  • R 7 is independently -NR 7A SO 2 R 7D .
  • R 7 is independently -NR 7A C(O)R 7C .
  • R 7 is independently -NR 7A C(O)OR 7C .
  • R 7 is
  • R 7 is independently -NR 7A OR 7C .
  • R 7 is independently -OH.
  • R 7 is independently -NH 2 .
  • R 7 is independently -COOH.
  • R 7 is independently -CONH2.
  • R 7 is independently -NO2.
  • R 7 is independently -SH.
  • R 7 is independently -CF3.
  • R 7 is independently -CHF 2 .
  • R 7 is independently -CH 2 F.
  • R 7 is independently -OCF3.
  • R 7 is independently -OCH2F.
  • R 7 is independently -OCHF2.
  • R 7 is independently–OCH3.
  • R 7 is independently–OCH 2 CH 3 . In embodiments, R 7 is independently–OCH 2 CH 2 CH 3 . In embodiments, R 7 is independently–OCH(CH 3 ) 2 . In embodiments, R 7 is independently– OC(CH3)3. In embodiments, R 7 is independently–SCH3. In embodiments, R 7 is independently –SCH2CH3. In embodiments, R 7 is independently–SCH2CH2CH3. In embodiments, R 7 is independently–SCH(CH 3 ) 2 . In embodiments, R 7 is independently–SC(CH 3 ) 3 . In embodiments, R 7 is independently–CH3. In embodiments, R 7 is independently–CH2CH3. In embodiments, R 7 is independently–CH2CH2CH3.
  • R 7 is independently–CH(CH3)2. In embodiments, R 7 is independently–C(CH 3 ) 3 . In embodiments, R 7 is independently–F. In embodiments, R 7 is independently–Cl. In embodiments, R 7 is independently–Br. In
  • R 7 is independently–I. [0275] In embodiments, R 7 is independently substituted or unsubstituted alkyl (e.g., C 1 -C 8 , C 1 - C 6 , C 1 -C 4 , or C 1 -C 2 ). In embodiments, R 7 is independently substituted alkyl (e.g., C 1 -C 8 , C 1 -C 6 , C1-C4, or C1-C2). In embodiments, R 7 is independently unsubstituted alkyl (e.g., C1-C8, C1-C6, C 1 -C 4 , or C 1 -C 2 ). In embodiments, R 7 is independently unsubstituted methyl.
  • R 7 is independently substituted or unsubstituted alkyl (e.g., C 1 -C 8 , C 1 - C 6 , C 1 -C 4 , or C 1 -C 2 ). In embodiments, R 7 is independently unsubstituted
  • R 7 is independently unsubstituted ethyl. In embodiments, R 7 is independently unsubstituted propyl. In embodiments, R 7 is independently unsubstituted isopropyl. In embodiments, R 7 is independently unsubstituted tert-butyl. In embodiments, R 7 is independently substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered).
  • R 7 is independently substituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered). In embodiments, R 7 is independently unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered). In embodiments, R 7 is independently substituted or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4- C 6 , or C 5 -C 6 ).
  • R 7 is independently substituted cycloalkyl (e.g., C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ).
  • R 7 is independently unsubstituted cycloalkyl (e.g., C 3 -C 8 , C 3 - C6, C4-C6, or C5-C6).
  • R 7 is independently substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • R 7 is independently substituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered). In embodiments, R 7 is independently unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered). In embodiments, R 7 is independently substituted or unsubstituted aryl (e.g., C 6 -C 10 or phenyl). In embodiments, R 7 is independently substituted aryl (e.g., C6-C10 or phenyl).
  • R 7 is independently unsubstituted aryl (e.g., C6-C10 or phenyl). In embodiments, R 7 is independently substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). In embodiments, R 7 is independently substituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). In embodiments, R 7 is independently unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
  • R 7 is independently halogen, -CX 7 3 , -CHX 7 2 , -CH 2 X 7 , -OCX 7 3 , - OCH2X 7 , -OCHX 7 2, -CN, substituted or unsubstituted alkyl, or substituted or unsubstituted heteroalkyl.
  • R 7 is independently halogen, -CX 7 3, -CHX 7 2, -CH2X 7 , -OCX 7 3, - OCH 2 X 7 , or -OCHX 7 2 .
  • R 7 is independently halogen.
  • R 7 is independently–Cl.
  • R 7A is independently hydrogen.
  • R 7A is
  • R 7A is independently -CHX 7A 2 . In embodiments, R 7A is independently -CH 2 X 7A . In embodiments, R 7A is independently -CN. In embodiments, R 7A is independently -COOH. In embodiments, R 7A is independently -CONH2. In embodiments, X 7A is independently–F, -Cl, -Br, or -I. [0278] In embodiments, R 7A is independently substituted or unsubstituted alkyl (e.g., C 1 -C 8 , C1-C6, C1-C4, or C1-C2).
  • R 7A is independently substituted alkyl (e.g., C1-C8, C1- C6, C1-C4, or C1-C2). In embodiments, R 7A is independently unsubstituted alkyl (e.g., C1-C8, C1- C 6 , C 1 -C 4 , or C 1 -C 2 ). In embodiments, R 7A is independently unsubstituted methyl.
  • R 7A is independently substituted alkyl (e.g., C1-C8, C1- C6, C1-C4, or C1-C2).
  • R 7A is independently unsubstituted alkyl (e.g., C1-C8, C1- C 6 , C 1 -C 4 , or C 1 -C 2 ). In embodiments, R 7A is independently unsubstituted methyl.
  • R 7A is independently unsubstituted ethyl. In embodiments, R 7A is independently unsubstituted propyl. In embodiments, R 7A is independently unsubstituted isopropyl. In embodiments, R 7A is independently unsubstituted tert-butyl. In embodiments, R 7A is
  • R 7A is independently substituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered).
  • R 7A is independently substituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered).
  • R 7A is independently unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered).
  • R 7A is independently substituted or unsubstituted cycloalkyl (e.g., C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ). In embodiments, R 7A is independently substituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6). In embodiments, R 7A is independently unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6).
  • R 7A is independently substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered). In embodiments, R 7A is independently substituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered). In embodiments, R 7A is independently unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • R 7A is independently substituted or unsubstituted aryl (e.g., C6-C10 or phenyl). In embodiments, R 7A is independently substituted aryl (e.g., C 6 -C 10 or phenyl). In embodiments, R 7A is independently unsubstituted aryl (e.g., C 6 - C10 or phenyl). In embodiments, R 7A is independently substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
  • R 7A is independently substituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). In embodiments, R 7A is independently unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). [0279] In embodiments, R 7B is independently hydrogen. In embodiments, R 7B is
  • R 7B is independently -CHX 7B 2 . In embodiments, R 7B is independently -CH2X 7B . In embodiments, R 7B is independently -CN. In embodiments, R 7B is independently -COOH. In embodiments, R 7B is independently -CONH 2 . In embodiments, X 7B is independently–F, -Cl, -Br, or -I. [0280] In embodiments, R 7B is independently substituted or unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2).
  • R 7B is independently substituted alkyl (e.g., C1-C8, C1- C 6 , C 1 -C 4 , or C 1 -C 2 ). In embodiments, R 7B is independently unsubstituted alkyl (e.g., C 1 -C 8 , C 1 - C6, C1-C4, or C1-C2). In embodiments, R 7B is independently unsubstituted methyl. In
  • R 7B is independently unsubstituted ethyl. In embodiments, R 7B is independently unsubstituted propyl. In embodiments, R 7B is independently unsubstituted isopropyl. In embodiments, R 7B is independently unsubstituted tert-butyl. In embodiments, R 7B is
  • R 7B is independently substituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered).
  • R 7B is independently substituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered).
  • R 7B is independently unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered).
  • R 7B is independently substituted or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6). In embodiments, R 7B is independently substituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6). In embodiments, R 7B is independently unsubstituted cycloalkyl (e.g., C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ).
  • R 7B is independently substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered). In embodiments, R 7B is independently substituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered). In embodiments, R 7B is independently unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • R 7B is independently substituted or unsubstituted aryl (e.g., C 6 -C 10 or phenyl). In embodiments, R 7B is independently substituted aryl (e.g., C6-C10 or phenyl). In embodiments, R 7B is independently unsubstituted aryl (e.g., C6- C10 or phenyl). In embodiments, R 7B is independently substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
  • R 7B is independently substituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). In embodiments, R 7B is independently unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). [0281] In embodiments, R 7A and R 7B substituents bonded to the same nitrogen atom may be joined to form a substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • a substituted or unsubstituted heterocycloalkyl e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered.
  • R 7A and R 7B substituents bonded to the same nitrogen atom may be joined to form a substituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • R 7A and R 7B substituents bonded to the same nitrogen atom may be joined to form an unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • R 7A and R 7B substituents bonded to the same nitrogen atom may be joined to form a substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
  • R 7A and R 7B substituents bonded to the same nitrogen atom may be joined to form a substituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
  • R 7A and R 7B substituents bonded to the same nitrogen atom may be joined to form an unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
  • R 7C is independently hydrogen. In embodiments, R 7C is
  • R 7C is independently -CX 7C 3.
  • R 7C is independently -CHX 7C 2.
  • R 7C is independently -CH2X 7C .
  • R 7C is independently -CN.
  • R 7C is independently -COOH.
  • R 7C is independently -CONH 2 .
  • X 7C is independently–F, -Cl, -Br, or -I.
  • R 7C is independently substituted or unsubstituted alkyl (e.g., C1-C8, C 1 -C 6 , C 1 -C 4 , or C 1 -C 2 ).
  • R 7C is independently substituted alkyl (e.g., C 1 -C 8 , C 1 - C 6 , C 1 -C 4 , or C 1 -C 2 ). In embodiments, R 7C is independently unsubstituted alkyl (e.g., C 1 -C 8 , C 1 - C6, C1-C4, or C1-C2). In embodiments, R 7C is independently unsubstituted methyl. In
  • R 7C is independently unsubstituted ethyl. In embodiments, R 7C is independently unsubstituted propyl. In embodiments, R 7C is independently unsubstituted isopropyl. In embodiments, R 7C is independently unsubstituted tert-butyl. In embodiments, R 7C is
  • R 7C is independently substituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered).
  • R 7C is independently substituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered).
  • R 7C is independently unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered).
  • R 7C is independently substituted or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6). In embodiments, R 7C is independently substituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6). In embodiments, R 7C is independently unsubstituted cycloalkyl (e.g., C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ).
  • R 7C is independently substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered). In embodiments, R 7C is independently substituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered). In embodiments, R 7C is independently unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • R 7C is independently substituted or unsubstituted aryl (e.g., C 6 -C 10 or phenyl). In embodiments, R 7C is independently substituted aryl (e.g., C6-C10 or phenyl). In embodiments, R 7C is independently unsubstituted aryl (e.g., C6- C10 or phenyl). In embodiments, R 7C is independently substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
  • R 7C is independently substituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). In embodiments, R 7C is independently unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). [0285] In embodiments, R 7D is independently hydrogen. In embodiments, R 7D is
  • R 7D is independently -CX 7D 3.
  • R 7D is independently -CHX 7D 2.
  • R 7D is independently -CH 2 X 7D .
  • R 7D is independently -CN.
  • R 7D is independently -COOH.
  • R 7D is independently -CONH 2 .
  • X 7D is independently–F, -Cl, -Br, or -I.
  • R 7D is independently substituted or unsubstituted alkyl (e.g., C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2 ).
  • R 7D is independently substituted alkyl (e.g., C 1 -C 8 , C 1 - C6, C1-C4, or C1-C2). In embodiments, R 7D is independently unsubstituted alkyl (e.g., C1-C8, C1- C6, C1-C4, or C1-C2). In embodiments, R 7D is independently unsubstituted methyl. In embodiments, R 7D is independently substituted alkyl (e.g., C 1 -C 8 , C 1 - C6, C1-C4, or C1-C2). In embodiments, R 7D is independently unsubstituted alkyl (e.g., C1-C8, C1- C6, C1-C4, or C1-C2). In embodiments, R 7D is independently unsubstituted methyl. In
  • R 7D is independently unsubstituted ethyl. In embodiments, R 7D is independently unsubstituted propyl. In embodiments, R 7D is independently unsubstituted isopropyl. In embodiments, R 7D is independently unsubstituted tert-butyl. In embodiments, R 7D is
  • R 7D is independently substituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered).
  • R 7D is independently substituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered).
  • R 7D is independently unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered).
  • R 7D is independently substituted or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6). In embodiments, R 7D is independently substituted cycloalkyl (e.g., C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ). In embodiments, R 7D is independently unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6).
  • R 7D is independently substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered). In embodiments, R 7D is independently substituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered). In embodiments, R 7D is independently unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • R 7D is independently substituted or unsubstituted aryl (e.g., C6-C10 or phenyl). In embodiments, R 7D is independently substituted aryl (e.g., C6-C10 or phenyl). In embodiments, R 7D is independently unsubstituted aryl (e.g., C6- C 10 or phenyl). In embodiments, R 7D is independently substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
  • R 7D is independently substituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). In embodiments, R 7D is independently unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). [0287] In embodiments, R 7 is independently substituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). [0287] In embodiments, R 7 is independently substituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). [0287] In embodiments, R 7 is independently
  • unsubstituted alkyl e.g., C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2
  • R 38 -substituted or unsubstituted heteroalkyl e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered
  • R 38 -substituted or unsubstituted cycloalkyl e.g., C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6
  • R 38 -substituted or unsubstituted heterocycloalkyl e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered
  • X 7 is independently–F, -Cl, -Br, or–I. In embodiments, R 7 is independently unsubstituted methyl. In embodiments, R 7 is independently unsubstituted ethyl. [0288] R 38 is independently oxo,
  • unsubstituted alkyl e.g., C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2
  • R 39 -substituted or unsubstituted heteroalkyl e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered
  • R 39 -substituted or unsubstituted cycloalkyl e.g., C3-C8, C3-C6, C4-C6, or C5-C6
  • R 39 -substituted or unsubstituted heterocycloalkyl e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered
  • R 39 -substituted or unsubstituted aryl e.g., C6
  • X 38 is independently–F, -Cl, -Br, or–I. In embodiments, R 38 is independently unsubstituted methyl. In embodiments, R 38 is independently unsubstituted ethyl. [0289] R 39 is independently oxo,
  • X 39 is independently–F, -Cl, -Br, or–I.
  • R 39 is independently unsubstituted methyl.
  • R 39 is independently unsubstituted ethyl.
  • R 40 is independently oxo,
  • X 40 is independently–F, -Cl, -Br, or–I. In embodiments, R 40 is independently unsubstituted methyl. In embodiments, R 40 is independently unsubstituted ethyl. [0291] In embodiments, R 7A is independently
  • R 38A -substituted or unsubstituted alkyl e.g., C1-C8, C1-C6, C1-C4, or C1-C2
  • R 38A -substituted or unsubstituted heteroalkyl e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered
  • R 38A -substituted or unsubstituted cycloalkyl e.g., C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6
  • R 38A - substituted or unsubstituted heterocycloalkyl e.g., 3 to 8 membered, 3 to 6
  • unsubstituted alkyl e.g., C1-C8, C1-C6, C1-C4, or C1-C2
  • unsubstituted heteroalkyl e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered
  • unsubstituted cycloalkyl e.g., C 3 -C 8 , C 3 - C6, C4-C6, or C5-C6
  • unsubstituted heterocycloalkyl e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered
  • unsubstituted aryl e.g., C6-C10 or phenyl
  • X 7A is independently–F, -Cl, -Br, or–I.
  • R 7A is independently hydrogen.
  • R 7A is independently unsubstituted methyl.
  • R 7A is independently unsubstituted ethyl.
  • R 7A and R 7B substituents bonded to the same nitrogen atom may optionally be joined to form a R 38A -substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered) or R 38A - substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
  • a R 38A -substituted or unsubstituted heterocycloalkyl e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered
  • R 38A - substituted or unsubstituted heteroaryl e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered
  • R 7A and R 7B substituents bonded to the same nitrogen atom may optionally be joined to form an unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered) or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
  • an unsubstituted heterocycloalkyl e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered
  • unsubstituted heteroaryl e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered.
  • R 7A and R 7B substituents bonded to the same nitrogen atom may optionally be joined to form a R 38A - substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • R 7A and R 7B substituents bonded to the same nitrogen atom may optionally be joined to form an unsubstituted
  • R 38A is independently oxo
  • X 38A is independently–F, -Cl, -Br, or–I.
  • R 38A is independently unsubstituted methyl.
  • R 38A is independently unsubstituted ethyl.
  • R 7B is independently
  • R 38B -substituted or unsubstituted alkyl e.g., C1-C8, C1-C6, C1-C4, or C1-C2
  • R 38B -substituted or unsubstituted heteroalkyl e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered
  • R 38B -substituted or unsubstituted cycloalkyl e.g., C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6
  • R 38B - substituted or unsubstituted heterocycloalkyl e.g., 3 to 8 membered, 3 to 6
  • unsubstituted alkyl e.g., C1-C8, C1-C6, C1-C4, or C1-C2
  • unsubstituted heteroalkyl e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered
  • unsubstituted cycloalkyl e.g., C3-C8, C3- C 6 , C 4 -C 6 , or C 5 -C 6
  • unsubstituted heterocycloalkyl e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered
  • unsubstituted aryl e.g., C6-C10 or phenyl
  • X 7B is independently–F, -Cl, -Br, or–I.
  • R 7B is independently hydrogen.
  • R 7B is independently unsubstituted methyl.
  • R 7B is independently unsubstituted ethyl.
  • R 7A and R 7B substituents bonded to the same nitrogen atom may optionally be joined to form a R 38B -substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered) or R 38B - substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
  • a R 38B -substituted or unsubstituted heterocycloalkyl e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered
  • R 38B - substituted or unsubstituted heteroaryl e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered
  • R 7A and R 7B substituents bonded to the same nitrogen atom may optionally be joined to form an unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered) or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
  • an unsubstituted heterocycloalkyl e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered
  • unsubstituted heteroaryl e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered.
  • R 7A and R 7B substituents bonded to the same nitrogen atom may optionally be joined to form a R 38B - substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • R 7A and R 7B substituents bonded to the same nitrogen atom may optionally be joined to form an unsubstituted
  • R 38B is independently oxo
  • X 38B is independently–F, -Cl, -Br, or–I.
  • R 38B is independently unsubstituted methyl.
  • R 38B is independently unsubstituted ethyl.
  • R 7C is independently
  • R 38C -substituted or unsubstituted alkyl e.g., C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2
  • R 38C -substituted or unsubstituted heteroalkyl e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered
  • R 38C -substituted or unsubstituted cycloalkyl e.g., C3-C8, C3-C6, C4-C6, or C5-C6
  • R 38C - substituted or unsubstituted heterocycloalkyl e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6
  • unsubstituted alkyl e.g., C 1 -C 8 , C1-C6, C1-C4, or C1-C2
  • unsubstituted heteroalkyl e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered
  • unsubstituted cycloalkyl e.g., C3-C8, C3- C 6 , C 4 -C 6 , or C 5 -C 6
  • unsubstituted heterocycloalkyl e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered
  • unsubstituted aryl e.g., C
  • X 7C is independently–F, -Cl, -Br, or–I.
  • R 7C is independently hydrogen.
  • R 7C is independently unsubstituted methyl.
  • R 7C is independently unsubstituted ethyl.
  • R 38C is independently oxo,
  • X 38C is independently–F, -Cl, -Br, or–I. In embodiments, R 38C is independently unsubstituted methyl. In embodiments, R 38C is independently unsubstituted ethyl. [0299] In embodiments, R 7D is independently
  • R 38D -substituted or unsubstituted alkyl e.g., C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2
  • R 38D -substituted or unsubstituted heteroalkyl e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered
  • R 38D -substituted or unsubstituted cycloalkyl e.g., C3-C8, C3-C6, C4-C6, or C5-C6
  • R 38D - substituted or unsubstituted heterocycloalkyl e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6
  • unsubstituted alkyl e.g., C 1 -C 8 , C1-C6, C1-C4, or C1-C2
  • unsubstituted heteroalkyl e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered
  • unsubstituted cycloalkyl e.g., C3-C8, C3- C 6 , C 4 -C 6 , or C 5 -C 6
  • unsubstituted heterocycloalkyl e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered
  • unsubstituted aryl e.g., C
  • X 7D is independently–F, -Cl, -Br, or–I.
  • R 7D is independently hydrogen.
  • R 7D is independently unsubstituted methyl.
  • R 7D is independently unsubstituted ethyl.
  • R 38D is independently oxo,
  • X 38D is independently–F, -Cl, -Br, or–I.
  • R 38D is independently unsubstituted methyl.
  • R 38D is independently unsubstituted ethyl.
  • R 8 is independently hydrogen, halogen, -CX 8 3, -CHX 8 2, - CH2X 8 , -OCX 8 3, -OCH2X 8 , -OCHX 8 2, -CN, -SOn8R 8D , -SOv8NR 8A R 8B , -NHC(O)NR 8A R 8B , -N(O) m8 , -NR 8A R 8B , -C(O)R 8C , -C(O)-OR 8C , -C(O)NR 8A R 8B , -OR 8D , -NR 8A SO 2 R 8D , -NR 8A C(O)R 8C ,
  • R 8 is independently hydrogen, halogen, -CX 8 3 , -CHX 8 2 , - CH2X 8 , -OCX 8 3, -OCH2X 8 , -OCHX 8 2, substituted or unsubstituted alkyl, or substituted or unsubstituted heteroalkyl.
  • R 8 is independently hydrogen, halogen, -CX 8 3, - CHX 8 2 , -CH 2 X 8 , -OCX 8 3 , -OCH 2 X 8 , -OCHX 8 2 , substituted or unsubstituted (C 1 -C 4 ) alkyl, or substituted or unsubstituted 2 to 4 membered heteroalkyl.
  • R 8 is hydrogen, halogen, -CH3, -CH2CH3, -CX 8 3, -CHX 8 2, -CH2X 8 , -OCH3, -OCX 8 3, -OCH2X 8 , -OCHX 8 2, -SCH3 , -SCX 8 3 , -SCH 2 X 8 , or -SCHX 8 2 .
  • R 8 is hydrogen,
  • R 8 is -CH 3 , -CH 2 CH 3 , -CF 3 , or -OCH 3 .
  • R 8 is -CH 3 , -CH 2 CH 3 , or -OCH 3 .
  • R 8 is -OCH3.
  • R 8 is independently hydrogen, halogen, -CX 8 3, - CHX 8 2 , -CH 2 X 8 , -OCX 8 3 , -OCH 2 X 8 , -OCHX 8 2 , -CN, substituted or unsubstituted alkyl, or substituted or unsubstituted heteroalkyl.
  • R 8 is independently hydrogen, halogen, -CX 8 3, -CHX 8 2, -CH2X 8 , -OCX 8 3, -OCH2X 8 , -OCHX 8 2, -CN, substituted or
  • R 8 is hydrogen
  • R 8 is hydrogen
  • R 8 is halogen or -CH 3 .
  • R 8 is -Cl or -CH 3 .
  • R 8 is -CH 3 .
  • R 8 is hydrogen.
  • R 8 is -CH3 or -CH2CH3. In embodiments, R 8 is -C(O)R 8C . In embodiments, R 8 is -C(O)CH 3 . In embodiments, R 8 is -C(O)CH 2 CH 3 . In embodiments, R 8 is -C(O)CH 2 CH 2 CH 3 . In embodiments, R 8 is -C(O)CH(CH 3 ) 2 . In embodiments, R 8 is -C(O)C(CH 3 ) 3 . In embodiments, R 8 is -C(O)CH2CH2CH2CH3. In embodiments, R 8 is -NHC(O)CH3. In embodiments, R 8 is -NHC(O)CH2CH3.
  • R 8 is -NHC(O)CH2CH2CH3. In embodiments, R 8 is -NHC(O)CH(CH 3 ) 2 . In embodiments, R 8 is -NHC(O)C(CH 3 ) 3 . In embodiments, R 8 is -NHC(O)CH2CH2CH2CH3. [0303] In embodiments, R 8 is independently hydrogen,
  • halogen -CX 8 3 , -CN, -OH, -NH 2 , -SH, -OCX 8 3 , -OCHX 8 2 , -OCH 2 X 8 , -CHX 8 2 , -CH 2 X 8 , substituted or unsubstituted C 1 -C 4 alkyl, substituted or unsubstituted 2 to 4 membered heteroalkyl, substituted or unsubstituted C3-C6 cycloalkyl, substituted or unsubstituted 3 to 6 membered heterocycloalkyl, substituted or unsubstituted phenyl, or substituted or unsubstituted 5 to 6 membered heteroaryl.
  • R 8 is independently hydrogen, halogen, -CX 8 3, -CN, -OH, -NH2, -SH, -OCX 8 3, -OCHX 8 2, -OCH2X 8 , -CHX 8 2, -CH2X 8 , unsubstituted C1-C4 alkyl, or unsubstituted 2 to 4 membered heteroalkyl.
  • R 8 is independently hydrogen.
  • R 8 is independently halogen.
  • R 8 is independently -CX 8 3.
  • R 8 is independently - CHX 8 2.
  • R 8 is independently -CH2X 8 .
  • R 8 is
  • R 8 independently -OCX 8 3 .
  • R 8 is independently -OCH 2 X 8 .
  • R 8 is independently -OCHX 8 2 .
  • R 8 is independently -CN.
  • R 8 is independently -SOn8R 8D .
  • R 8 is independently -SOv8NR 8A R 8B .
  • R 8 is independently -NHC(O)NR 8A R 8B .
  • R 8 is independently -N(O) m8 .
  • R 8 is independently -NR 8A R 8B .
  • R 8 is independently -C(O)R 8C .
  • R 8 is independently -C(O)-OR 8C .
  • R 8 is
  • R 8 independently -C(O)NR 8A R 8B .
  • R 8 is independently -OR 8D .
  • R 8 is independently -SR 8D .
  • R 8 is independently -NR 8A SO 2 R 8D .
  • R 8 is independently -NR 8A C(O)R 8C . In embodiments, R 8 is
  • R 8 is independently -NR 8A C(O)OR 8C .
  • R 8 is independently -NR 8A OR 8C .
  • R 8 is independently -OH.
  • R 8 is independently -NH 2 .
  • R 8 is independently -COOH.
  • R 8 is independently -CONH 2 .
  • R 8 is independently -NO2.
  • R 8 is independently -SH.
  • R 8 is independently -CF 3 .
  • R 8 is independently -CHF 2 .
  • R 8 is independently -CH 2 F.
  • R 8 is independently -OCF 3 .
  • R 8 is independently -OCH2F.
  • R 8 is independently -OCHF2. In embodiments, R 8 is independently–OCH 3 . In embodiments, R 8 is independently–OCH 2 CH 3 . In embodiments, R 8 is independently–OCH 2 CH 2 CH 3 . In embodiments, R 8 is independently– OCH(CH3)2. In embodiments, R 8 is independently–OC(CH3)3. In embodiments, R 8 is independently–SCH3. In embodiments, R 8 is independently–SCH2CH3. In embodiments, R 8 is independently–SCH 2 CH 2 CH 3 . In embodiments, R 8 is independently–SCH(CH 3 ) 2 . In embodiments, R 8 is independently–SC(CH3)3. In embodiments, R 8 is independently–CH3. In embodiments, R 8 is independently–CH2CH3. In embodiments, R 8 is independently–O
  • R 8 is independently–CH(CH 3 ) 2 . In embodiments, R 8 is independently–C(CH 3 ) 3 . In embodiments, R 8 is independently–F. In embodiments, R 8 is independently–Cl. In embodiments, R 8 is independently–Br. In embodiments, R 8 is independently–I. In embodiments, X 8 is independently–F. In embodiments, X 8 is
  • R 8 is independently substituted or unsubstituted alkyl (e.g., C1-C8, C1- C6, C1-C4, or C1-C2). In embodiments, R 8 is independently substituted alkyl (e.g., C1-C8, C1-C6, C 1 -C 4 , or C 1 -C 2 ). In embodiments, R 8 is independently unsubstituted alkyl (e.g., C 1 -C 8 , C 1 -C 6 , C1-C4, or C1-C2).
  • R 8 is independently unsubstituted methyl. In embodiments, R 8 is independently unsubstituted ethyl. In embodiments, R 8 is independently unsubstituted propyl. In embodiments, R 8 is independently unsubstituted isopropyl. In embodiments, R 8 is independently unsubstituted tert-butyl. In embodiments, R 8 is independently substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered).
  • R 8 is independently substituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered). In embodiments, R 8 is independently unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered). In embodiments, R 8 is independently substituted or unsubstituted cycloalkyl (e.g., C 3 -C 8 , C 3 -C 6 , C 4 - C6, or C5-C6).
  • R 8 is independently substituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6). In embodiments, R 8 is independently unsubstituted cycloalkyl (e.g., C3-C8, C3- C 6 , C 4 -C 6 , or C 5 -C 6 ). In embodiments, R 8 is independently substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • R 8 is independently substituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered). In embodiments, R 8 is independently unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered). In embodiments, R 8 is independently substituted or unsubstituted aryl (e.g., C 6 -C 10 or phenyl). In embodiments, R 8 is independently substituted aryl (e.g., C 6 -C 10 or phenyl).
  • R 8 is independently unsubstituted aryl (e.g., C6-C10 or phenyl). In embodiments, R 8 is independently substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). In embodiments, R 8 is independently substituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). In embodiments, R 8 is independently unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). [0306] In embodiments, R 8 is independently hydrogen,
  • R 8 is independently
  • R 8 is independently -C(O)R 8C or -C(O)OR 8C , wherein R 8C is substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl.
  • R 8 is independently -C(O)R 8C ,
  • R 8C is substituted or unsubstituted C1-C6 alkyl.
  • R 8 is or .
  • R 8 is In embodiments, R 8 is independently E.
  • R 8A is independently hydrogen. In embodiments, R 8A is
  • R 8A is independently -CX 8A 3 .
  • R 8A is independently -CHX 8A 2 .
  • R 8A is independently -CH2X 8A .
  • R 8A is independently -CN.
  • R 8A is independently -COOH.
  • R 8A is independently -CONH2.
  • X 8A is independently–F, -Cl, -Br, or -I.
  • R 8A is independently substituted or unsubstituted alkyl (e.g., C 1 -C 8 , C1-C6, C1-C4, or C1-C2).
  • R 8A is independently substituted alkyl (e.g., C1-C8, C1- C 6 , C 1 -C 4 , or C 1 -C 2 ). In embodiments, R 8A is independently unsubstituted alkyl (e.g., C 1 -C 8 , C 1 - C 6 , C 1 -C 4 , or C 1 -C 2 ). In embodiments, R 8A is independently unsubstituted methyl. In
  • R 8A is independently unsubstituted ethyl. In embodiments, R 8A is independently unsubstituted propyl. In embodiments, R 8A is independently unsubstituted isopropyl. In embodiments, R 8A is independently unsubstituted tert-butyl. In embodiments, R 8A is
  • R 8A is independently substituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered).
  • R 8A is independently substituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered).
  • R 8A is independently unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered).
  • R 8A is independently substituted or unsubstituted cycloalkyl (e.g., C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ). In embodiments, R 8A is independently substituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6). In embodiments, R 8A is independently unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6).
  • R 8A is independently substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • R 8A is independently substituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • R 8A is independently unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • R 8A is independently substituted or unsubstituted aryl (e.g., C6-C10 or phenyl). In embodiments, R 8A is independently substituted aryl (e.g., C6-C10 or phenyl). In embodiments, R 8A is independently unsubstituted aryl (e.g., C6- C 10 or phenyl). In embodiments, R 8A is independently substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
  • R 8A is independently substituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). In embodiments, R 8A is independently unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). [0309] In embodiments, R 8B is independently hydrogen. In embodiments, R 8B is
  • R 8B is independently -CX 8B 3 .
  • R 8B is independently -CHX 8B 2 .
  • R 8B is independently -CH 2 X 8B .
  • R 8B is independently -CN.
  • R 8B is independently -COOH.
  • R 8B is independently -CONH2.
  • X 8B is independently–F, -Cl, -Br, or -I.
  • R 8B is independently substituted or unsubstituted alkyl (e.g., C 1 -C 8 , C1-C6, C1-C4, or C1-C2).
  • R 8B is independently substituted alkyl (e.g., C1-C8, C1- C6, C1-C4, or C1-C2). In embodiments, R 8B is independently unsubstituted alkyl (e.g., C1-C8, C1- C 6 , C 1 -C 4 , or C 1 -C 2 ). In embodiments, R 8B is independently unsubstituted methyl.
  • R 8B is independently substituted alkyl (e.g., C1-C8, C1- C6, C1-C4, or C1-C2).
  • R 8B is independently unsubstituted alkyl (e.g., C1-C8, C1- C 6 , C 1 -C 4 , or C 1 -C 2 ). In embodiments, R 8B is independently unsubstituted methyl.
  • R 8B is independently unsubstituted ethyl. In embodiments, R 8B is independently unsubstituted propyl. In embodiments, R 8B is independently unsubstituted isopropyl. In embodiments, R 8B is independently unsubstituted tert-butyl. In embodiments, R 8B is
  • R 8B is independently substituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered).
  • R 8B is independently substituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered).
  • R 8B is independently unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered).
  • R 8B is independently substituted or unsubstituted cycloalkyl (e.g., C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ). In embodiments, R 8B is independently substituted cycloalkyl (e.g., C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ). In embodiments, R 8B is independently unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6).
  • R 8B is independently substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • R 8B is independently substituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • R 8B is independently unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • R 8B is independently substituted or unsubstituted aryl (e.g., C6-C10 or phenyl). In embodiments, R 8B is independently substituted aryl (e.g., C 6 -C 10 or phenyl). In embodiments, R 8B is independently unsubstituted aryl (e.g., C 6 - C10 or phenyl). In embodiments, R 8B is independently substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
  • R 8B is independently substituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). In embodiments, R 8B is independently unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). [0311] In embodiments, R 8A and R 8B substituents bonded to the same nitrogen atom may be joined to form a substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • R 8A and R 8B substituents bonded to the same nitrogen atom may be joined to form a substituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • R 8A and R 8B substituents bonded to the same nitrogen atom may be joined to form an unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • R 8A and R 8B substituents bonded to the same nitrogen atom may be joined to form a substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
  • R 8A and R 8B substituents bonded to the same nitrogen atom may be joined to form a substituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
  • R 8A and R 8B substituents bonded to the same nitrogen atom may be joined to form an unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
  • R 8C is independently hydrogen. In embodiments, R 8C is
  • R 8C is independently -CX 8C 3. In embodiments, R 8C is independently -CHX 8C 2. In embodiments, R 8C is independently -CH 2 X 8C . In embodiments, R 8C is independently -CN. In embodiments, R 8C is independently -COOH. In embodiments, R 8C is independently -CONH 2 . In embodiments, X 8C is independently–F, -Cl, -Br, or -I. [0314] In embodiments, R 8C is independently substituted or unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2).
  • R 8C is independently substituted alkyl (e.g., C1-C8, C1- C 6 , C 1 -C 4 , or C 1 -C 2 ). In embodiments, R 8C is independently unsubstituted alkyl (e.g., C 1 -C 8 , C 1 - C6, C1-C4, or C1-C2). In embodiments, R 8C is independently unsubstituted methyl. In
  • R 8C is independently unsubstituted ethyl. In embodiments, R 8C is independently unsubstituted propyl. In embodiments, R 8C is independently unsubstituted isopropyl. In embodiments, R 8C is independently unsubstituted tert-butyl. In embodiments, R 8C is
  • R 8C is independently unsubstituted pentyl. In embodiments, R 8C is independently unsubstituted hexyl. In embodiments, R 8C is independently unsubstituted heptyl. In embodiments, R 8C is
  • R 8C is independently unsubstituted octyl.
  • R 8C is independently substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered).
  • R 8C is independently substituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered).
  • R 8C is independently unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered).
  • R 8C is independently substituted or unsubstituted cycloalkyl (e.g., C 3 -C 8 , C 3 -C 6 , C4-C6, or C5-C6).
  • R 8C is independently substituted cycloalkyl (e.g., C3-C8, C3- C6, C4-C6, or C5-C6).
  • R 8C is independently unsubstituted cycloalkyl (e.g., C3- C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ).
  • R 8C is independently substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • R 8C is independently substituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • R 8C is independently unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered). In embodiments, R 8C is independently substituted or unsubstituted aryl (e.g., C6-C10 or phenyl). In embodiments, R 8C is independently substituted aryl (e.g., C 6 -C 10 or phenyl). In embodiments, R 8C is independently unsubstituted aryl (e.g., C6-C10 or phenyl).
  • R 8C is independently substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). In embodiments, R 8C is independently substituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). In embodiments, R 8C is independently unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). [0315] In embodiments, R 8D is independently hydrogen. In embodiments, R 8D is
  • R 8D is independently -CX 8D 3 .
  • R 8D is independently -CHX 8D 2 .
  • R 8D is independently -CH2X 8D .
  • R 8D is independently -CN.
  • R 8D is independently -COOH.
  • R 8D is independently -CONH2.
  • X 8D is independently–F, -Cl, -Br, or -I.
  • R 8D is independently substituted or unsubstituted alkyl (e.g., C 1 -C 8 , C1-C6, C1-C4, or C1-C2).
  • R 8D is independently substituted alkyl (e.g., C1-C8, C1- C6, C1-C4, or C1-C2). In embodiments, R 8D is independently unsubstituted alkyl (e.g., C1-C8, C1- C 6 , C 1 -C 4 , or C 1 -C 2 ). In embodiments, R 8D is independently unsubstituted methyl.
  • R 8D is independently substituted alkyl (e.g., C1-C8, C1- C6, C1-C4, or C1-C2).
  • R 8D is independently unsubstituted alkyl (e.g., C1-C8, C1- C 6 , C 1 -C 4 , or C 1 -C 2 ). In embodiments, R 8D is independently unsubstituted methyl.
  • R 8D is independently unsubstituted ethyl. In embodiments, R 8D is independently unsubstituted propyl. In embodiments, R 8D is independently unsubstituted isopropyl. In embodiments, R 8D is independently unsubstituted tert-butyl. In embodiments, R 8D is
  • R 8D is independently substituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered).
  • R 8D is independently substituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered).
  • R 8D is independently unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered).
  • R 8D is independently substituted or unsubstituted cycloalkyl (e.g., C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ). In embodiments, R 8D is independently substituted cycloalkyl (e.g., C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ). In embodiments, R 8D is independently unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6).
  • R 8D is independently substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • R 8D is independently substituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • R 8D is independently unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • R 8D is independently substituted or unsubstituted aryl (e.g., C6-C10 or phenyl). In embodiments, R 8D is independently substituted aryl (e.g., C 6 -C 10 or phenyl). In embodiments, R 8D is independently unsubstituted aryl (e.g., C 6 - C10 or phenyl). In embodiments, R 8D is independently substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
  • R 8D is independently substituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). In embodiments, R 8D is independently unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). [0317] In embodiments, R 8 is independently hydrogen,
  • unsubstituted alkyl e.g., C1-C8, C1-C6, C1-C4, or C1-C2
  • R 41 -substituted or unsubstituted heteroalkyl e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered
  • R 41 -substituted or unsubstituted cycloalkyl e.g., C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6
  • R 41 -substituted or unsubstituted heterocycloalkyl e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered
  • R 41 -substituted or unsubstituted aryl e.g., C6
  • X 8 is independently–F, -Cl, -Br, or–I.
  • R 8 is independently hydrogen.
  • R 8 is independently unsubstituted methyl.
  • R 8 is independently unsubstituted ethyl.
  • R 41 is independently oxo,
  • R 42 -substituted or unsubstituted alkyl e.g., C1-C8, C1-C6, C1-C4, or C1-C2
  • R 42 -substituted or unsubstituted heteroalkyl e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered
  • R 42 -substituted or unsubstituted cycloalkyl e.g., C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6
  • R 42 -substituted or unsubstituted heterocycloalkyl e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered
  • X 41 is independently–F, -Cl, -Br, or–I. In embodiments, R 41 is independently unsubstituted methyl. In embodiments, R 41 is independently unsubstituted ethyl. [0319] R 42 is independently oxo,
  • X 42 is independently–F, -Cl, -Br, or–I.
  • R 42 is independently unsubstituted methyl.
  • R 42 is independently unsubstituted ethyl.
  • R 43 is independently oxo,
  • X 43 is independently–F, -Cl, -Br, or–I. In embodiments, R 43 is independently unsubstituted methyl. In embodiments, R 43 is independently unsubstituted ethyl. [0321] In embodiments, R 8A is independently
  • R 41A -substituted or unsubstituted alkyl e.g., C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2
  • R 41A -substituted or unsubstituted heteroalkyl e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered
  • R 41A -substituted or unsubstituted cycloalkyl e.g., C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6
  • R 41A - substituted or unsubstituted heterocycloalkyl e.g.
  • unsubstituted alkyl e.g., C 1 -C 8 , C1-C6, C1-C4, or C1-C2
  • unsubstituted heteroalkyl e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered
  • unsubstituted cycloalkyl e.g., C 3 -C 8 , C 3 - C 6 , C 4 -C 6 , or C 5 -C 6
  • unsubstituted heterocycloalkyl e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered
  • unsubstituted aryl e.
  • X 8A is independently–F, -Cl, -Br, or–I.
  • R 8A is independently hydrogen.
  • R 8A is independently unsubstituted methyl.
  • R 8A is independently unsubstituted ethyl.
  • R 8A and R 8B substituents bonded to the same nitrogen atom may optionally be joined to form a R 41A -substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered) or R 41A - substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
  • a R 41A -substituted or unsubstituted heterocycloalkyl e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered
  • R 41A - substituted or unsubstituted heteroaryl e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered
  • R 8A and R 8B substituents bonded to the same nitrogen atom may optionally be joined to form an unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered) or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
  • an unsubstituted heterocycloalkyl e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered
  • unsubstituted heteroaryl e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered.
  • R 8A and R 8B substituents bonded to the same nitrogen atom may optionally be joined to form a R 41A - substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • R 8A and R 8B substituents bonded to the same nitrogen atom may optionally be joined to form an unsubstituted
  • R 41A is independently oxo
  • X 41A is independently–F, -Cl, -Br, or–I. In embodiments, R 41A is independently unsubstituted methyl. In embodiments, R 41A is independently unsubstituted ethyl. [0324] In embodiments, R 8B is independently
  • R 41B -substituted or unsubstituted alkyl e.g., C1-C8, C1-C6, C1-C4, or C1-C2
  • R 41B -substituted or unsubstituted heteroalkyl e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered
  • R 41B -substituted or unsubstituted cycloalkyl e.g., C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6
  • R 41B - substituted or unsubstituted heterocycloalkyl e.g., 3 to 8 membered, 3 to 6
  • unsubstituted alkyl e.g., C1-C8, C 1 -C 6 , C 1 -C 4 , or C 1 -C 2
  • unsubstituted heteroalkyl e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered
  • unsubstituted cycloalkyl e.g., C 3 -C 8 , C 3 - C6, C4-C6, or C5-C6
  • unsubstituted heterocycloalkyl e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered
  • unsubstituted aryl e.g., C6-C10 or
  • X 8B is independently–F, -Cl, -Br, or–I.
  • R 8B is independently hydrogen.
  • R 8B is independently unsubstituted methyl.
  • R 8B is independently unsubstituted ethyl.
  • R 8A and R 8B substituents bonded to the same nitrogen atom may optionally be joined to form a R 41B -substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered) or R 41B - substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
  • a R 41B -substituted or unsubstituted heterocycloalkyl e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered
  • R 41B - substituted or unsubstituted heteroaryl e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered
  • R 8A and R 8B substituents bonded to the same nitrogen atom may optionally be joined to form an unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered) or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
  • an unsubstituted heterocycloalkyl e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered
  • unsubstituted heteroaryl e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered.
  • R 8A and R 8B substituents bonded to the same nitrogen atom may optionally be joined to form a R 41B - substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • R 8A and R 8B substituents bonded to the same nitrogen atom may optionally be joined to form an unsubstituted
  • R 41B is independently oxo
  • X 41B is independently–F, -Cl, -Br, or–I. In embodiments, R 41B is independently unsubstituted methyl. In embodiments, R 41B is independently unsubstituted ethyl. [0327] In embodiments, R 8C is independently
  • R 41C -substituted or unsubstituted alkyl e.g., C1-C8, C1-C6, C1-C4, or C1-C2
  • R 41C -substituted or unsubstituted heteroalkyl e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered
  • R 41C -substituted or unsubstituted cycloalkyl e.g., C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6
  • R 41C - substituted or unsubstituted heterocycloalkyl e.g., 3 to 8 membered, 3 to 6
  • unsubstituted alkyl e.g., C1-C8, C1-C6, C1-C4, or C1-C2
  • unsubstituted heteroalkyl e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered
  • unsubstituted cycloalkyl e.g., C 3 -C 8 , C 3 - C6, C4-C6, or C5-C6
  • unsubstituted heterocycloalkyl e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered
  • unsubstituted aryl e.g., C6-C10 or phenyl
  • X 8C is independently–F, -Cl, -Br, or–I.
  • R 8C is independently hydrogen.
  • R 8C is independently unsubstituted methyl.
  • R 8C is independently unsubstituted ethyl.
  • R 41C is independently oxo
  • X 41C is independently–F, -Cl, -Br, or–I. In embodiments, R 41C is independently unsubstituted methyl. In embodiments, R 41C is independently unsubstituted ethyl. [0329] In embodiments, R 8D is independently
  • R 41D -substituted or unsubstituted alkyl e.g., C1-C8, C1-C6, C1-C4, or C1-C2
  • R 41D -substituted or unsubstituted heteroalkyl e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered
  • R 41D -substituted or unsubstituted cycloalkyl e.g., C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6
  • R 41D - substituted or unsubstituted heterocycloalkyl e.g., 3 to 8 membered, 3 to 6
  • unsubstituted alkyl e.g., C1-C8, C1-C6, C1-C4, or C1-C2
  • unsubstituted heteroalkyl e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered
  • unsubstituted cycloalkyl e.g., C3-C8, C3- C 6 , C 4 -C 6 , or C 5 -C 6
  • unsubstituted heterocycloalkyl e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered
  • unsubstituted aryl e.g., C6-C10 or phenyl
  • X 8D is independently–F, -Cl, -Br, or–I.
  • R 8D is independently hydrogen.
  • R 8D is independently unsubstituted methyl.
  • R 8D is independently unsubstituted ethyl.
  • R 41D is independently oxo
  • X 41D is independently–F, -Cl, -Br, or–I. In embodiments, R 41D is independently unsubstituted methyl. In embodiments, R 41D is independently unsubstituted ethyl.
  • n1 may independently be 0. n1 may independently be 1. n1 may independently be 2. n1 may independently be 3. n1 may independently be 4. n2 may independently be 0. n2 may independently be 1. n2 may independently be 2. n2 may independently be 3. n2 may independently be 4. n7 may independently be 0. n7 may independently be 1. n7 may independently be 2. n7 may independently be 3. n7 may independently be 4. n8 may independently be 0. n8 may independently be 1. n8 may independently be 2. n8 may independently be 3. n8 may independently be 4. v1 may independently be 1. v1 may independently be 2. v2 may independently be 1. v2 may independently be 2. v7 may
  • Each X, X 1 , X 2 , X 7 , and X 8 is independently–F, -Cl, -Br, or–I.
  • X 1 may independently be–F.
  • X 1 may independently be–Cl.
  • X 1 may independently be–Br.
  • X 1 may independently be –I.
  • X 2 may independently be–F.
  • X 2 may independently be–Cl.
  • X 2 may independently be–Br.
  • X 2 may independently be–I.
  • X 7 may independently be–F.
  • X 7 may independently be–Cl.
  • X 7 may independently be–Br.
  • E is a covalent cysteine modifier moiety (e.g., as described in FIG.25, wherein E is the moiety attached to DG01 or DG02).
  • Each X, X 15 , X 16 , X 17 and X 18 is independently–F, -Cl, -Br, or–I.
  • the symbols n15, n16, n17, v15, v16, and v17, are independently an integer from 0 to 4.
  • the symbols m15, m16, and m17 are independently 1 or 2.
  • E is: .
  • R 15 is hydrogen; R 16 is hydrogen; and R 17 is hydrogen.
  • R 15 is independently hydrogen, halogen, -CX 15 3 , -CHX 15 2 , - CH 2 X 15 , -CN, -SO n15 R 15D , -SO v15 NR 15A R 15B , ⁇ NHNR 15A R 15B , ⁇ ONR 15A R 15B ,
  • ⁇ NHC (O)NHNR 15A R 15B , ⁇ NHC(O)NR 15A R 15B , -N(O) m15 , -NR 15A R 15B , -C(O)R 15C ,
  • -C(O)-OR 15C -C(O)NR 15A R 15B , -OR 15D , -NR 15A SO 2 R 15D , -NR 15A C(O)R 15C , - NR 15A C(O)OR 15C , -NR 15A OR 15C , -OCX 15 3 , -OCHX 15 2 , -OCH 2 X 15 , substituted or unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), substituted or unsubstituted cycloalkyl (e.g., C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 membere
  • R 16 is independently hydrogen, halogen, -CX 16 3, -CHX 16 2, - CH 2 X 16 , -CN, -SO n16 R 16D , -SO v16 NR 16A R 16B , ⁇ NHNR 16A R 16B , ⁇ ONR 16A R 16B ,
  • ⁇ NHC (O)NHNR 16A R 16B , ⁇ NHC(O)NR 16A R 16B , -N(O) m16 , -NR 16A R 16B , -C(O)R 16C ,
  • R 17 is independently hydrogen, halogen, -CX 17 3, -CHX 17 2, - CH 2 X 17 , -CN, -SO n17 R 17D , -SO v17 NR 17A R 17B , ⁇ NHNR 17A R 17B , ⁇ ONR 17A R 17B ,
  • ⁇ NHC (O)NHNR 17A R 17B , ⁇ NHC(O)NR 17A R 17B , -N(O) m17 , -NR 17A R 17B , -C(O)R 17C ,
  • -C(O)-OR 17C -C(O)NR 17A R 17B , -OR 17D , -NR 17A SO 2 R 17D , -NR 17A C(O)R 17C , - NR 17A C(O)OR 17C , -NR 17A OR 17C , -OCX 17 3 , -OCHX 17 2 , -OCH 2 X 17 , substituted or unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), substituted or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), substituted or unsubstit
  • R 18 is independently hydrogen, -CX 18 3 , -CHX 18 2 , - CH 2 X 18 , -C(O)R 18C , -C(O)OR 18C , -C(O)NR 18A R 18B , substituted or unsubstituted alkyl (e.g., C 1 - C8, C1-C6, C1-C4, or C1-C2), substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), substituted or unsubstituted cycloalkyl (e.g., C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ), substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered
  • Each R 15A , R 15B , R 15C , R 15D , R 16A , R 16B , R 16C , R 16D , R 17A , R 17B , R 17C , R 17D , R 18A , R 18B , R 18C , R 18D is independently hydrogen, -CX3, -CN, -COOH, -CONH2, -CHX2, -CH2X, substituted or unsubstituted alkyl (e.g., C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2 ), substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), substituted or unsubstituted cycloalkyl (e.g., C3-C8, C3-C
  • Each X, X 15 , X 16 , X 17 and X 18 is independently–F, -Cl, -Br, or –I.
  • the symbols n15, n16, n17, v15, v16, and v17, are each independently an integer from 0 to 4.
  • the symbols m15, m16, and m17 are independently 1 or 2.
  • E is: and X 17 is -Cl. In embodiments, E is: . In embodiments, X 17 is -Cl.
  • E is: and R 15 , R 16 , and R 17 are independently
  • E is: .
  • R 15 , R 16 , and R 17 are independently hydrogen.
  • E is: In embodiments, E is: In
  • E is: In embodiments, E is: In embodiments,
  • E is: In embodiments, E is: In embodiments, E is: In embodiments, E is: In embodiments, E is: In embodiments, E is: In embodiments, E is: In embodiments, E is: In embodiments, E is: In embodiments, E is: In embodiments, E is: In embodiments, E is: In embodiments, E is: In embodiments, E is: In embodiments, E is: In embodiments, E is: In embodiments, E is: In embodiments, E is: In embodiments, E is: In embodiments, E is: In embodiments, E is: In embodiments, E is: In embodiments, E is: In embodiments, E is: In embodiments, E is: In embodiments, E is: In embodiments, E is: In embodiments, E is: In embodiments, E is: In embodiments, E is: In embodiments, E is: In embodiments, E is: In embodiments, E is: In embodiments, E is: In embodiments, E is: In embodiments, E is: In embodiments, E
  • X 18 may independently be–I.
  • n15 may independently be 0. n15 may independently be 1. n15 may independently be 2.
  • n15 may independently be 3.
  • n15 may independently be 4.
  • n16 may independently be 0.
  • n16 may independently be 1.
  • n16 may independently be 2.
  • n16 may independently be 3.
  • n16 may independently be 4.
  • n17 may independently be 0.
  • n17 may independently be 1.
  • n17 may independently be 2.
  • n17 may independently be 3.
  • n17 may independently be 4.
  • v15 may independently be 2.
  • v15 may independently be 3.
  • 4. v16 may independently be 0.
  • v16 may independently be 0.
  • v16 may independently be 1.
  • v16 may independently be 2.
  • v16 may independently be 3.
  • 4. v17 may independently be 0.
  • v16 may independently be 0.
  • v16 may independently be 1.
  • v16
  • R 15 is hydrogen. In embodiments, R 15 is halogen. In embodiments, R 15 is -CX 15 3 . In embodiments, R 15 is -CHX 15 2 . In embodiments, R 15 is -CH 2 X 15 . In embodiments, R 15 is–CN. In embodiments, R 15 is -SOn15R 15D . In embodiments, R 15 is -SOv15NR 15A R 15B .
  • R 15 is -NR 15A SO2R 15D . In embodiments, R 15 is -NR 15A C(O)R 15C . In embodiments, R 15 is -NR 15A C(O)OR 15C . In embodiments, R 15 is -NR 15A OR 15C . In embodiments, R 15 is -OCX 15 3 . In embodiments, R 15 is -OCHX 15 2. In embodiments, R 15 is -OCH2X 15 . In embodiments, R 15 is independently -OH. In embodiments, R 15 is independently -NH2. In embodiments, R 15 is independently -COOH. In embodiments, R 15 is independently -CONH 2 . In embodiments, R 15 is independently -NO 2 .
  • R 15 is independently -SH. In embodiments, R 15 is independently -CF3. In embodiments, R 15 is independently -CHF2. In embodiments, R 15 is independently -CH2F. In embodiments, R 15 is independently -OCF 3 . In embodiments, R 15 is independently -OCH 2 F. In embodiments, R 15 is independently -OCHF 2 . In embodiments, R 15 is independently–OCH 3 . In embodiments, R 15 is independently–OCH2CH3. In embodiments, R 15 is independently– OCH2CH2CH3. In embodiments, R 15 is independently–OCH(CH3)2. In embodiments, R 15 is independently–OC(CH 3 ) 3 . In embodiments, R 15 is independently–SCH 3 .
  • R 15 is independently–SCH2CH3. In embodiments, R 15 is independently–SCH2CH2CH3. In embodiments, R 15 is independently–SCH(CH3)2. In embodiments, R 15 is independently– SC(CH 3 ) 3 . In embodiments, R 15 is independently–CH 3 . In embodiments, R 15 is independently– CH2CH3. In embodiments, R 15 is independently–CH2CH2CH3. In embodiments, R 15 is independently–CH(CH3)2. In embodiments, R 15 is independently–C(CH3)3. In embodiments, R 15 is independently–F. In embodiments, R 15 is independently–Cl. In embodiments, R 15 is independently–Br. In embodiments, R 15 is independently–I.
  • R 15 is independently substituted or unsubstituted alkyl (e.g., C1-C8, C1- C 6 , C 1 -C 4 , or C 1 -C 2 ). In embodiments, R 15 is independently substituted alkyl (e.g., C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2 ). In embodiments, R 15 is independently unsubstituted alkyl (e.g., C 1 -C 8 , C 1 -C 6 , C1-C4, or C1-C2). In embodiments, R 15 is independently unsubstituted methyl.
  • R 15 is independently unsubstituted methyl.
  • R 15 is independently unsubstituted ethyl. In embodiments, R 15 is independently unsubstituted propyl. In embodiments, R 15 is independently unsubstituted isopropyl. In embodiments, R 15 is independently unsubstituted tert-butyl. In embodiments, R 15 is independently substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered).
  • R 15 is independently substituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered). In embodiments, R 15 is independently unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered). In embodiments, R 15 is independently substituted or unsubstituted cycloalkyl (e.g., C 3 -C 8 , C 3 -C 6 , C4-C6, or C5-C6).
  • R 15 is independently substituted cycloalkyl (e.g., C3-C8, C3- C6, C4-C6, or C5-C6). In embodiments, R 15 is independently unsubstituted cycloalkyl (e.g., C3- C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ). In embodiments, R 15 is independently substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • R 15 is independently substituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered). In embodiments, R 15 is independently unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered). In embodiments, R 15 is independently substituted or unsubstituted aryl (e.g., C 6 -C 10 or phenyl). In embodiments, R 15 is independently substituted aryl (e.g., C 6 -C 10 or phenyl).
  • R 15 is independently unsubstituted aryl (e.g., C6-C10 or phenyl). In embodiments, R 15 is independently substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). In embodiments, R 15 is independently substituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). In embodiments, R 15 is independently unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). [0351] In embodiments, R 15A is independently hydrogen. In embodiments, R 15A is
  • R 15A is independently -CX 15A 3 .
  • R 15A is independently -CHX 15A 2 .
  • R 15A is independently -CH2X 15A .
  • R 15A is independently -CN.
  • R 15A is independently -COOH.
  • R 15A is independently -CONH 2 .
  • X 15A is independently–F, -Cl, -Br, or -I.
  • R 15A is independently substituted or unsubstituted alkyl (e.g., C1-C8, C1- C6, C1-C4, or C1-C2).
  • R 15A is independently substituted alkyl (e.g., C1-C8, C1- C 6 , C 1 -C 4 , or C 1 -C 2 ).
  • R 15A is independently unsubstituted alkyl (e.g., C 1 -C 8 , C 1 - C6, C1-C4, or C1-C2).
  • R 15A is independently unsubstituted methyl. In embodiments, R 15A is independently unsubstituted ethyl. In embodiments, R 15A is independently unsubstituted propyl. In embodiments, R 15A is independently unsubstituted isopropyl. In embodiments, R 15A is independently unsubstituted tert-butyl. In embodiments, R 15A is independently substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered). In embodiments, R 15A is
  • heteroalkyl e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6
  • R 15A is independently unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered).
  • R 15A is independently substituted or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6).
  • R 15A is independently substituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6).
  • R 15A is independently unsubstituted cycloalkyl (e.g., C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ).
  • R 15A is independently substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • R 15A is independently substituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • R 15A is independently unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered). In embodiments, R 15A is independently substituted or unsubstituted aryl (e.g., C 6 -C 10 or phenyl). In embodiments, R 15A is independently substituted aryl (e.g., C6-C10 or phenyl). In embodiments, R 15A is independently unsubstituted aryl (e.g., C6- C10 or phenyl).
  • R 15A is independently substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). In embodiments, R 15A is independently substituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). In embodiments, R 15A is independently unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). [0353] In embodiments, R 15B is independently hydrogen. In embodiments, R 15B is
  • R 15B is independently -CX 15B 3. In embodiments, R 15B is independently -CHX 15B 2. In embodiments, R 15B is independently -CH 2 X 15B . In embodiments, R 15B is independently -CN. In embodiments, R 15B is independently -COOH. In embodiments, R 15B is independently -CONH 2 . In
  • X 15B is independently–F, -Cl, -Br, or -I.
  • R 15B is independently substituted or unsubstituted alkyl (e.g., C1-C8, C1- C 6 , C 1 -C 4 , or C 1 -C 2 ).
  • R 15B is independently substituted alkyl (e.g., C 1 -C 8 , C 1 - C6, C1-C4, or C1-C2).
  • R 15B is independently unsubstituted alkyl (e.g., C1-C8, C1- C6, C1-C4, or C1-C2).
  • R 15B is independently unsubstituted methyl. In embodiments, R 15B is independently unsubstituted ethyl. In embodiments, R 15B is independently unsubstituted propyl. In embodiments, R 15B is independently unsubstituted isopropyl. In embodiments, R 15B is independently unsubstituted tert-butyl. In embodiments, R 15B is independently substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered). In embodiments, R 15B is
  • heteroalkyl e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6
  • R 15B is independently unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered).
  • R 15B is independently substituted or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6).
  • R 15B is independently substituted cycloalkyl (e.g., C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ).
  • R 15B is independently unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6).
  • R 15B is independently substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • R 15B is independently substituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • R 15B is independently unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered). In embodiments, R 15B is independently substituted or unsubstituted aryl (e.g., C6-C10 or phenyl). In embodiments, R 15B is independently substituted aryl (e.g., C6-C10 or phenyl). In embodiments, R 15B is independently unsubstituted aryl (e.g., C6- C 10 or phenyl).
  • R 15B is independently substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). In embodiments, R 15B is independently substituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). In embodiments, R 15B is independently unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
  • R 15A and R 15B substituents bonded to the same nitrogen atom may be joined to form a substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • R 15A and R 15B substituents bonded to the same nitrogen atom may be joined to form a substituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • R 15A and R 15B substituents bonded to the same nitrogen atom may be joined to form an unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered). [0356] In embodiments, R 15A and R 15B substituents bonded to the same nitrogen atom may be joined to form a substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
  • R 15A and R 15B substituents bonded to the same nitrogen atom may be joined to form a substituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). In embodiments, R 15A and R 15B substituents bonded to the same nitrogen atom may be joined to form an unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
  • R 15C is independently hydrogen.
  • R 15C is independently -CX 15C 3.
  • R 15C is independently -CHX 15C 2.
  • R 15C is independently -CH 2 X 15C .
  • R 15C is independently -CN.
  • R 15C is independently -COOH.
  • R 15C is independently -CONH2.
  • X 15C is independently–F, -Cl, -Br, or -I.
  • R 15C is independently substituted or unsubstituted alkyl (e.g., C 1 -C 8 , C 1 - C 6 , C 1 -C 4 , or C 1 -C 2 ).
  • R 15C is independently substituted alkyl (e.g., C 1 -C 8 , C 1 - C6, C1-C4, or C1-C2).
  • R 15C is independently unsubstituted alkyl (e.g., C1-C8, C1- C 6 , C 1 -C 4 , or C 1 -C 2 ).
  • R 15C is independently unsubstituted methyl. In embodiments, R 15C is independently unsubstituted ethyl. In embodiments, R 15C is independently unsubstituted propyl. In embodiments, R 15C is independently unsubstituted isopropyl. In embodiments, R 15C is independently unsubstituted tert-butyl. In embodiments, R 15C is independently substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered). In embodiments, R 15C is
  • heteroalkyl e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6
  • R 15C is independently unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered).
  • R 15C is independently substituted or unsubstituted cycloalkyl (e.g., C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ).
  • R 15C is independently substituted cycloalkyl (e.g., C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ).
  • R 15C is independently unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6).
  • R 15C is independently substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • R 15C is independently substituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered). In embodiments, R 15C is independently unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered). In embodiments, R 15C is independently substituted or unsubstituted aryl (e.g., C6-C10 or phenyl). In embodiments, R 15C is independently substituted aryl (e.g., C 6 -C 10 or phenyl).
  • R 15C is independently unsubstituted aryl (e.g., C 6 - C 10 or phenyl). In embodiments, R 15C is independently substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). In embodiments, R 15C is independently substituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). In embodiments, R 15C is independently unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). [0359] In embodiments, R 15D is independently hydrogen.
  • R 15D is independently hydrogen.
  • R 15D is independently -CX 15D 3. In embodiments, R 15D is independently -CHX 15D 2. In embodiments, R 15D is independently -CH 2 X 15D . In embodiments, R 15D is independently -CN. In embodiments, R 15D is independently -COOH. In embodiments, R 15D is independently -CONH2. In embodiments, R 15D is independently -CX 15D 3. In embodiments, R 15D is independently -CHX 15D 2. In embodiments, R 15D is independently -CH 2 X 15D . In embodiments, R 15D is independently -CN. In embodiments, R 15D is independently -COOH. In embodiments, R 15D is independently -CONH2. In
  • X 15D is independently–F, -Cl, -Br, or -I.
  • R 15D is independently substituted or unsubstituted alkyl (e.g., C 1 -C 8 , C 1 - C 6 , C 1 -C 4 , or C 1 -C 2 ).
  • R 15D is independently substituted alkyl (e.g., C 1 -C 8 , C 1 - C6, C1-C4, or C1-C2).
  • R 15D is independently unsubstituted alkyl (e.g., C1-C8, C1- C 6 , C 1 -C 4 , or C 1 -C 2 ).
  • R 15D is independently unsubstituted methyl. In embodiments, R 15D is independently unsubstituted ethyl. In embodiments, R 15D is independently unsubstituted propyl. In embodiments, R 15D is independently unsubstituted isopropyl. In embodiments, R 15D is independently unsubstituted tert-butyl. In embodiments, R 15D is independently substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered). In embodiments, R 15D is
  • heteroalkyl e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6
  • R 15D is independently unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered).
  • R 15D is independently substituted or unsubstituted cycloalkyl (e.g., C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ).
  • R 15D is independently substituted cycloalkyl (e.g., C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ).
  • R 15D is independently unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6).
  • R 15D is independently substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • R 15D is independently substituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered). In embodiments, R 15D is independently unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered). In embodiments, R 15D is independently substituted or unsubstituted aryl (e.g., C6-C10 or phenyl). In embodiments, R 15D is independently substituted aryl (e.g., C 6 -C 10 or phenyl).
  • R 15D is independently unsubstituted aryl (e.g., C 6 - C 10 or phenyl). In embodiments, R 15D is independently substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). In embodiments, R 15D is independently substituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). In embodiments, R 15D is independently unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). [0361] In embodiments, R 15 is independently hydrogen,
  • X 15 is independently–F, -Cl, -Br, or–I.
  • R 15 is independently hydrogen.
  • R 15 is independently unsubstituted methyl.
  • R 15 is independently unsubstituted ethyl.
  • R 72 is independently oxo,
  • X 72 is independently–F, -Cl, -Br, or–I. In embodiments, R 72 is independently unsubstituted methyl. In embodiments, R 72 is independently unsubstituted ethyl. [0363] R 73 is independently oxo,
  • X 73 is independently–F, -Cl, -Br, or–I. In embodiments, R 73 is independently unsubstituted methyl. In embodiments, R 73 is independently unsubstituted ethyl. [0364] R 74 is independently oxo,
  • X 74 is independently–F, -Cl, -Br, or–I.
  • R 74 is independently unsubstituted methyl.
  • R 74 is independently unsubstituted ethyl.
  • R 16 is hydrogen.
  • R 16 is halogen.
  • R 16 is -CX 16 3 .
  • R 16 is -CHX 16 2 .
  • R 16 is -CH 2 X 16 .
  • R 16 is–CN. In embodiments, R 16 is -SO n16 R 16D . In embodiments, R 16
  • R 16 is -SOv16NR 16A R 16B .
  • R 16 is ⁇ NHNR 16A R 16B .
  • R 16 is ⁇ ONR 16A R 16B .
  • R 16 is ⁇ NHC(O)NR 16A R 16B .
  • R 16 is -N(O)m16.
  • R 16 is -NR 16A R 16B .
  • R 16 is -C(O)R 16C .
  • R 16 is -C(O)-OR 16C .
  • R 16 is -C(O)NR 16A R 16B .
  • R 16 is -OR 16D . In embodiments, R 16 is -NR 16A SO2R 16D . In embodiments, R 16 is -NR 16A C(O)R 16C . In embodiments, R 16 is -NR 16A C(O)OR 16C . In
  • R 16 is -NR 16A OR 16C . In embodiments, R 16 is -OCX 16 3 . In embodiments, R 16 is -OCHX 16 2. In embodiments, R 16 is independently -OH. In embodiments, R 16 is
  • R 16 is independently -NH2. In embodiments, R 16 is independently -COOH. In embodiments, R 16 is independently -CONH 2 . In embodiments, R 16 is independently -NO 2 . In embodiments, R 16 is independently -SH. In embodiments, R 16 is independently -CF3. In embodiments, R 16 is independently -CHF2. In embodiments, R 16 is independently -CH2F. In embodiments, R 16 is independently -OCF 3 . In embodiments, R 16 is independently -OCH 2 F. In embodiments, R 16 is independently -OCHF2. In embodiments, R 16 is independently–OCH3. In embodiments, R 16 is independently–OCH2CH3. In embodiments, R 16 is independently–OCH2CH2CH3.
  • R 16 is independently–OCH(CH 3 ) 2 . In embodiments, R 16 is independently– OC(CH 3 ) 3 . In embodiments, R 16 is independently–SCH 3 . In embodiments, R 16 is independently –SCH2CH3. In embodiments, R 16 is independently–SCH2CH2CH3. In embodiments, R 16 is independently–SCH(CH3)2. In embodiments, R 16 is independently–SC(CH3)3. In
  • R 16 is independently–CH 3 . In embodiments, R 16 is independently–CH 2 CH 3 . In embodiments, R 16 is independently–CH2CH2CH3. In embodiments, R 16 is independently– CH(CH3)2. In embodiments, R 16 is independently–C(CH3)3. In embodiments, R 16 is independently–F. In embodiments, R 16 is independently–Cl. In embodiments, R 16 is independently–Br. In embodiments, R 16 is independently–I. [0366] In embodiments, R 16 is independently substituted or unsubstituted alkyl (e.g., C1-C8, C1- C6, C1-C4, or C1-C2).
  • R 16 is independently substituted or unsubstituted alkyl (e.g., C1-C8, C1- C6, C1-C4, or C1-C2).
  • R 16 is independently substituted alkyl (e.g., C1-C8, C1-C6, C 1 -C 4 , or C 1 -C 2 ). In embodiments, R 16 is independently unsubstituted alkyl (e.g., C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2 ). In embodiments, R 16 is independently unsubstituted methyl. In embodiments, R 16 is independently unsubstituted ethyl. In embodiments, R 16 is independently unsubstituted propyl. In embodiments, R 16 is independently unsubstituted isopropyl.
  • R 16 is independently unsubstituted tert-butyl. In embodiments, R 16 is independently substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered). In embodiments, R 16 is independently substituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered).
  • R 16 is independently unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered). In embodiments, R 16 is independently substituted or unsubstituted cycloalkyl (e.g., C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ). In embodiments, R 16 is independently substituted cycloalkyl (e.g., C 3 -C 8 , C 3 - C6, C4-C6, or C5-C6).
  • R 16 is independently unsubstituted cycloalkyl (e.g., C3- C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ).
  • R 16 is independently substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • R 16 is independently substituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • R 16 is independently unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered). In embodiments, R 16 is independently substituted or unsubstituted aryl (e.g., C6-C10 or phenyl). In embodiments, R 16 is independently substituted aryl (e.g., C 6 -C 10 or phenyl). In embodiments, R 16 is independently unsubstituted aryl (e.g., C6-C10 or phenyl).
  • R 16 is independently substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). In embodiments, R 16 is independently substituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). In embodiments, R 16 is independently unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). [0367] In embodiments, R 16A is independently hydrogen. In embodiments, R 16A is independently hydrogen. In embodiments, R 16A is
  • R 16A is independently -CX 16A 3 .
  • R 16A is independently -CHX 16A 2 .
  • R 16A is independently -CH2X 16A .
  • R 16A is independently -CN.
  • R 16A is independently -COOH.
  • R 16A is independently -CONH2.
  • X 16A is independently–F, -Cl, -Br, or -I.
  • R 16A is independently substituted or unsubstituted alkyl (e.g., C1-C8, C1- C6, C1-C4, or C1-C2).
  • R 16A is independently substituted alkyl (e.g., C1-C8, C1- C 6 , C 1 -C 4 , or C 1 -C 2 ).
  • R 16A is independently unsubstituted alkyl (e.g., C 1 -C 8 , C 1 - C 6 , C 1 -C 4 , or C 1 -C 2 ).
  • R 16A is independently unsubstituted methyl. In embodiments, R 16A is independently unsubstituted ethyl. In embodiments, R 16A is independently unsubstituted propyl. In embodiments, R 16A is independently unsubstituted isopropyl. In embodiments, R 16A is independently unsubstituted tert-butyl. In embodiments, R 16A is independently substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered). In embodiments, R 16A is
  • heteroalkyl e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6
  • R 16A is independently unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered).
  • R 16A is independently substituted or unsubstituted cycloalkyl (e.g., C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ).
  • R 16A is independently substituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6).
  • R 16A is independently unsubstituted cycloalkyl (e.g., C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ).
  • R 16A is independently substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • R 16A is independently substituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • R 16A is independently unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered). In embodiments, R 16A is independently substituted or unsubstituted aryl (e.g., C 6 -C 10 or phenyl). In embodiments, R 16A is independently substituted aryl (e.g., C6-C10 or phenyl). In embodiments, R 16A is independently unsubstituted aryl (e.g., C6- C10 or phenyl).
  • R 16A is independently substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). In embodiments, R 16A is independently substituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). In embodiments, R 16A is independently unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). [0369] In embodiments, R 16B is independently hydrogen. In embodiments, R 16B is independently -CX 16B 3. In embodiments, R 16B is independently -CHX 16B 2. In embodiments, R 16B is independently -CH 2 X 16B . In embodiments, R 16B is independently -CN. In embodiments, R 16B is independently -COOH. In embodiments, R 16B is independently -CONH2. In
  • X 16B is independently–F, -Cl, -Br, or -I.
  • R 16B is independently substituted or unsubstituted alkyl (e.g., C 1 -C 8 , C 1 - C 6 , C 1 -C 4 , or C 1 -C 2 ).
  • R 16B is independently substituted alkyl (e.g., C 1 -C 8 , C 1 - C6, C1-C4, or C1-C2).
  • R 16B is independently unsubstituted alkyl (e.g., C1-C8, C1- C 6 , C 1 -C 4 , or C 1 -C 2 ).
  • R 16B is independently unsubstituted methyl. In embodiments, R 16B is independently unsubstituted ethyl. In embodiments, R 16B is independently unsubstituted propyl. In embodiments, R 16B is independently unsubstituted isopropyl. In embodiments, R 16B is independently unsubstituted tert-butyl. In embodiments, R 16B is independently substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered). In embodiments, R 16B is
  • heteroalkyl e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6
  • R 16B is independently unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered).
  • R 16B is independently substituted or unsubstituted cycloalkyl (e.g., C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ).
  • R 16B is independently substituted cycloalkyl (e.g., C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ).
  • R 16B is independently unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6).
  • R 16B is independently substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • R 16B is independently substituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered). In embodiments, R 16B is independently unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered). In embodiments, R 16B is independently substituted or unsubstituted aryl (e.g., C6-C10 or phenyl). In embodiments, R 16B is independently substituted aryl (e.g., C 6 -C 10 or phenyl).
  • R 16B is independently unsubstituted aryl (e.g., C 6 - C 10 or phenyl). In embodiments, R 16B is independently substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). In embodiments, R 16B is independently substituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). In embodiments, R 16B is independently unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
  • R 16A and R 16B substituents bonded to the same nitrogen atom may be joined to form a substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • R 16A and R 16B substituents bonded to the same nitrogen atom may be joined to form a substituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • R 16A and R 16B substituents bonded to the same nitrogen atom may be joined to form an unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered). [0372] In embodiments, R 16A and R 16B substituents bonded to the same nitrogen atom may be joined to form a substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
  • R 16A and R 16B substituents bonded to the same nitrogen atom may be joined to form a substituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). In embodiments, R 16A and R 16B substituents bonded to the same nitrogen atom may be joined to form an unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). [0373] In embodiments, R 16C is independently hydrogen. In embodiments, R 16C is
  • R 16C is independently -CX 16C 3. In embodiments, R 16C is independently -CHX 16C 2. In embodiments, R 16C is independently -CH2X 16C . In embodiments, R 16C is independently -CN. In embodiments, R 16C is independently -COOH. In embodiments, R 16C is independently -CONH 2 . In
  • X 16C is independently–F, -Cl, -Br, or -I.
  • R 16C is independently substituted or unsubstituted alkyl (e.g., C1-C8, C1- C 6 , C 1 -C 4 , or C 1 -C 2 ).
  • R 16C is independently substituted alkyl (e.g., C 1 -C 8 , C 1 - C 6 , C 1 -C 4 , or C 1 -C 2 ).
  • R 16C is independently unsubstituted alkyl (e.g., C 1 -C 8 , C 1 - C6, C1-C4, or C1-C2).
  • R 16C is independently unsubstituted methyl. In embodiments, R 16C is independently unsubstituted ethyl. In embodiments, R 16C is independently unsubstituted propyl. In embodiments, R 16C is independently unsubstituted isopropyl. In embodiments, R 16C is independently unsubstituted tert-butyl. In embodiments, R 16C is independently substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered). In embodiments, R 16C is
  • heteroalkyl e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6
  • R 16C is independently unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered).
  • R 16C is independently substituted or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6).
  • R 16C is independently substituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6).
  • R 16C is independently unsubstituted cycloalkyl (e.g., C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ).
  • R 16C is independently substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • R 16C is independently substituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • R 16C is independently unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered). In embodiments, R 16C is independently substituted or unsubstituted aryl (e.g., C 6 -C 10 or phenyl). In embodiments, R 16C is independently substituted aryl (e.g., C6-C10 or phenyl). In embodiments, R 16C is independently unsubstituted aryl (e.g., C6- C10 or phenyl).
  • R 16C is independently substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). In embodiments, R 16C is independently substituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). In embodiments, R 16C is independently unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). [0375] In embodiments, R 16D is independently hydrogen. In embodiments, R 16D is
  • R 16D is independently -CX 16D 3. In embodiments, R 16D is independently -CHX 16D 2. In embodiments, R 16D is independently -CH 2 X 16D . In embodiments, R 16D is independently -CN. In embodiments, R 16D is independently -COOH. In embodiments, R 16D is independently -CONH 2 . In
  • X 16D is independently–F, -Cl, -Br, or -I.
  • R 16D is independently substituted or unsubstituted alkyl (e.g., C1-C8, C1- C 6 , C 1 -C 4 , or C 1 -C 2 ).
  • R 16D is independently substituted alkyl (e.g., C 1 -C 8 , C 1 - C6, C1-C4, or C1-C2).
  • R 16D is independently unsubstituted alkyl (e.g., C1-C8, C1- C6, C1-C4, or C1-C2).
  • R 16D is independently unsubstituted methyl. In embodiments, R 16D is independently unsubstituted ethyl. In embodiments, R 16D is independently unsubstituted propyl. In embodiments, R 16D is independently unsubstituted isopropyl. In embodiments, R 16D is independently unsubstituted tert-butyl. In embodiments, R 16D is independently substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered). In embodiments, R 16D is
  • heteroalkyl e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6
  • R 16D is independently unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered).
  • R 16D is independently substituted or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6).
  • R 16D is independently substituted cycloalkyl (e.g., C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ).
  • R 16D is independently unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6).
  • R 16D is independently substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • R 16D is independently substituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • R 16D is independently unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered). In embodiments, R 16D is independently substituted or unsubstituted aryl (e.g., C6-C10 or phenyl). In embodiments, R 16D is independently substituted aryl (e.g., C6-C10 or phenyl). In embodiments, R 16D is independently unsubstituted aryl (e.g., C6- C 10 or phenyl).
  • R 16D is independently substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). In embodiments, R 16D is independently substituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). In embodiments, R 16D is independently unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). [0377] In embodiments, R 16 is independently hydrogen,
  • X 16 is independently–F, -Cl, -Br, or–I.
  • R 16 is independently hydrogen.
  • R 16 is independently unsubstituted methyl.
  • R 16 is independently unsubstituted ethyl.
  • R 75 is independently oxo,
  • X 75 is independently–F, -Cl, -Br, or–I. In embodiments, R 75 is independently unsubstituted methyl. In embodiments, R 75 is independently unsubstituted ethyl. [0379] R 76 is independently oxo,
  • X 76 is independently–F, -Cl, -Br, or–I. In embodiments, R 76 is independently unsubstituted methyl. In embodiments, R 76 is independently unsubstituted ethyl. [0380] R 77 is independently oxo,
  • X 77 is independently–F, -Cl, -Br, or–I. In embodiments, R 77 is independently unsubstituted methyl. In embodiments, R 77 is independently unsubstituted ethyl. [0381] In embodiments, R 17 is hydrogen. In embodiments, R 17 is halogen. In embodiments, R 17 is -CX 17 3 . In embodiments, R 17 is -CHX 17 2 . In embodiments, R 17 is -CH 2 X 17 . In
  • R 17 is–CN. In embodiments, R 17 is -SOn17R 17D . In embodiments, R 17
  • R 17 is -SO v17 NR 17A R 17B .
  • R 17 is ⁇ NHNR 17A R 17B .
  • R 17 is ⁇ ONR 17A R 17B .
  • R 17 is ⁇ NHC(O)NR 17A R 17B .
  • R 17 is -N(O)m17.
  • R 17 is -NR 17A R 17B .
  • R 17 is -C(O)R 17C .
  • R 17 is -C(O)-OR 17C .
  • R 17 is -C(O)NR 17A R 17B .
  • R 17 is -OR 17D . In embodiments, R 17 is -NR 17A SO2R 17D . In embodiments, R 17 is -NR 17A C(O)R 17C . In embodiments, R 17 is -NR 17A C(O)OR 17C . In embodiments, R 17 is -NR 17A OR 17C . In embodiments, R 17 is -OCX 17 3 . In embodiments, R 17 is -OCHX 17 2. In embodiments, R 17 is independently -OH. In embodiments, R 17 is
  • R 17 is independently -NH2. In embodiments, R 17 is independently -COOH. In embodiments, R 17 is independently -CONH 2 . In embodiments, R 17 is independently -NO 2 . In embodiments, R 17 is independently -SH. In embodiments, R 17 is independently -CF3. In embodiments, R 17 is independently -CHF2. In embodiments, R 17 is independently -CH2F. In embodiments, R 17 is independently -OCF 3 . In embodiments, R 17 is independently -OCH 2 F. In embodiments, R 17 is independently -OCHF 2 . In embodiments, R 17 is independently–OCH 3 . In embodiments, R 17 is independently–OCH2CH3. In embodiments, R 17 is independently–OCH2CH2CH3.
  • R 17 is independently–OCH(CH3)2. In embodiments, R 17 is independently– OC(CH 3 ) 3 . In embodiments, R 17 is independently–SCH 3 . In embodiments, R 17 is independently –SCH2CH3. In embodiments, R 17 is independently–SCH2CH2CH3. In embodiments, R 17 is independently–SCH(CH3)2. In embodiments, R 17 is independently–SC(CH3)3. In
  • R 17 is independently–CH 3 . In embodiments, R 17 is independently–CH 2 CH 3 . In embodiments, R 17 is independently–CH2CH2CH3. In embodiments, R 17 is independently– CH(CH3)2. In embodiments, R 17 is independently–C(CH3)3. In embodiments, R 17 is independently–F. In embodiments, R 17 is independently–Cl. In embodiments, R 17 is independently–Br. In embodiments, R 17 is independently–I. [0382] In embodiments, R 17 is independently substituted or unsubstituted alkyl (e.g., C1-C8, C1- C 6 , C 1 -C 4 , or C 1 -C 2 ).
  • R 17 is independently substituted or unsubstituted alkyl (e.g., C1-C8, C1- C 6 , C 1 -C 4 , or C 1 -C 2 ).
  • R 17 is independently substituted alkyl (e.g., C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2 ). In embodiments, R 17 is independently unsubstituted alkyl (e.g., C 1 -C 8 , C 1 -C 6 , C1-C4, or C1-C2). In embodiments, R 17 is independently unsubstituted methyl. In embodiments, R 17 is independently unsubstituted ethyl. In embodiments, R 17 is independently unsubstituted propyl. In embodiments, R 17 is independently unsubstituted isopropyl.
  • R 17 is independently unsubstituted tert-butyl. In embodiments, R 17 is independently substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered). In embodiments, R 17 is independently substituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered).
  • R 17 is independently unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered).
  • R 17 is independently substituted or unsubstituted cycloalkyl (e.g., C 3 -C 8 , C 3 -C 6 , C4-C6, or C5-C6).
  • R 17 is independently substituted cycloalkyl (e.g., C3-C8, C3- C6, C4-C6, or C5-C6).
  • R 17 is independently unsubstituted cycloalkyl (e.g., C3- C8, C3-C6, C4-C6, or C5-C6).
  • R 17 is independently substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • R 17 is independently substituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • R 17 is independently unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered). In embodiments, R 17 is independently substituted or unsubstituted aryl (e.g., C6-C10 or phenyl). In embodiments, R 17 is independently substituted aryl (e.g., C 6 -C 10 or phenyl). In embodiments, R 17 is independently unsubstituted aryl (e.g., C 6 -C 10 or phenyl).
  • R 17 is independently substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). In embodiments, R 17 is independently substituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). In embodiments, R 17 is independently unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). [0383] In embodiments, R 17A is independently hydrogen. In embodiments, R 17A is
  • R 17A is independently -CX 17A 3 .
  • R 17A is independently -CHX 17A 2 .
  • R 17A is independently -CH 2 X 17A .
  • R 17A is independently -CN.
  • R 17A is independently -COOH.
  • R 17A is independently -CONH2.
  • X 17A is independently–F, -Cl, -Br, or -I.
  • R 17A is independently substituted or unsubstituted alkyl (e.g., C 1 -C 8 , C 1 - C6, C1-C4, or C1-C2).
  • R 17A is independently substituted alkyl (e.g., C1-C8, C1- C6, C1-C4, or C1-C2).
  • R 17A is independently unsubstituted alkyl (e.g., C1-C8, C1- C 6 , C 1 -C 4 , or C 1 -C 2 ).
  • R 17A is independently unsubstituted methyl. In embodiments, R 17A is independently unsubstituted ethyl. In embodiments, R 17A is independently unsubstituted propyl. In embodiments, R 17A is independently unsubstituted isopropyl. In embodiments, R 17A is independently unsubstituted tert-butyl. In embodiments, R 17A is independently substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered). In embodiments, R 17A is
  • heteroalkyl e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6
  • R 17A is independently unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered).
  • R 17A is independently substituted or unsubstituted cycloalkyl (e.g., C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ).
  • R 17A is independently substituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6).
  • R 17A is independently unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6).
  • R 17A is independently substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • R 17A is independently substituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • R 17A is independently unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered). In embodiments, R 17A is independently substituted or unsubstituted aryl (e.g., C 6 -C 10 or phenyl). In embodiments, R 17A is independently substituted aryl (e.g., C 6 -C 10 or phenyl). In embodiments, R 17A is independently unsubstituted aryl (e.g., C 6 - C10 or phenyl).
  • R 17A is independently substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). In embodiments, R 17A is independently substituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). In embodiments, R 17A is independently unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). [0385] In embodiments, R 17B is independently hydrogen. In embodiments, R 17B is
  • R 17B is independently -CX 17B 3 .
  • R 17B is independently -CHX 17B 2 .
  • R 17B is independently -CH2X 17B .
  • R 17B is independently -CN.
  • R 17B is independently -COOH.
  • R 17B is independently -CONH 2 .
  • X 17B is independently–F, -Cl, -Br, or -I.
  • R 17B is independently substituted or unsubstituted alkyl (e.g., C1-C8, C1- C6, C1-C4, or C1-C2).
  • R 17B is independently substituted alkyl (e.g., C1-C8, C1- C 6 , C 1 -C 4 , or C 1 -C 2 ).
  • R 17B is independently unsubstituted alkyl (e.g., C 1 -C 8 , C 1 - C6, C1-C4, or C1-C2).
  • R 17B is independently unsubstituted methyl. In embodiments, R 17B is independently unsubstituted ethyl. In embodiments, R 17B is independently unsubstituted propyl. In embodiments, R 17B is independently unsubstituted isopropyl. In embodiments, R 17B is independently unsubstituted tert-butyl. In embodiments, R 17B is independently substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered). In embodiments, R 17B is
  • heteroalkyl e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6
  • R 17B is independently unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered).
  • R 17B is independently substituted or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6).
  • R 17B is independently substituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6).
  • R 17B is independently unsubstituted cycloalkyl (e.g., C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ).
  • R 17B is independently substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • R 17B is independently substituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • R 17B is independently unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered). In embodiments, R 17B is independently substituted or unsubstituted aryl (e.g., C 6 -C 10 or phenyl). In embodiments, R 17B is independently substituted aryl (e.g., C6-C10 or phenyl). In embodiments, R 17B is independently unsubstituted aryl (e.g., C6- C10 or phenyl).
  • R 17B is independently substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). In embodiments, R 17B is independently substituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). In embodiments, R 17B is independently unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
  • R 17A and R 17B substituents bonded to the same nitrogen atom may be joined to form a substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • R 17A and R 17B substituents bonded to the same nitrogen atom may be joined to form a substituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • R 17A and R 17B substituents bonded to the same nitrogen atom may be joined to form an unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered). [0388] In embodiments, R 17A and R 17B substituents bonded to the same nitrogen atom may be joined to form a substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
  • R 17A and R 17B substituents bonded to the same nitrogen atom may be joined to form a substituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). In embodiments, R 17A and R 17B substituents bonded to the same nitrogen atom may be joined to form an unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). [0389] In embodiments, R 17C is independently hydrogen. In embodiments, R 17C is
  • R 17C is independently -CX 17C 3 .
  • R 17C is independently -CHX 17C 2 .
  • R 17C is independently -CH2X 17C .
  • R 17C is independently -CN.
  • R 17C is independently -COOH.
  • R 17C is independently -CONH2.
  • X 17C is independently–F, -Cl, -Br, or -I.
  • R 17C is independently substituted or unsubstituted alkyl (e.g., C1-C8, C1- C6, C1-C4, or C1-C2).
  • R 17C is independently substituted alkyl (e.g., C1-C8, C1- C 6 , C 1 -C 4 , or C 1 -C 2 ).
  • R 17C is independently unsubstituted alkyl (e.g., C 1 -C 8 , C 1 - C 6 , C 1 -C 4 , or C 1 -C 2 ).
  • R 17C is independently unsubstituted methyl. In embodiments, R 17C is independently unsubstituted ethyl. In embodiments, R 17C is independently unsubstituted propyl. In embodiments, R 17C is independently unsubstituted isopropyl. In embodiments, R 17C is independently unsubstituted tert-butyl. In embodiments, R 17C is independently substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered). In embodiments, R 17C is
  • heteroalkyl e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6
  • R 17C is independently unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered).
  • R 17C is independently substituted or unsubstituted cycloalkyl (e.g., C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ).
  • R 17C is independently substituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6).
  • R 17C is independently unsubstituted cycloalkyl (e.g., C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ).
  • R 17C is independently substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • R 17C is independently substituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • R 17C is independently unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered). In embodiments, R 17C is independently substituted or unsubstituted aryl (e.g., C 6 -C 10 or phenyl). In embodiments, R 17C is independently substituted aryl (e.g., C6-C10 or phenyl). In embodiments, R 17C is independently unsubstituted aryl (e.g., C6- C10 or phenyl).
  • R 17C is independently substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). In embodiments, R 17C is independently substituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). In embodiments, R 17C is independently unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). [0391] In embodiments, R 17D is independently hydrogen. In embodiments, R 17D is independently -CX 17D 3. In embodiments, R 17D is independently -CHX 17D 2. In embodiments, R 17D is independently -CH 2 X 17D . In embodiments, R 17D is independently -CN. In embodiments, R 17D is independently -COOH. In embodiments, R 17D is independently -CONH2. In
  • X 17D is independently–F, -Cl, -Br, or -I.
  • R 17D is independently substituted or unsubstituted alkyl (e.g., C 1 -C 8 , C 1 - C 6 , C 1 -C 4 , or C 1 -C 2 ).
  • R 17D is independently substituted alkyl (e.g., C 1 -C 8 , C 1 - C6, C1-C4, or C1-C2).
  • R 17D is independently unsubstituted alkyl (e.g., C1-C8, C1- C 6 , C 1 -C 4 , or C 1 -C 2 ).
  • R 17D is independently unsubstituted methyl. In embodiments, R 17D is independently unsubstituted ethyl. In embodiments, R 17D is independently unsubstituted propyl. In embodiments, R 17D is independently unsubstituted isopropyl. In embodiments, R 17D is independently unsubstituted tert-butyl. In embodiments, R 17D is independently substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered). In embodiments, R 17D is
  • heteroalkyl e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6
  • R 17D is independently unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered).
  • R 17D is independently substituted or unsubstituted cycloalkyl (e.g., C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ).
  • R 17D is independently substituted cycloalkyl (e.g., C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ).
  • R 17D is independently unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6).
  • R 17D is independently substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • R 17D is independently substituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered). In embodiments, R 17D is independently unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered). In embodiments, R 17D is independently substituted or unsubstituted aryl (e.g., C6-C10 or phenyl). In embodiments, R 17D is independently substituted aryl (e.g., C 6 -C 10 or phenyl).
  • R 17D is independently unsubstituted aryl (e.g., C 6 - C 10 or phenyl). In embodiments, R 17D is independently substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). In embodiments, R 17D is independently substituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). In embodiments, R 17D is independently unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). [0393] In embodiments, R 17 is independently hydrogen,
  • X 17 is independently–F, -Cl, -Br, or–I.
  • R 17 is independently hydrogen.
  • R 17 is independently unsubstituted methyl.
  • R 17 is independently unsubstituted ethyl.
  • R 78 is independently oxo,
  • X 78 is independently–F, -Cl, -Br, or–I.
  • R 78 is independently unsubstituted methyl.
  • R 78 is independently unsubstituted ethyl.
  • R 79 is independently oxo,
  • X 79 is independently–F, -Cl, -Br, or–I. In embodiments, R 79 is independently unsubstituted methyl. In embodiments, R 79 is independently unsubstituted ethyl. [0396] R 80 is independently oxo,
  • X 80 is independently–F, -Cl, -Br, or–I.
  • R 80 is independently unsubstituted methyl.
  • R 80 is independently unsubstituted ethyl.
  • R 18 is hydrogen.
  • R 18 is halogen.
  • R 18 is -CX 18 3 .
  • R 18 is -CHX 18 2 .
  • R 18 is -CH 2 X 18 .
  • R 18 is–CN. In embodiments, R 18 is -SO n18 R 18D . In embodiments, R 18
  • R 18 is -SOv18NR 18A R 18B .
  • R 18 is ⁇ NHNR 18A R 18B .
  • R 18 is ⁇ ONR 18A R 18B .
  • R 18 is ⁇ NHC(O)NR 18A R 18B .
  • R 18 is -N(O)m18.
  • R 18 is -NR 18A R 18B .
  • R 18 is -C(O)R 18C .
  • R 18 is -C(O)-OR 18C .
  • R 18 is -C(O)NR 18A R 18B .
  • R 18 is -OR 18D . In embodiments, R 18 is -NR 18A SO2R 18D . In embodiments, R 18 is -NR 18A C(O)R 18C . In embodiments, R 18 is -NR 18A C(O)OR 18C . In
  • R 18 is -NR 18A OR 18C . In embodiments, R 18 is -OCX 18 3 . In embodiments, R 18 is -OCHX 18 2. In embodiments, R 18 is independently -OH. In embodiments, R 18 is
  • R 18 is independently -NH2. In embodiments, R 18 is independently -COOH. In embodiments, R 18 is independently -CONH 2 . In embodiments, R 18 is independently -NO 2 . In embodiments, R 18 is independently -SH. In embodiments, R 18 is independently -CF3. In embodiments, R 18 is independently -CHF2. In embodiments, R 18 is independently -CH2F. In embodiments, R 18 is independently -OCF 3 . In embodiments, R 18 is independently -OCH 2 F. In embodiments, R 18 is independently -OCHF2. In embodiments, R 18 is independently–OCH3. In embodiments, R 18 is independently–OCH2CH3. In embodiments, R 18 is independently–OCH2CH2CH3.
  • R 18 is independently–OCH(CH 3 ) 2 . In embodiments, R 18 is independently– OC(CH 3 ) 3 . In embodiments, R 18 is independently–SCH 3 . In embodiments, R 18 is independently –SCH2CH3. In embodiments, R 18 is independently–SCH2CH2CH3. In embodiments, R 18 is independently–SCH(CH3)2. In embodiments, R 18 is independently–SC(CH3)3. In
  • R 18 is independently–CH 3 . In embodiments, R 18 is independently–CH 2 CH 3 . In embodiments, R 18 is independently–CH2CH2CH3. In embodiments, R 18 is independently– CH(CH3)2. In embodiments, R 18 is independently–C(CH3)3. In embodiments, R 18 is independently–F. In embodiments, R 18 is independently–Cl. In embodiments, R 18 is independently–Br. In embodiments, R 18 is independently–I. [0398] In embodiments, R 18 is independently substituted or unsubstituted alkyl (e.g., C1-C8, C1- C6, C1-C4, or C1-C2).
  • R 18 is independently substituted or unsubstituted alkyl (e.g., C1-C8, C1- C6, C1-C4, or C1-C2).
  • R 18 is independently substituted alkyl (e.g., C1-C8, C1-C6, C 1 -C 4 , or C 1 -C 2 ). In embodiments, R 18 is independently unsubstituted alkyl (e.g., C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2 ). In embodiments, R 18 is independently unsubstituted methyl. In embodiments, R 18 is independently unsubstituted ethyl. In embodiments, R 18 is independently unsubstituted propyl. In embodiments, R 18 is independently unsubstituted isopropyl.
  • R 18 is independently unsubstituted tert-butyl. In embodiments, R 18 is independently substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered). In embodiments, R 18 is independently substituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered).
  • R 18 is independently unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered). In embodiments, R 18 is independently substituted or unsubstituted cycloalkyl (e.g., C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ). In embodiments, R 18 is independently substituted cycloalkyl (e.g., C 3 -C 8 , C 3 - C6, C4-C6, or C5-C6).
  • R 18 is independently unsubstituted cycloalkyl (e.g., C3- C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ).
  • R 18 is independently substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • R 18 is independently substituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • R 18 is independently unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered). In embodiments, R 18 is independently substituted or unsubstituted aryl (e.g., C6-C10 or phenyl). In embodiments, R 18 is independently substituted aryl (e.g., C 6 -C 10 or phenyl). In embodiments, R 18 is independently unsubstituted aryl (e.g., C6-C10 or phenyl).
  • R 18 is independently substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). In embodiments, R 18 is independently substituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). In embodiments, R 18 is independently unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). [0399] In embodiments, R 18A is independently hydrogen. In embodiments, R 18A is independently hydrogen. In embodiments, R 18A is
  • R 18A is independently -CX 18A 3 .
  • R 18A is independently -CHX 18A 2 .
  • R 18A is independently -CH2X 18A .
  • R 18A is independently -CN.
  • R 18A is independently -COOH.
  • R 18A is independently -CONH2.
  • X 18A is independently–F, -Cl, -Br, or -I.
  • R 18A is independently substituted or unsubstituted alkyl (e.g., C1-C8, C1- C6, C1-C4, or C1-C2).
  • R 18A is independently substituted alkyl (e.g., C1-C8, C1- C 6 , C 1 -C 4 , or C 1 -C 2 ).
  • R 18A is independently unsubstituted alkyl (e.g., C 1 -C 8 , C 1 - C 6 , C 1 -C 4 , or C 1 -C 2 ).
  • R 18A is independently unsubstituted methyl. In embodiments, R 18A is independently unsubstituted ethyl. In embodiments, R 18A is independently unsubstituted propyl. In embodiments, R 18A is independently unsubstituted isopropyl. In embodiments, R 18A is independently unsubstituted tert-butyl. In embodiments, R 18A is independently substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered). In embodiments, R 18A is
  • heteroalkyl e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6
  • R 18A is independently unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered).
  • R 18A is independently substituted or unsubstituted cycloalkyl (e.g., C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ).
  • R 18A is independently substituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6).
  • R 18A is independently unsubstituted cycloalkyl (e.g., C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ).
  • R 18A is independently substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • R 18A is independently substituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • R 18A is independently unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered). In embodiments, R 18A is independently substituted or unsubstituted aryl (e.g., C 6 -C 10 or phenyl). In embodiments, R 18A is independently substituted aryl (e.g., C6-C10 or phenyl). In embodiments, R 18A is independently unsubstituted aryl (e.g., C6- C10 or phenyl).
  • R 18A is independently substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). In embodiments, R 18A is independently substituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). In embodiments, R 18A is independently unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). [0401]
  • R 18B is independently hydrogen. In embodiments, R 18B is independently -CX 18B 3. In embodiments, R 18B is independently -CHX 18B 2. In embodiments, R 18B is independently -CH 2 X 18B . In embodiments, R 18B is independently -CN. In embodiments, R 18B is independently -COOH. In embodiments, R 18B is independently -CONH2. In
  • X 18B is independently–F, -Cl, -Br, or -I.
  • R 18B is independently substituted or unsubstituted alkyl (e.g., C 1 -C 8 , C 1 - C 6 , C 1 -C 4 , or C 1 -C 2 ).
  • R 18B is independently substituted alkyl (e.g., C 1 -C 8 , C 1 - C6, C1-C4, or C1-C2).
  • R 18B is independently unsubstituted alkyl (e.g., C1-C8, C1- C 6 , C 1 -C 4 , or C 1 -C 2 ).
  • R 18B is independently unsubstituted methyl. In embodiments, R 18B is independently unsubstituted ethyl. In embodiments, R 18B is independently unsubstituted propyl. In embodiments, R 18B is independently unsubstituted isopropyl. In embodiments, R 18B is independently unsubstituted tert-butyl. In embodiments, R 18B is independently substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered). In embodiments, R 18B is
  • heteroalkyl e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6
  • R 18B is independently unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered).
  • R 18B is independently substituted or unsubstituted cycloalkyl (e.g., C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ).
  • R 18B is independently substituted cycloalkyl (e.g., C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ).
  • R 18B is independently unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6).
  • R 18B is independently substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • R 18B is independently substituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered). In embodiments, R 18B is independently unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered). In embodiments, R 18B is independently substituted or unsubstituted aryl (e.g., C6-C10 or phenyl). In embodiments, R 18B is independently substituted aryl (e.g., C 6 -C 10 or phenyl).
  • R 18B is independently unsubstituted aryl (e.g., C 6 - C 10 or phenyl). In embodiments, R 18B is independently substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). In embodiments, R 18B is independently substituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). In embodiments, R 18B is independently unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
  • R 18A and R 18B substituents bonded to the same nitrogen atom may be joined to form a substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).
  • R 18A and R 18B substituents bonded to the same nitrogen atom may be joined to form a substituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
PCT/US2017/066839 2016-12-15 2017-12-15 Compositions and methods for treating cancer Ceased WO2018112420A1 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
US16/468,948 US11136297B2 (en) 2016-12-15 2017-12-15 Compositions and methods for treating cancer
KR1020197020051A KR20190095355A (ko) 2016-12-15 2017-12-15 암의 치료를 위한 조성물 및 방법
JP2019532079A JP7191828B2 (ja) 2016-12-15 2017-12-15 がん治療のための組成物および方法
RU2019121922A RU2019121922A (ru) 2016-12-15 2017-12-15 Композиции и способы лечения рака
BR112019012263-0A BR112019012263A2 (pt) 2016-12-15 2017-12-15 composições e métodos para tratar câncer
EP17881029.7A EP3555077B1 (en) 2016-12-15 2017-12-15 Compositions and methods for treating cancer
CA3047125A CA3047125A1 (en) 2016-12-15 2017-12-15 Compositions and methods for treating cancer
AU2017378487A AU2017378487B2 (en) 2016-12-15 2017-12-15 Compositions and methods for treating cancer
CN201780086355.9A CN110291084A (zh) 2016-12-15 2017-12-15 用于治疗癌症的组合物和方法
MX2019007030A MX392368B (es) 2016-12-15 2017-12-15 Composiciones y metodos para el tratamiento del cancer
IL267247A IL267247B (en) 2016-12-15 2019-06-11 Compositions and methods for treating cancer
US18/194,410 US12077507B2 (en) 2016-12-15 2023-03-31 Compositions and methods for treating cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662434971P 2016-12-15 2016-12-15
US62/434,971 2016-12-15

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US16/468,948 A-371-Of-International US11136297B2 (en) 2016-12-15 2017-12-15 Compositions and methods for treating cancer
US202117492741A Continuation 2016-12-15 2021-10-04

Publications (1)

Publication Number Publication Date
WO2018112420A1 true WO2018112420A1 (en) 2018-06-21

Family

ID=62559666

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/066839 Ceased WO2018112420A1 (en) 2016-12-15 2017-12-15 Compositions and methods for treating cancer

Country Status (12)

Country Link
US (2) US11136297B2 (https=)
EP (1) EP3555077B1 (https=)
JP (1) JP7191828B2 (https=)
KR (1) KR20190095355A (https=)
CN (1) CN110291084A (https=)
AU (1) AU2017378487B2 (https=)
BR (1) BR112019012263A2 (https=)
CA (1) CA3047125A1 (https=)
IL (1) IL267247B (https=)
MX (1) MX392368B (https=)
RU (1) RU2019121922A (https=)
WO (1) WO2018112420A1 (https=)

Cited By (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10633381B2 (en) 2016-05-18 2020-04-28 Mirati Therapeutics, Inc. KRas G12C inhibitors
US10647715B2 (en) 2017-11-15 2020-05-12 Mirati Therapeutics, Inc. KRas G12C inhibitors
US10689377B2 (en) 2017-11-15 2020-06-23 Mirati Therapeutics, Inc. KRas G12C inhibitors
WO2020146779A1 (en) * 2019-01-11 2020-07-16 The Regents Of The University Of California mTORC1 INHIBITORS FOR ACTIVATING AUTOPHAGY
WO2021091956A1 (en) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
WO2021091967A1 (en) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
WO2021091982A1 (en) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
WO2021108683A1 (en) 2019-11-27 2021-06-03 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
WO2021257736A1 (en) 2020-06-18 2021-12-23 Revolution Medicines, Inc. Methods for delaying, preventing, and treating acquired resistance to ras inhibitors
WO2022060583A1 (en) 2020-09-03 2022-03-24 Revolution Medicines, Inc. Use of sos1 inhibitors to treat malignancies with shp2 mutations
WO2022060836A1 (en) 2020-09-15 2022-03-24 Revolution Medicines, Inc. Indole derivatives as ras inhibitors in the treatment of cancer
US20220112308A1 (en) * 2020-04-30 2022-04-14 Genentech, Inc. Kras specific antibodies and uses thereof
CN114681600A (zh) * 2018-10-19 2022-07-01 杭州纽安津生物科技有限公司 通用性多肽疫苗及其在制备治疗/预防胰腺癌药物中的应用
US11453683B1 (en) 2019-08-29 2022-09-27 Mirati Therapeutics, Inc. KRas G12D inhibitors
WO2022235864A1 (en) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Ras inhibitors
WO2022235870A1 (en) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Ras inhibitors for the treatment of cancer
US11548888B2 (en) 2019-01-10 2023-01-10 Mirati Therapeutics, Inc. KRas G12C inhibitors
WO2022261514A3 (en) * 2021-06-11 2023-02-09 RNAimmune, Inc. Multiplexed tp53 and pan-ras mrna cancer vaccines
WO2023060253A1 (en) 2021-10-08 2023-04-13 Revolution Medicines, Inc. Ras inhibitors
WO2023114954A1 (en) 2021-12-17 2023-06-22 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
US11702418B2 (en) 2019-12-20 2023-07-18 Mirati Therapeutics, Inc. SOS1 inhibitors
EP4227307A1 (en) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors
US11890285B2 (en) 2019-09-24 2024-02-06 Mirati Therapeutics, Inc. Combination therapies
US11932633B2 (en) 2018-05-07 2024-03-19 Mirati Therapeutics, Inc. KRas G12C inhibitors
WO2024102421A2 (en) 2022-11-09 2024-05-16 Revolution Medicines, Inc. Compounds, complexes, and methods for their preparation and of their use
EP4138875A4 (en) * 2020-04-23 2024-08-28 The Regents of the University of California RAS INHIBITORS AND USES THEREOF
WO2024206858A1 (en) 2023-03-30 2024-10-03 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
WO2024211663A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors
WO2024211712A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors
WO2024216016A1 (en) 2023-04-14 2024-10-17 Revolution Medicines, Inc. Crystalline forms of a ras inhibitor
WO2024216048A1 (en) 2023-04-14 2024-10-17 Revolution Medicines, Inc. Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
US12122787B2 (en) 2019-09-20 2024-10-22 Shanghai Jemincare Pharmaceuticals Co., Ltd Fused pyridone compound, and preparation method therefor and use thereof
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US12208099B2 (en) 2018-09-10 2025-01-28 Mirati Therapeutics, Inc. Combination therapies
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
US12281113B2 (en) 2020-09-11 2025-04-22 Mirati Therapeutics, Inc. Crystalline forms of a KRas G12C inhibitor
US12336995B2 (en) 2018-09-10 2025-06-24 Mirati Therapeutics, Inc. Combination therapies
US12377101B2 (en) 2018-12-05 2025-08-05 Mirati Therapeutics, Inc. Combination therapies
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
US12398154B2 (en) 2020-12-15 2025-08-26 Mirati Therapeutics, Inc. Azaquinazoline pan-KRas inhibitors
US12421253B2 (en) 2020-12-16 2025-09-23 Mirati Therapeutics, Inc. Tetrahydropyridopyrimidine pan-KRas inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US12485122B2 (en) 2018-09-10 2025-12-02 Mirati Therapeutics, Inc. Combination of palbociclib and adagrasib for lung cancer
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
US12527795B2 (en) 2018-09-10 2026-01-20 Mirati Therapeutics, Inc. Compositions of adagrasib and mTOR inhibitors and methods of treatment therewith
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2836482B1 (en) 2012-04-10 2019-12-25 The Regents of The University of California Compositions and methods for treating cancer
KR20190095355A (ko) * 2016-12-15 2019-08-14 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 암의 치료를 위한 조성물 및 방법
CN110825862B (zh) * 2019-11-06 2022-12-06 北京诺道认知医学科技有限公司 基于药学知识图谱的智能问答方法及装置
CN114044754A (zh) * 2021-11-23 2022-02-15 贵州大学 一类5-三氟甲基-4-吡唑衍生物的制备方法及其在抑制肿瘤细胞上的应用
KR20260027943A (ko) * 2023-05-26 2026-03-03 레볼루션 메디슨즈, 인크. Ras 억제제

Citations (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4861760A (en) 1985-10-03 1989-08-29 Merck & Co., Inc. Ophthalmological composition of the type which undergoes liquid-gel phase transition
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
US5010175A (en) 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
WO1991019735A1 (en) 1990-06-14 1991-12-26 Bartlett Paul A Libraries of modified peptides with protease resistance
WO1992000091A1 (en) 1990-07-02 1992-01-09 Bioligand, Inc. Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
WO1993020242A1 (en) 1992-03-30 1993-10-14 The Scripps Research Institute Encoded combinatorial chemical libraries
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
US5403841A (en) 1991-01-15 1995-04-04 Alcon Laboratories, Inc. Use of carrageenans in topical ophthalmic compositions
WO1996005309A2 (en) 1994-08-17 1996-02-22 The Rockefeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US5538848A (en) 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
US5539083A (en) 1994-02-23 1996-07-23 Isis Pharmaceuticals, Inc. Peptide nucleic acid combinatorial libraries and improved methods of synthesis
US5593853A (en) 1994-02-09 1997-01-14 Martek Corporation Generation and screening of synthetic drug libraries
US5605798A (en) 1993-01-07 1997-02-25 Sequenom, Inc. DNA diagnostic based on mass spectrometry
US5777324A (en) 1996-09-19 1998-07-07 Sequenom, Inc. Method and apparatus for maldi analysis
US5858659A (en) 1995-11-29 1999-01-12 Affymetrix, Inc. Polymorphism detection
US5919626A (en) 1997-06-06 1999-07-06 Orchid Bio Computer, Inc. Attachment of unmodified nucleic acids to silanized solid phase surfaces
US5925525A (en) 1989-06-07 1999-07-20 Affymetrix, Inc. Method of identifying nucleotide differences
US5952174A (en) 1994-02-07 1999-09-14 Orchid Biocomputer, Inc. Ligase/polymerase-mediated genetic bit analysis of single nucleotide polymorphisms and its use in genetic analysis
WO1999067641A2 (en) 1998-06-24 1999-12-29 Illumina, Inc. Decoding of array sensors with microspheres
US6017696A (en) 1993-11-01 2000-01-25 Nanogen, Inc. Methods for electronic stringency control for molecular biological analysis and diagnostics
US6045996A (en) 1993-10-26 2000-04-04 Affymetrix, Inc. Hybridization assays on oligonucleotide arrays
US6051380A (en) 1993-11-01 2000-04-18 Nanogen, Inc. Methods and procedures for molecular biological analysis and diagnostics
US6068818A (en) 1993-11-01 2000-05-30 Nanogen, Inc. Multicomponent devices for molecular biological analysis and diagnostics
WO2000039587A1 (en) 1998-12-28 2000-07-06 Illumina, Inc. Composite arrays utilizing microspheres
US6251639B1 (en) 1999-09-13 2001-06-26 Nugen Technologies, Inc. Methods and compositions for linear isothermal amplification of polynucleotide sequences, using a RNA-DNA composite primer
US20090298075A1 (en) 2008-03-28 2009-12-03 Pacific Biosciences Of California, Inc. Compositions and methods for nucleic acid sequencing
US20110319290A1 (en) 2010-06-08 2011-12-29 Nugen Technologies, Inc. Methods and Compositions for Multiplex Sequencing
WO2013155223A1 (en) 2012-04-10 2013-10-17 The Regents Of The University Of California Compositions and methods for treating cancer
WO2015054572A1 (en) 2013-10-10 2015-04-16 Araxes Pharma Llc Inhibitors of kras g12c
US20160243223A1 (en) * 2009-12-01 2016-08-25 Oncomed Pharmaceuticals, Inc. Methods for treating cancers comprising k-ras mutations
US9610287B2 (en) 2011-06-20 2017-04-04 H. Lundbeck A/S Method of administration of 4-((1R,3S)-6-chloro-3-phenyl-indan-1-yl)-1,2,2-trimethyl-piperazine and the salts thereof in the treatment of schizophrenia

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5242794A (en) 1984-12-13 1993-09-07 Applied Biosystems, Inc. Detection of specific sequences in nucleic acids
US5977322A (en) 1995-06-14 1999-11-02 The Regents Of The University Of California High affinity human antibodies to tumor antigens
WO2003037274A2 (en) * 2001-11-01 2003-05-08 Icagen, Inc. Pyrazole-amides and-sulfonamides
US6939994B1 (en) 2004-09-23 2005-09-06 Catalytic Distillation Technologies Process for the production of bisphenol-A
JP5460054B2 (ja) 2005-11-23 2014-04-02 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム 腫瘍形成性ｒａｓ特異的細胞障害性化合物およびその使用法
BRPI0718677A2 (pt) * 2006-11-03 2013-11-26 Irm Llc Compostos e composições como inibidores de quinases proteicas
KR101061599B1 (ko) 2008-12-05 2011-09-02 한국과학기술연구원 비정상 세포 성장 질환의 치료를 위한 단백질 키나아제 저해제인 신규 인다졸 유도체, 이의 약학적으로 허용가능한염 및 이를 유효성분으로 함유하는 약학적 조성물
WO2013025939A2 (en) * 2011-08-16 2013-02-21 Indiana University Research And Technology Corporation Compounds and methods for treating cancer by inhibiting the urokinase receptor
KR20130077390A (ko) 2011-12-29 2013-07-09 제이더블유중외제약 주식회사 단백질 키나아제 저해활성을 가지는 6-아미노-3-카복스아미도인다졸 유도체
HUE037689T2 (hu) 2012-09-14 2018-09-28 Hoffmann La Roche Pirazol-karboxamid származékok mint TAAR-modulátorok különféle rendellenességek, mint például depresszió, cukorbetegség és Parkinson-kór kezelésében történõ alkalmazásra
CA2904393A1 (en) 2013-03-15 2014-09-25 Araxes Pharma Llc Covalent inhibitors of kras g12c
KR20190095355A (ko) * 2016-12-15 2019-08-14 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 암의 치료를 위한 조성물 및 방법

Patent Citations (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4861760A (en) 1985-10-03 1989-08-29 Merck & Co., Inc. Ophthalmological composition of the type which undergoes liquid-gel phase transition
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
US5010175A (en) 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
US5925525A (en) 1989-06-07 1999-07-20 Affymetrix, Inc. Method of identifying nucleotide differences
WO1991019735A1 (en) 1990-06-14 1991-12-26 Bartlett Paul A Libraries of modified peptides with protease resistance
WO1992000091A1 (en) 1990-07-02 1992-01-09 Bioligand, Inc. Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
US5403841A (en) 1991-01-15 1995-04-04 Alcon Laboratories, Inc. Use of carrageenans in topical ophthalmic compositions
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
WO1993020242A1 (en) 1992-03-30 1993-10-14 The Scripps Research Institute Encoded combinatorial chemical libraries
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
US5605798A (en) 1993-01-07 1997-02-25 Sequenom, Inc. DNA diagnostic based on mass spectrometry
US6045996A (en) 1993-10-26 2000-04-04 Affymetrix, Inc. Hybridization assays on oligonucleotide arrays
US6068818A (en) 1993-11-01 2000-05-30 Nanogen, Inc. Multicomponent devices for molecular biological analysis and diagnostics
US6017696A (en) 1993-11-01 2000-01-25 Nanogen, Inc. Methods for electronic stringency control for molecular biological analysis and diagnostics
US6051380A (en) 1993-11-01 2000-04-18 Nanogen, Inc. Methods and procedures for molecular biological analysis and diagnostics
US5952174A (en) 1994-02-07 1999-09-14 Orchid Biocomputer, Inc. Ligase/polymerase-mediated genetic bit analysis of single nucleotide polymorphisms and its use in genetic analysis
US5593853A (en) 1994-02-09 1997-01-14 Martek Corporation Generation and screening of synthetic drug libraries
US5539083A (en) 1994-02-23 1996-07-23 Isis Pharmaceuticals, Inc. Peptide nucleic acid combinatorial libraries and improved methods of synthesis
WO1996005309A2 (en) 1994-08-17 1996-02-22 The Rockefeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US5538848A (en) 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
US6043031A (en) 1995-03-17 2000-03-28 Sequenom, Inc. DNA diagnostics based on mass spectrometry
US5858659A (en) 1995-11-29 1999-01-12 Affymetrix, Inc. Polymorphism detection
US5777324A (en) 1996-09-19 1998-07-07 Sequenom, Inc. Method and apparatus for maldi analysis
US5919626A (en) 1997-06-06 1999-07-06 Orchid Bio Computer, Inc. Attachment of unmodified nucleic acids to silanized solid phase surfaces
WO1999067641A2 (en) 1998-06-24 1999-12-29 Illumina, Inc. Decoding of array sensors with microspheres
WO2000039587A1 (en) 1998-12-28 2000-07-06 Illumina, Inc. Composite arrays utilizing microspheres
US6251639B1 (en) 1999-09-13 2001-06-26 Nugen Technologies, Inc. Methods and compositions for linear isothermal amplification of polynucleotide sequences, using a RNA-DNA composite primer
US20090298075A1 (en) 2008-03-28 2009-12-03 Pacific Biosciences Of California, Inc. Compositions and methods for nucleic acid sequencing
US20160243223A1 (en) * 2009-12-01 2016-08-25 Oncomed Pharmaceuticals, Inc. Methods for treating cancers comprising k-ras mutations
US20110319290A1 (en) 2010-06-08 2011-12-29 Nugen Technologies, Inc. Methods and Compositions for Multiplex Sequencing
US9610287B2 (en) 2011-06-20 2017-04-04 H. Lundbeck A/S Method of administration of 4-((1R,3S)-6-chloro-3-phenyl-indan-1-yl)-1,2,2-trimethyl-piperazine and the salts thereof in the treatment of schizophrenia
WO2013155223A1 (en) 2012-04-10 2013-10-17 The Regents Of The University Of California Compositions and methods for treating cancer
US20150087628A1 (en) * 2012-04-10 2015-03-26 The Regents Of The University Of California Compositions and methods for treating cancer
WO2015054572A1 (en) 2013-10-10 2015-04-16 Araxes Pharma Llc Inhibitors of kras g12c

Non-Patent Citations (65)

* Cited by examiner, † Cited by third party
Title
"Remington: The Science and Practice of Pharmacy", 2003, LIPPINCOTT, WILLIAMS & WILKINS
ADAMS, P.D.OSWALD, R.E.: "NMR assignment of Cdc42(T35A), an active Switch I mutant of Cdc42", BIOMOL NMR ASSIGN, vol. 1, 2007, pages 225 - 227
ADIBEKIAN, A.MARTIN, B.R.CHANG, J.W.HSU, K.-L.TSUBOI, K.BACHOVCHIN, D.A.SPEERS, A.E.BROWN, S.J.SPICER, T.FERNANDEZ-VEGA, V. ET AL.: "Confirming Target Engagement for Reversible Inhibitors in Vivo by Kinetically Tuned Activity-Based Probes", J. AM. CHEM. SOC., vol. 134, 2012, pages 10345 - 10348, XP055638547, DOI: 10.1021/ja303400u
BACHOVCHIN, D.A.BROWN, S.J.ROSEN, H.CRAVATT, B.F.: "Identification of selective inhibitors of uncharacterized enzymes by high-throughput screening with fluorescent activity-based probes", NATURE BIOTECHNOLOGY, vol. 27, 2009, pages 387 - 394, XP055227709, DOI: 10.1038/nbt.1531
BERGE ET AL.: "Pharmaceutical Salts", JOURNAL OF PHARMACEUTICAL SCIENCE, vol. 66, 1977, pages 1 - 19, XP002675560, DOI: 10.1002/jps.2600660104
BURNS, M.C.SUN, Q.DANIELS, R.N.CAMPER, D.KENNEDY, J.P.PHAN, J.OLEJNICZAK, E.T.LEE, T.WATERSON, A.G.ROSSANESE, O.W. ET AL.: "Approach for targeting Ras with small molecules that activate SOS-mediated nucleotide exchange", PROC NATL ACAD SCI USA, vol. 111, 2014, pages 3401 - 3406
CAMPBELL ET AL., J. ORG. CHEM., vol. 59, 1994, pages 658
CARELLI, J.D.SETHOFER, S.G.SMITH, G.A.MILLER, H.R.SIMARD, J.L.MERRICK, W.C.JAIN, R.K.ROSS, N.T.TAUNTON, J.: "Ternatin and improved synthetic variants kill cancer cells by targeting the elongation factor-l A ternary complex", ELIFE, vol. 4, 2015, pages el0222
CHEN ET AL., J. AMER. CHEM. SOC., vol. 116, 1994, pages 2661
CHO ET AL., SCIENCE, vol. 261, 1993, pages 1303
DATABASE PUBCHEM. [O] 13 May 2010 (2010-05-13), "3-Methyl-N,1-diphenylpyrazole-4-carboxamide", XP055493850, Database accession no. CID 45285671 *
DOMAILLE, P.J.CAMPBELL-BURK, S.L.KRAULIS, P.J.VAN AKEN, T.LAUE, E.D.: "Solution Structure and Dynamics of Ras p21.cntdot.GDP Determined by Heteronuclear Three- and Four-Dimensional NMR Spectroscopy", BIOCHEMISTRY, vol. 33, 1994, pages 3515 - 3531
ERLANSON, D.A., WELLS, J.A., AND BRAISTED, A.C.: "Tethering: Fragment-Based Drug Discovery", ANNU. REV. BIOPHYS. BIOMOL. STRUCT., vol. 33, 2004, pages 199 - 223, XP008069432, DOI: 10.1146/annurev.biophys.33.110502.140409
FETICS, S.K.GUTERRES, H.KEARNEY, B.M.BUHRMAN, G.MA, B.NUSSINOV, R.MATTOS, C.: "Allosteric effects of the oncogenic RasQ61L mutant on Raf-RBD", STRUCTURE, vol. 23, 2015, pages 505 - 516
FINGL ET AL.: "THE PHARMACOLOGICAL BASIS OF THERAPEUTICS", 1975, pages: l
FORBES ET AL., BR J CANCER, 2006
FORBES, S.A.FORBES, S.A.BINDAL, N.BINDAL, N.BAMFORD, S.BAMFORD, S.KOK, C.Y.COLE, C.COLE, C.KOK, C.Y. ET AL.: "COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer", NUCLEIC ACIDS RESEARCH, vol. 39, 2010, pages D945 - D950
FORD, B.SKOWRONEK, K.BOYKEVISCH, S.BAR-SAGI, D.NASSAR, N.: "Structure of the G60A mutant of Ras: implications for the dominant negative effect", J. BIOL. CHEM., vol. 280, 2005, pages 25697 - 25705
FOWLER, M.L.MCPHAIL, J.A.JENKINS, M.L.MASSON, G.R.RUTAGANIRA, F.U.SHOKAT, K.M.WILLIAMS, R.L.BURKE, J.E.: "Using hydrogen deuterium exchange mass spectrometry to engineer optimized constructs for crystallization of protein complexes: Case study of PI4KIIIP with Rabll", PROTEIN SCIENCE, vol. 25, 2016, pages 826 - 839
FURKA, INT. J. PEPT. PROT. RES., vol. 37, 1991, pages 487 - 493
GALLAGHER, E.S.HUDGENS, J.W.: "Hydrogen/ Deuterium Exchange-Mass Spectrometry", 2016, ELSEVIER, article "Mapping Protein-Ligand Interactions with Proteolytic Fragmentation"
HALL, B.E.YANG, S.S.BORIACK-SJODIN, P.A.KURIYAN, J.BAR-SAGI, D.: "Structure-based mutagenesis reveals distinct functions for Ras switch 1 and switch 2 in Sos-catalyzed guanine nucleotide exchange", J. BIOL. CHEM., vol. 276, 2001, pages 27629 - 27637
HIRSCHMANN ET AL., J. AMER. CHEM. SOC., vol. 114, 1992, pages 9217 - 9218
HOBBS ET AL., PROC. NAT. ACAD. SCI. USA, vol. 90, 1993, pages 6909 - 6913
HOUGHTON ET AL., NATURE, vol. 354, 1991, pages 84 - 88
HUNTER, J.C., MANANDHAR, A., CARRASCO, M.A., GURBANI, D., GONDI, S., WESTOVER, K.D.: "Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations", MOLECULAR CANCER RESEARCH, vol. 13, 2015, pages 1325 - 1335
ITO, Y.ITO, Y.YAMASAKI, K.KAMIYA, A.YAMASAKI, K.SHIROUZU, M.IWAHARA, J.IWAHARA, J.YOKOYAMA, S.TERADA, T. ET AL.: "Regional Polysterism in the GTP-Bound Form of the Human c-Ha-Ras Protein f", J. BIOCHEMISTRY, vol. 36, 1997, pages 9109 - 9119
JOHN, J.SOHMEN, R.FEUERSTEIN, J.LINKE, R.WITTINGHOFER, A.GOODY, R.S.: "Kinetics of interaction of nucleotides with nucleotide-free H-ras p21", BIOCHEMISTRY, vol. 29, 1990, pages 6058 - 6065
JOHNSON, C.W.BUHRMAN, G.TING, P.Y.COLICELLI, J.MATTOS, C.: "Expression, purification, crystallization and X-ray data collection for RAS and its mutants", DATA BRIEF, vol. 6, 2016, pages 423 - 427
JONES, S.LAMBERT, S.WILLIAMS, G. T.BEST, J. M.SAMPSON, J. R.CHEADLE, J. P.: "Increased frequency of the k-ras G12C mutation in MYH polyposis colorectal adenomas.", BRITISH JOURNAL OF CANCER, vol. 90, no. 8, 2004, pages 1591 - 1593
KALBITZER, H.R.SPOERNER, M.GANSER, P.HOZSA, C.KREMER, W.: "Fundamental Link between Folding States and Functional States of Proteins", J. AM. CHEM. SOC., vol. 131, 2009, pages 16714 - 16719
LAI, A.C.CREWS, C.M.: "Induced protein degradation: an emerging drug discovery paradigm", NATURE PUBLISHING GROUP, vol. 16, 2017, pages 101 - 114, XP055865254, DOI: 10.1038/nrd.2016.211
LEE ET AL., NATURE, 2010
LIANG ET AL., SCIENCE, vol. 274, 1996, pages 1520 - 1522
LIEBERMAN, PHARMACEUTICAL DOSAGE FORMS, vol. 1-3, 1992
LIM, S.M.WESTOVER, K.D.FICARRO, S.B.HARRISON, R.A.CHOI, H.G.PACOLD, M.E.CARRASCO, M.HUNTER, J.KIM, N.D.XIE, T. ET AL.: "Therapeutic Targeting of Oncogenic K-Ras by a Covalent Catalytic Site Inhibitor", ANGEW. CHEM. INT. ED., vol. 53, 2013, pages 199 - 204, XP055693103, DOI: 10.1002/anie.201307387
LITO, P.SOLOMON, M.LI, L.HANSEN, R.ROSEN, N.: "Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism", SCIENCE, vol. 351, 2016, pages 604 - 608
LLOYD, THE ART, SCIENCE AND TECHNOLOGY OF PHARMACEUTICAL COMPOUNDING, 1999
MATSUMOTO, S.MIYANO, N.BABA, S.LIAO, J.KAWAMURA, T.TSUDA, C.TAKEDA, A.YAMAMOTO, M.KUMASAKA, T.KATAOKA, T. ET AL.: "Molecular Mechanism for Conformational Dynamics of Ras GTP Elucidated from In-Situ Structural Transition in Crystal", SCIENTIFIC REPORTS, vol. 6, 2016, pages 517
MAURER, T., MAURER, T., GARRENTON, L.S., GARRENTON, L.S., OH, A., OH, A., PITTS, K., PITTS, K., ANDERSON, D.J., ANDERSON, D.J.: "Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity", PROC NATL ACAD SCI USA, vol. 109, 2012, pages 5299 - 5304, XP002719655, DOI: 10.1073/pnas.1116510109
MCCORMICK, F.: "K-Ras protein as a drug target", J MOL MED, 2016, pages 1 - 6
MCGREGOR, L.M.JENKINS, M.L.KERWIN, C.BURKE, J.E.SHOKAT, K.M.: "Expanding the Scope of Electrophiles Capable of Targeting K-Ras Oncogenes", BIOCHEMISTRY, vol. 56, 2017, pages 3178 - 3183, XP055442614, DOI: 10.1021/acs.biochem.7b00271
MILBURN, M.V.TONG, L.DEVOS, A.M.BRUNGER, A.YAMAIZUMI, Z.NISHIMURA, S.KIM, S.H.: "Molecular switch for signal transduction: structural differences between active and inactive forms of protooncogenic ras proteins", SCIENCE, vol. 247, 1990, pages 939 - 945
MINTO, J., PHARMACOL. EXP. THER., vol. 281, 1997, pages 93 - 102
MURAOKA, S.SHIMA, F.ARAKI, M.INOUE, T.YOSHIMOTO, A.IJIRI, Y.SEKI, N.TAMURA, A.KUMASAKA, T.YAMAMOTO, M. ET AL.: "Crystal structures of the state 1 conformations of the GTP-bound H-Ras protein and its oncogenic G12V and Q61L mutants", FEBS LETTERS, vol. 586, 2012, pages 1715 - 1718, XP028520637, DOI: 10.1016/j.febslet.2012.04.058
OSTREM, J.M.L.SHOKAT, K.M.: "Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design", NATURE PUBLISHING GROUP, vol. 15, 2016, pages 771 - 785
OSTREM, J.M.PETERS, U.SOS, M.L.WELLS, J.A.SHOKAT, K.M.: "K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions", NATURE, vol. 503, 2013, pages 548 - 551
PATGIRI, A., YADAV, K.K., ARORA, P.S., BAR-SAGI, D.: "An orthosteric inhibitor of the Ras-Sos interaction", NAT CHEM BIOL, vol. 7, 2011, pages 585 - 587, XP055028796, DOI: 10.1038/nchembio.612
PATRICELLI, M.P.JANES, M.R.LI, L.S.HANSEN, R.PETERS, U.KESSLER, L.V.CHEN, Y.KUCHARSKI, J.M.FENG, J.ELY, T. ET AL.: "Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State", CANCER DISCOVERY, vol. 6, 2016, pages 316 - 329, XP055529432, DOI: 10.1158/2159-8290.CD-15-1105
PICKAR, DOSAGE CALCULATIONS, 1999
SCHUBBERT ET AL., MOL.CELL BIOL., 2007, pages 7765 - 70
See also references of EP3555077A4
SHIMA, F.SHIMA, F.YOSHIKAWA, Y.YOSHIKAWA, Y.YE, M.YE, M.ARAKI, M.ARAKI, M.MATSUMOTO, S.MATSUMOTO, S. ET AL.: "In silico discovery of small-molecule Ras inhibitors that display antitumor activity by blocking the Ras-effector interaction", PROC NATL ACAD SCI USA, vol. 110, 2013, pages 8182 - 8187, XP055798372, DOI: 10.1073/pnas.1217730110
SPENCER-SMITH, R.KOIDE, A.ZHOU, Y.EGUCHI, R.R.SHA, F.GAJWANI, P.SANTANA, D.GUPTA, A.JACOBS, M.HERRERO-GARCIA, E. ET AL.: "Inhibition of RAS function through targeting an allosteric regulatory site", NAT CHEM BIOL, vol. 13, 2017, pages 62 - 68
SPOERNER, M.HERRMANN, C.VETTER, I.R.KALBITZER, H.R.WITTINGHOFER, A.: "Dynamic properties of the Ras switch I region and its importance for binding to effectors", PROC NATL ACAD SCI USA, vol. 98, 2001, pages 4944 - 4949, XP008148834, DOI: 10.1073/pnas.081441398
SPOERNER, M.WITTINGHOFER, A.KALBITZER, H.R.: "Perturbation of the conformational equilibria in Ras by selective mutations as studied by 31P NMR spectroscopy", FEBS LETTERS, vol. 578, 2004, pages 305 - 310, XP071246876, DOI: 10.1016/j.febslet.2004.11.020
STEPHEN, A.G.ESPOSITO, D.BAGNI, R.K.MCCORMICK, F.: "Dragging Ras Back in the Ring", CANCER CELL, vol. 25, 2014, pages 272 - 281, XP028633347, DOI: 10.1016/j.ccr.2014.02.017
SUN, Q.BURKE, J.P.PHAN, J.BURNS, M.C.OLEJNICZAK, E.T.WATERSON, A.G.LEE, T.ROSSANESE, O.W.AND FESIK, S.W.: "Discovery of Small Molecules that Bind to K-Ras and Inhibit Sos-Mediated Activation", ANGEW. CHEM., vol. 124, 2012, pages 6244 - 6247
THAPAR, R.WILLIAMS, J.G.CAMPBELL, S.L.: "NMR Characterization of Full-length Farnesylated and Non-farnesylated H-Ras and its Implications for Raf Activation", JOURNAL OF MOLECULAR BIOLOGY, vol. 343, 2004, pages 1391 - 1408, XP022340770, DOI: 10.1016/j.jmb.2004.08.106
VADAS, O.BURKE, J.E.: "Probing the dynamic regulation of peripheral membrane proteins using hydrogen deuterium exchange-MS (HDX-MS", BIOCHM. SOC. TRANS., vol. 43, 2015, pages 773 - 786
VAUGHN ET AL., NATURE BIOTECHNOLOGY, vol. 14, no. 3, 1996, pages 309 - 314
VIGIL, D.CHERFILS, J.ROSSMAN, K.L.DER, C.J.: "Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy?", NAT. REV. CANCER, vol. 10, 2010, pages 842 - 857
WELSCH, M.E.KAPLAN, A.CHAMBERS, J.M.STOKES, M.E.BOS, P.H.ZASK, A.ZHANG, Y.SANCHEZ-MARTIN, M.BADGLEY, M.A.HUANG, C.S. ET AL.: "Multivalent Small-Molecule Pan-RAS Inhibitors", CELL, vol. 168, 2017, pages 878 - 889
YANG, W.FUCINI, R.V.FAHR, B.T.LAM, M.B.LU, Y.RANDAL, M.LIND, K.E.CARY, D.R.COLUSSI, D.LU, W. ET AL.: "Fragment-Based Discovery of Nonpeptidic BACE-1 Inhibitors Using Tethering", BIOCHEMISTRY, vol. 48, 2009, pages 4488 - 4496
ZHAO, Q.OUYANG, X.WAN, X.GAJIWALA, K.S.KATH, J.C.JONES, L.H.BURLINGAME, A.L.TAUNTON, J.: "Broad-Spectrum Kinase Profiling in Live Cells with Lysine-Targeted Sulfonyl Fluoride Probes", J. AM. CHEM. SOC., vol. 139, 2017, pages 680 - 685, XP055696664, DOI: 10.1021/jacs.6b08536

Cited By (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10633381B2 (en) 2016-05-18 2020-04-28 Mirati Therapeutics, Inc. KRas G12C inhibitors
US11267812B2 (en) 2016-05-18 2022-03-08 Mirati Therapeutics, Inc. KRAS G12C inhibitors
US10647715B2 (en) 2017-11-15 2020-05-12 Mirati Therapeutics, Inc. KRas G12C inhibitors
US10689377B2 (en) 2017-11-15 2020-06-23 Mirati Therapeutics, Inc. KRas G12C inhibitors
US11932633B2 (en) 2018-05-07 2024-03-19 Mirati Therapeutics, Inc. KRas G12C inhibitors
US12527795B2 (en) 2018-09-10 2026-01-20 Mirati Therapeutics, Inc. Compositions of adagrasib and mTOR inhibitors and methods of treatment therewith
US12336995B2 (en) 2018-09-10 2025-06-24 Mirati Therapeutics, Inc. Combination therapies
US12208099B2 (en) 2018-09-10 2025-01-28 Mirati Therapeutics, Inc. Combination therapies
US12485122B2 (en) 2018-09-10 2025-12-02 Mirati Therapeutics, Inc. Combination of palbociclib and adagrasib for lung cancer
CN114681600A (zh) * 2018-10-19 2022-07-01 杭州纽安津生物科技有限公司 通用性多肽疫苗及其在制备治疗/预防胰腺癌药物中的应用
US12377101B2 (en) 2018-12-05 2025-08-05 Mirati Therapeutics, Inc. Combination therapies
US11548888B2 (en) 2019-01-10 2023-01-10 Mirati Therapeutics, Inc. KRas G12C inhibitors
WO2020146779A1 (en) * 2019-01-11 2020-07-16 The Regents Of The University Of California mTORC1 INHIBITORS FOR ACTIVATING AUTOPHAGY
US11964989B2 (en) 2019-08-29 2024-04-23 Mirati Therapeutics, Inc. KRas G12D inhibitors
US11453683B1 (en) 2019-08-29 2022-09-27 Mirati Therapeutics, Inc. KRas G12D inhibitors
US12122787B2 (en) 2019-09-20 2024-10-22 Shanghai Jemincare Pharmaceuticals Co., Ltd Fused pyridone compound, and preparation method therefor and use thereof
US11890285B2 (en) 2019-09-24 2024-02-06 Mirati Therapeutics, Inc. Combination therapies
EP4696316A2 (en) 2019-11-04 2026-02-18 Revolution Medicines, Inc. Ras inhibitors
EP4656201A2 (en) 2019-11-04 2025-12-03 Revolution Medicines, Inc. Ras inhibitors
WO2021091956A1 (en) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
WO2021091967A1 (en) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
WO2021091982A1 (en) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
WO2021108683A1 (en) 2019-11-27 2021-06-03 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
US12304915B2 (en) 2019-12-20 2025-05-20 Mirati Therapeutics, Inc. SOS1 inhibitors
US11702418B2 (en) 2019-12-20 2023-07-18 Mirati Therapeutics, Inc. SOS1 inhibitors
EP4138875A4 (en) * 2020-04-23 2024-08-28 The Regents of the University of California RAS INHIBITORS AND USES THEREOF
US20220112308A1 (en) * 2020-04-30 2022-04-14 Genentech, Inc. Kras specific antibodies and uses thereof
WO2021257736A1 (en) 2020-06-18 2021-12-23 Revolution Medicines, Inc. Methods for delaying, preventing, and treating acquired resistance to ras inhibitors
WO2022060583A1 (en) 2020-09-03 2022-03-24 Revolution Medicines, Inc. Use of sos1 inhibitors to treat malignancies with shp2 mutations
US12286431B2 (en) 2020-09-11 2025-04-29 Mirati Therapeutics, Inc. Crystalline forms of a KRas G12C inhibitor
US12281113B2 (en) 2020-09-11 2025-04-22 Mirati Therapeutics, Inc. Crystalline forms of a KRas G12C inhibitor
WO2022060836A1 (en) 2020-09-15 2022-03-24 Revolution Medicines, Inc. Indole derivatives as ras inhibitors in the treatment of cancer
US12398154B2 (en) 2020-12-15 2025-08-26 Mirati Therapeutics, Inc. Azaquinazoline pan-KRas inhibitors
US12421253B2 (en) 2020-12-16 2025-09-23 Mirati Therapeutics, Inc. Tetrahydropyridopyrimidine pan-KRas inhibitors
WO2022235864A1 (en) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Ras inhibitors
WO2022235870A1 (en) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Ras inhibitors for the treatment of cancer
WO2022261514A3 (en) * 2021-06-11 2023-02-09 RNAimmune, Inc. Multiplexed tp53 and pan-ras mrna cancer vaccines
WO2023060253A1 (en) 2021-10-08 2023-04-13 Revolution Medicines, Inc. Ras inhibitors
WO2023114954A1 (en) 2021-12-17 2023-06-22 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
EP4227307A1 (en) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2024102421A2 (en) 2022-11-09 2024-05-16 Revolution Medicines, Inc. Compounds, complexes, and methods for their preparation and of their use
WO2024206858A1 (en) 2023-03-30 2024-10-03 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
WO2024211663A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors
WO2024211712A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors
WO2024216016A1 (en) 2023-04-14 2024-10-17 Revolution Medicines, Inc. Crystalline forms of a ras inhibitor
WO2024216048A1 (en) 2023-04-14 2024-10-17 Revolution Medicines, Inc. Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Also Published As

Publication number Publication date
US20200131135A1 (en) 2020-04-30
US11136297B2 (en) 2021-10-05
RU2019121922A3 (https=) 2021-12-17
CA3047125A1 (en) 2018-06-21
JP7191828B2 (ja) 2022-12-19
JP2020514254A (ja) 2020-05-21
MX2019007030A (es) 2020-01-15
MX392368B (es) 2025-03-24
CN110291084A (zh) 2019-09-27
AU2017378487A1 (en) 2019-07-04
BR112019012263A2 (pt) 2020-01-28
IL267247A (en) 2019-08-29
RU2019121922A (ru) 2021-01-18
US12077507B2 (en) 2024-09-03
KR20190095355A (ko) 2019-08-14
EP3555077A4 (en) 2021-01-06
EP3555077B1 (en) 2023-04-19
IL267247B (en) 2022-02-01
EP3555077A1 (en) 2019-10-23
AU2017378487B2 (en) 2022-03-31
US20240109845A1 (en) 2024-04-04

Similar Documents

Publication Publication Date Title
US12077507B2 (en) Compositions and methods for treating cancer
US12365693B2 (en) Compositions and methods for treating cancer
EP3350181B1 (en) Her3 ligands and uses thereof
EP3519402A1 (en) Inhibitors of kras g12c mutant proteins
US20230052528A1 (en) Taspase1 inhibitors and uses thereof
WO2023141635A2 (en) Her3 ligands and uses thereof
HK40016602A (en) Compositions and methods for treating cancer
HK40016602B (en) Compositions and methods for treating cancer
US20150266836A1 (en) Aromatic sulfide compounds and methods and use thereof
HK40013658A (en) Compositions and methods for treating cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17881029

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3047125

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2019532079

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112019012263

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2017378487

Country of ref document: AU

Date of ref document: 20171215

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20197020051

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2017881029

Country of ref document: EP

Effective date: 20190715

ENP Entry into the national phase

Ref document number: 112019012263

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20190614